

# Progress Toward *In Vivo* Use of siRNAs-II

Garrett R Rettig<sup>1</sup> and Mark A Behlke<sup>1</sup>

<sup>1</sup>Integrated DNA Technologies, Inc., Coralville, Iowa, USA

RNA interference (RNAi) has been extensively employed for *in vivo* research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of *in vivo* RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact *in vivo* use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.

Received 2 September 2011; accepted 8 November 2011; published online 20 December 2011. doi:10.1038/mt.2011.263

## INTRODUCTION

Researchers have been searching for new and improved methods to efficiently alter gene expression for decades. The landmark discovery in 1998 identifying double-stranded RNA (dsRNA) as a sequence-specific, mRNA-interfering species<sup>1</sup> triggered studies in a variety of systems that uncovered evolutionary conservation of some form of RNA interference (RNAi) across almost all phyla. Mechanistically, RNAi is now well-understood and numerous review articles are available that provide the reader with a thorough understanding of the basic biochemistry involved.<sup>2-4</sup> Briefly, 21-nucleotide (nt) small interfering RNA (siRNA) duplexes are the functional molecules that provide sequence-specific target selection and subsequent mRNA cleavage when part of the multicomponent RNA-induced silencing complex (RISC).<sup>5,6</sup> The characteristic 2-nt overhangs at the 3'-ends of each strand are recognized by the PAZ domain of Argonaute 2 (Ago2) which is a key protein component of RISC. PAZ domain-binding aids in orienting the siRNA in RISC, defining polarity. Loaded RISC scans available mRNA sequences and Ago2 mediates cleavage of the mRNA where sufficient homology exists to the siRNA guide strand. This initial cleavage event converts the mRNA into a substrate for further degradation by cellular 5'- and 3'-exonucleases. Importantly, administration of siRNAs in cell culture can achieve IC<sub>50</sub> values in the low picomolar range, demonstrating that RNAi is a very potent mechanism of gene inhibition. These factors are favorable for therapeutics and have been significant drivers motivating development of methods to use RNAi *in vivo*.

Five years ago, a review appeared in *Molecular Therapy* that addressed the rapid ascent of RNAi from discovery to a routine tool used in research with therapeutic aspirations.<sup>7</sup> One of the concluding statements of the review was as follows: "RNAi-based drugs are already in clinical trials and it is hopeful that a siRNA therapeutic will receive US Food and Drug Administration approval in the not so distant future." At that time, around 100

published reports of *in vivo* use of siRNAs could be found. Today, *in vivo* studies with siRNA have become almost commonplace and results from various ongoing clinical trials are awaited with anticipation. According to recent reviews,<sup>8,9</sup> nearly 30 clinical trials have been opened studying over 20 unique siRNA/small hairpin RNA (shRNA)-based drugs. This includes participation by 13 biotechnology/pharmaceutical companies and 3 academic-based research centers. Today, a search in PubMed with the specified keywords "siRNA *in vivo*" or "RNAi *in vivo*" returns almost 7,000 references.

The present review contains little discussion about basic RNAi biochemistry and focuses on recent advancements relevant to the use of siRNAs as an *in vivo* research tool or therapeutic. Like the previous review, the present work is generally restricted to the use of chemically synthesized siRNAs with a focus on chemistry and methodology. Optimism for commercially available RNAi therapeutics is justified; however, discussions of advancements in this field will also serve to highlight those characteristics of siRNA-based therapeutics that are currently hurdles to this technology becoming an US Food and Drug Administration-approved platform for treatment of human disease.

This review will first discuss recent improvements in siRNA site selection, design, chemical modification, and methods to reduce off-target effects (OTEs)—*i.e.*, the practical aspects of siRNA technology that are important to understand before starting *in vivo* studies. It will then provide illustrative examples of the use of different approaches to perform experiments *in vivo* using synthetic siRNAs. Far too many studies have been published in recent years to mention every contribution in the field. The authors apologize in advance to those whose work was not included herein. Manuscripts discussed in the siRNA *in vivo* studies are summarized in **Table 1**; more detailed features of these studies are shown in **Supplementary Table S1**. A large number of reports that employ synthetic siRNAs in animal studies are discussed in

**Table 1 Summary of Studies using siRNA *in vivo***

Delivery route	siRNA formulation			
	Naked	Liposome	Polymer	Conjugates/other
<i>Intravenous</i>				
Cancer	Tammali <sup>211</sup>	Judge, <sup>148</sup> Santel, <sup>74</sup> Koldehoff, <sup>176</sup> Lee, <sup>164</sup> Aleku, <sup>156</sup> Lin <sup>145</sup>	Poeck, <sup>113</sup> Bartlett, <sup>188</sup> Davis, <sup>151</sup> Kamlah, <sup>180</sup> Li, <sup>181</sup> de Wolff, <sup>300</sup> Heidel, <sup>187</sup> Xiong <sup>143</sup>	Shahzad, <sup>197</sup> McNamara, <sup>201</sup> Dassie, <sup>202</sup> Kortylewski, <sup>210</sup> Lu <sup>217</sup>
Viral infection		Yokota, <sup>159</sup> Morrissey, <sup>163</sup> Geisbert, <sup>166</sup> Wu, <sup>267</sup> Geisbert <sup>165</sup>	Robbins, <sup>112</sup> Zhou <sup>182</sup>	Neff <sup>52</sup>
Other disease states	van de Water <sup>212</sup>	Zimmermann, <sup>64</sup> Frank- Kamenetsky, <sup>150</sup> Khoury, <sup>160,161</sup> Love, <sup>168</sup> Peer, <sup>174</sup> Leuschner <sup>171</sup>	Ishimoto, <sup>189</sup> Kim, <sup>195</sup> Ghosn, <sup>183</sup> Kumar, <sup>194</sup> Polach <sup>162</sup>	Nishina, <sup>65</sup> Sato, <sup>173</sup> Alvarez-Erviti <sup>198</sup>
Whole animal imaging, PK/PD, design	Viel, <sup>132</sup> Bartlett, <sup>137</sup> Gao <sup>225</sup>	Gary, <sup>133</sup> Svensson, <sup>139</sup> Wei, <sup>140</sup> Yagi, <sup>142</sup> Strapps, <sup>68</sup> Judge, <sup>128</sup> Semple, <sup>169</sup> Adami, <sup>172</sup> Akinc <sup>175</sup>	Glud, <sup>48</sup> Merkel, <sup>301</sup> Malek, <sup>130</sup> Mudd, <sup>134</sup> Bartlett, <sup>136</sup> El Andaloussi, <sup>191</sup> Xiong, <sup>143</sup> Ghosn, <sup>183</sup> Heidel, <sup>138</sup> Basha <sup>170</sup>	Huang, <sup>141</sup> Wolfrum, <sup>204</sup> Kuwahara <sup>206</sup>
<i>Intraperitoneal</i>				
Cancer	Tesniere <sup>223</sup>	Huang, <sup>144</sup> Landen, <sup>218</sup> Halder, <sup>219</sup> Goldberg, <sup>220</sup> Amarzguioui <sup>222</sup>	Kaestner <sup>221</sup>	
Viral infection		Lundberg <sup>226</sup>		
Other disease states	Choi <sup>302</sup>		Nawroth, <sup>230</sup> Tesz, <sup>294</sup> Howard, <sup>229</sup> Tesz <sup>294</sup>	
Whole animal imaging, PK/PD		Lin <sup>145</sup>		
<i>Oral</i>				
CNS	Altier, <sup>231</sup> Taishi, <sup>232</sup> Senechal, <sup>233</sup> McCormack, <sup>234</sup> Wang, <sup>235</sup> Querbes <sup>236</sup>	LaCroix-Fralish, <sup>238</sup> Dore-Savard, <sup>239</sup> Dong, <sup>240</sup> Cardoso <sup>241</sup>	Wilson, <sup>291</sup> Laroui, <sup>292</sup> Aouadi <sup>293</sup> Michiue <sup>244</sup>	Uno, <sup>209</sup> DiFiglia, <sup>237</sup> Al-Jamal <sup>245</sup>
Topical	Gonzalez-Gonzalez, <sup>249</sup> Hickerson, <sup>43</sup> Hickerson, <sup>251</sup> Leachman <sup>250</sup>	Takanashi <sup>254</sup>	Uchida, <sup>252</sup> Yi <sup>257</sup>	Wu <sup>255</sup>
Intratatumoral	Laursen, <sup>56</sup> Singhal, <sup>259</sup> Suo, <sup>260</sup> Jonson, <sup>264</sup> Mook <sup>303</sup>	Dharmapuri, <sup>261</sup> Liu, <sup>262</sup> Seth <sup>268</sup>	Yamato, <sup>265</sup> Gillespie, <sup>269</sup> Chen, <sup>270</sup> Won <sup>273</sup>	Golzio, <sup>271</sup> Nakai <sup>272</sup>
Intranasal	Yueksekdag, <sup>274</sup> Fulton, <sup>278</sup> DeVincenzo, <sup>279</sup> DeVincenzo, <sup>280</sup> Zamora <sup>281</sup>		Howard <sup>227</sup>	
Optical	Kleinman, <sup>286</sup> Kaiser, <sup>288</sup> Kleinman <sup>287</sup>	Murata, <sup>284</sup> Turchinovich <sup>285</sup>		
Other routes	Sellick, <sup>296</sup> Ripoll, <sup>299</sup> Morgan <sup>289</sup>		Kinouchi, <sup>190</sup> Akita <sup>298</sup>	

this review. As this is a still a relatively young field that is rapidly developing and exploring a wide variety of new methodologies, not all of these reports will prove to be reproducible. Readers are cautioned to evaluate individual techniques carefully and to not expect that all of the methods discussed herein will work when applied to their system of interest.

## CONSIDERATIONS FOR *IN VIVO* USE OF siRNAs

### Site selection

Early work on siRNA efficacy demonstrated that not all siRNAs are equipotent. Initial attempts to predict which sites to target within a long mRNA target focused on defining similarities between experimentally validated siRNAs. The principles learned from these studies established a general set of characteristics that enrich for potent siRNAs based on their sequence and thermodynamics.<sup>10–13</sup> These works as well as other contributing efforts have been

recently reviewed.<sup>14–16</sup> Most of the “first-generation design tools” were developed from a relatively small number of validated siRNAs and focused on specific features of the siRNA itself with no consideration given to structure of the target mRNA. However, the basic principles established (overall guanine–cytosine-content, asymmetric thermostability, etc.) remain important criteria for effective siRNA design today.

More advanced predictive models (“second-generation” algorithms) have been developed in recent years. The ability of these models to predict potent sequences was improved by using thousands of sequences as training sets<sup>17–19</sup> and by employing more sophisticated machine learning tools. Automated neural networks (ANN) and support vector machines (SVM) have been used which permit a broader range of attributes of a given sequence to be considered in the selection analysis routine. It is well established that structure in the mRNA target can have significant effects on the

ultimate potency of a site to mediate RNAi knockdown,<sup>20,21</sup> and the following examples from the literature further highlight the significant role that mRNA secondary structure can play. A direct correlation was demonstrated between the RNAi knockdown efficiency and the local free energy of the target region of mRNA.<sup>22</sup> Similar studies regarding the accessibility of mRNA to guide strand/RISC processing have calculated the probability that the mRNA target is unpaired,<sup>23</sup> measured the energy required to disrupt mRNA secondary structure,<sup>24</sup> considered multiple secondary structures for both mRNA and siRNAs as a partition function calculation<sup>25</sup> and have shown that the local structure of the target region is an important predictor of siRNA functionality.<sup>26</sup> These studies established methods to incorporate calculations of mRNA and siRNA structural features into site selection algorithms which improve their predictive ability over calculations that only consider the siRNA sequence. Recent publications provide a more detailed discussion of this topic.<sup>27–30</sup> The noted reviews, and others not cited, provide tables referencing publicly available training sets of siRNA knockdown data as well as online tools which can be useful for siRNA design.

### Chemical modification of siRNAs

It is well-established that chemically synthesized siRNAs have a host of issues that affect functionality, especially when used in an *in vivo* setting where the full repertoire of immune-competent cells are present. Nuclease stability, strand loading, OTEs, immunogenicity, biodistribution, potency and half-life are all factors to consider for improvement in making siRNAs suitable for any *in vivo* use, especially therapeutics. Several recent reviews provide thorough discussions of the chemical modification strategies available for use in siRNAs and illustrate the chemical structures used.<sup>31–33</sup> In this section, we will highlight the most recent advances, examining how use of chemical modifications and new variations in structural designs in siRNAs can improve function.

Overcoming nuclease degradation is a significant challenge when administering nucleic acids of any kind *in vivo*. For siRNAs, the mechanism of cleavage proceeds by transesterification, so most chemical modifications which replace the hydroxyl at the 2'-position provide some protection from degradation in a position-specific manner. Likewise, backbone modifications also make RNA a less labile substrate for nucleases. Many of these backbone modifications and 2'-ribose modifications not only increase nuclease stability but also confer increased binding affinity or duplex stabilization.<sup>34</sup> Modifications at the 2'-position have been most extensively studied and DNA, 2'-O-methyl RNA (2'OMe), 2'-O-methoxyethyl (2'MOE), locked nucleic acids (LNA), 2'-fluoro (2'F), 2'-fluoro- $\beta$ -D-arabinonucleotide (FANA), and other modifications have been used as RNA replacements with varying levels of success. The extent of chemical modification needed varies with use. For example, methods that employ *in vivo* administration of naked siRNAs may require greater stabilization than siRNAs injected as a complex with a polymeric delivery vehicle, which itself provides physical protection to the RNA cargo, particularly when extracellular.

2'OMe RNA is the most commonly used modification. This is a naturally occurring nucleotide and no toxicity has been reported from its use. In fact, use of 2'OMe modification generally reduces

the toxicity of synthetic dsRNAs when introduced into mammalian cells. Hoerter and Walter demonstrated that a 5'-3' exonuclease played a significant role in guide strand degradation.<sup>35</sup> The same thermodynamic asymmetry of siRNAs which drives guide strand incorporation into RISC (lower thermodynamic stability at the 5'-end of the guide strand) renders this region more susceptible to 5'-exonuclease activity because of the decreased double-stranded nature of the duplex. The guide (antisense) strand was completely degraded after only 3 hours in 3% human serum; whereas, the passenger (sense) strand, with a thermodynamically stabilized 5'-end, showed 50% retention of the full-length strand for the duration of the assay. Modification with 2'OMe residues at the 5'-end of the guide strand and full passenger strand modification<sup>36</sup> can prevent siRNA degradation for 6 hours and significantly limits the effects of nuclease attack over 48 hours in 10% serum, yet retains potency. Choung and colleagues also showed that using 2'OMe modifications in a simple alternating pattern in both strands extends stability in 10% human serum to 24 hours. Similarly, Kraynack and Baker demonstrated that fully 2'OMe-modified passenger strands were tolerated and led to Ago2-dependent RISC activity with retained potency.<sup>37</sup> In addition to a 5'-3' exonuclease activity, an RNase A-like endonuclease activity in serum may significantly contribute to siRNA degradation and turnover<sup>38,39</sup> and inhibitors of RNase A improve siRNA function and half-life.<sup>40</sup> At least in single-stranded form, the 2'OMe modification confers significant stability from endonuclease attack but provides less protection from exonuclease degradation,<sup>41</sup> suggesting that other modifications that impart greater nuclease resistance may have a particularly significant role near sequence termini. Not surprisingly, sequence of the siRNA directly affects nuclease stability in the absence of chemical modification<sup>42</sup> and some unmodified sequences may have sufficient inherent stability to use *in vivo*.<sup>43</sup>

The 2'F modification has also been extensively used in siRNAs. The RNA aptamer field has a long history of using the 2'F modification and experience suggests that substitution of a fluorine at the 2'-position is generally well-tolerated *in vivo*.<sup>44</sup> However, the toxicology of the 2'F modification has not been as extensively studied as 2'OMe RNA. Interestingly, one study demonstrated that a fully 2'F-modified siRNA was nearly as potent as the unmodified siRNA in reducing green fluorescent protein (GFP) expression, yet was capable of surviving an 18-hour incubation with a RNase that completely degraded an unmodified siRNA.<sup>45</sup> Nevertheless, 2'F is usually used in combination with 2'OMe modification. The 2'-FANA modification is similar to 2'F; however, in FANA the 2'-fluorine orientation is equatorial, or in the  $\beta$ -position. Unlike most other modifications discussed to this point, only a small number of 2'-FANA-modified siRNAs have been studied to date. This modification was demonstrated to improve luciferase knockdown up to fourfold as measured by reduced luciferase activity and mRNA levels. In addition, stability of a 2'FANA-modified siRNA in 10% fetal calf serum was extended from <15 minutes (unmodified siRNA) to about 6 hours.<sup>46</sup>

LNAs are a bicyclic nucleic acid where the 2'-position of the ribose is connected to the 4'-position via a methylene bridge. This modification locks the sugar backbone in the 3'-endo conformation (RNA form) which leads to increased duplex stability (higher

melting temperature or  $T_m$ ) and improved nuclease resistance. The LNA modification must be used sparingly in siRNAs as extensive substitution generally results in loss of potency. siRNAs that are minimally modified with LNA residues can maintain potency and can show increased serum stability beyond 72 hours whereas the same sequence in unmodified form is completely degraded in just 5 hours in mouse serum.<sup>47</sup> Similar results were reported for mice dosed intravenously (i.v.) with chitosan-formulated siRNAs which were sparingly modified with LNA bases.<sup>47,48</sup> These formulations showed effective GFP knockdown in bronchoepithelium. Antisense oligonucleotides (ASOs) that are heavily modified with LNA bases and phosphorothioate (PS) internucleoside linkages can cause significant hepatotoxicity in mice.<sup>49</sup> Similar reports have not appeared for LNA-modified siRNAs, possibly because of an inherent lower toxicity of this type of compound (dsRNA with phosphodiester linkages) or use of a reduced number of modified residues.

Although DNA is not normally thought of as a “chemical modification,” substitution of DNA in place of RNA residues in a siRNA nevertheless represents modification and introduces changes in the steric and electronic characteristics from the natural siRNA design. Chang and colleagues used a deoxyinosine/2'OMe/DNA mixer hybrid passenger strand duplexed with an unmodified guide strand to suppress *HER2* expression.<sup>50,51</sup> Ui-Tei and colleagues incorporated DNA bases into the seed region (bases 2–8 from the 5'-end of the guide strand) which maintained siRNA potency and simultaneously decreased OTEs.<sup>52</sup> The improvement in sequence specificity may result from the reduced stability of a DNA/RNA hybrid duplex as compared to an RNA/RNA hybrid.

Work from Wengel, Kjems, and colleagues has produced a variety of novel chemical modifications that can be used in siRNA. By alkylating the 2'-oxygen with various substituents, they have shown aminoethyl-, guanidinoethyl-, cyanoethyl- and allyl-modifications to be effective at increasing serum stability.<sup>53</sup> Of perhaps greater utility, properties of unlocked nucleic acids (UNAs, which are acyclic, lacking a C2–C3 bond in the ribose ring) as modifiers for siRNAs were described in several recent publications.<sup>54</sup> UNAs have been successfully combined with LNAs to improve the relative stability of siRNA termini.<sup>55</sup> Furthermore, siRNAs having UNA modification of all bases of their 3'-overhangs showed increased stability in mouse serum as well as improved EGFP knockdown when dosed subcutaneously (s.c.) in a xenograft tumor model of human pancreatic cancer in mice.<sup>56</sup> UNAs have also been used in a high-throughput study to identify key locations of destabilization in siRNAs that could lead to a reduction in OTEs,<sup>57</sup> which is discussed in greater detail below.

Alterations to the sugar-phosphate backbone can significantly increase nuclease stability. The most commonly used chemistry in this class is the PS modification, where a nonbridging oxygen is replaced by a sulfur group in the internucleoside phosphate linkage. This modification has extensive historical usage *in vivo* and as a drug in human clinical trials; its pharmacology and toxicology are well established, at least in the context of single-stranded ASOs.<sup>58–62</sup> Limited use of the PS modification can improve nuclease stability while retaining functional potency.<sup>36</sup> Furthermore, PS-modified siRNAs may show improved cellular uptake in the absence of a transfection reagent;<sup>63</sup> however, naked delivery is always less potent than assisted delivery. A landmark report that first demonstrated

systemic dosing of siRNAs to nonhuman primates utilized a siRNA containing PS linkages as well as 2'OMe-modified residues to silence *Apob*.<sup>64</sup> In another report, a 27/29-nt siRNA containing similar backbone and 2'-modification was conjugated to  $\alpha$ -tocopherol (vitamin E) at the 5'-end of the guide strand.<sup>65</sup> Endogenous dicing of the  $\alpha$ -tocopherol-conjugated anti-*Apob* siRNA was confirmed by northern blot analysis to produce a functional 21-nt siRNA. Apolipoprotein B (APOB) levels in mice were reduced in the liver following i.v. administration, while control nontocopherol-modified anti-*Apob* siRNA showed no evidence for silencing.

The role of chemical modifications in siRNAs used *in vivo* will be further discussed in specific examples below.

### siRNA design

Endogenous siRNAs are 21-nt dsRNAs with a 19-nt central duplex domain and 2-nt 3'-overhangs on each strand. The first generation of chemically synthesized artificial siRNAs mimicked the natural product but replaced the 2-nt 3'-RNA overhangs with DNA, typically using a “TT” dimer.<sup>6</sup> It soon became clear that use of DNA bases in the overhangs slightly reduced potency compared with the natural RNA design and offered no real advantages.<sup>66–68</sup> Furthermore, a recent report demonstrated that dT overhangs in siRNAs can inhibit thymidylate synthase, an important enzyme for cell growth and metabolism, leading to unwanted OTEs.<sup>69</sup> It is therefore preferred to employ target sequence-matched RNA or RNA derivatives in the overhang, at least on the guide strand. Asymmetric designs, where a single 3'-overhang is positioned on the guide strand, appear to bias loading of that strand (which is desirable) and can offer further increases in potency.<sup>70</sup> An asymmetric 21/23-nt duplex of this design was employed to suppress APOB expression in nonhuman primates.<sup>64</sup>

A variety of siRNA design variants have been described which may improve on some properties of the natural 21-nt structure. Despite good evidence for some of these designs having increased potency or decreased side effects, synthetic 21-nt siRNAs remain the primary compounds in use today. A recent review by Chang and colleagues discusses the various design strategies tried to date to improve properties of synthetic triggers of RNAi.<sup>71</sup> The present review will only briefly consider a subset of these design variants and readers are referred to Chang for more details.

Blunt RNA duplexes in the 19–23-nt length range have been extensively used, especially when heavily modified with 2'OMe RNA in patterns which reduce loading of the passenger strand into RISC.<sup>72–74</sup> Compounds of this design are being taken into clinical trials by Silence Therapeutics.<sup>8,9</sup> Absence of a 3'-overhang limits PAZ domain binding, which may adversely affect potency. However, the single-stranded 3'-overhang in traditional siRNAs is highly susceptible to nuclease attack so its retained presence *in vivo* is not assured. Longer 25-nt blunt designs which are also highly 2'OMe-modified have also been used with good results.<sup>75</sup> Although duplexes of this length would normally be processed by Dicer to 21-nt size, the chemical modification patterns employed in this study prevent dicing from occurring, which did not seem to interfere with RISC loading or functional potency.<sup>76</sup>

The natural pathway for RISC formation starts with processing of a long dsRNA by a Dicer/TRBP heterodimer complex.<sup>77–79</sup>



The nascent 21-nt siRNA remains associated with Dicer/TRBP and is transferred to Ago2,<sup>80,81</sup> where it is converted to single-stranded form with the guide strand being retained with Ago2/RISC.<sup>82,83</sup> RISC is now activated and capable of the sequence-specific cleavage of a target mRNA. It was proposed in 2005 that invoking the natural RISC loading pathway by using synthetic Dicer-substrates as triggers of RNAi might show improved potency or different properties than are seen using synthetic Dicer products. Small synthetic dsRNAs in the 25–30-nt size range were tested for the ability to function as siRNAs, and it was found that, for some sites, these longer duplexes were indeed more potent than the cognate 21-nt siRNAs.<sup>84</sup> However, at other sites, the two designs were equipotent or the 21-nt siRNAs were more potent. The original compounds tested were blunt, unmodified RNA duplexes which were processed by Dicer into multiple 21-nt siRNAs. The dominant 21-nt species varied with sequence context in an unpredictable way. Use of asymmetric RNA duplexes having a 25-nt passenger strand and a 27-nt guide strand with a single 2-nt 3'-overhang on the guide strand showed much more predictable dicing patterns. Substitution of two DNA bases at the 3'-end of the passenger strand (at the blunt end) further improved reliability of Dicer cleavage, and this new design was proposed for general use as a Dicer-substrate siRNA (DsiRNA).<sup>85</sup> It was observed that the duplex orientation during dicing of these compounds influenced strand loading in RISC. Dicer has now been shown to directly participate in strand selection and the positioning of the siRNA within the Dicer complex and is pivotal in determining which strand remains with Ago2 in RISC.<sup>86</sup> Like 21-nt siRNAs, 27-nt DsiRNAs can be modified with 2'OMe or 2'F substitutions and show improved properties, such as increased nuclease stability and reduced immune activation, so long as the appropriate domain remains unmodified as a site for Dicer cleavage to occur.<sup>65,87–89</sup> Increasing the length of synthetic shRNAs may also improve potency;<sup>90</sup> however, these long, structured RNAs are difficult to manufacture. Conversely, it was shown that synthetic hairpins which are shorter than 21-nt in length may also have improved function,<sup>91,92</sup> and these compounds present no barriers for synthesis.

siRNA variants which are shorter than the traditional 21-nt size have also been successful. Asymmetric siRNAs having a 19-nt guide strand paired with a passenger strand as short as 15-nt retained high functionality while eliminating all potential OTEs from the passenger strand, which was too short to function in RISC.<sup>93,94</sup> Other groups have found that shorter siRNAs show reduced potency compared with siRNAs of traditional length.<sup>95</sup> A more complex design was used effectively by Petrova and colleagues, who reported use of 2'OMe-modified “fork-siRNA” duplexes that improve nuclease resistance and prolonged silencing of *ABCB1* twice as long as an unmodified analog.<sup>96</sup> The “fork-siRNA” work is based on earlier publications that reported 3'-sense strand thermodynamic destabilization caused by incorporating strategically positioned mismatches led to improved antisense strand incorporation into RISC and increased siRNA potency.<sup>97,98</sup>

## OTEs

OTEs include both activation of the innate immune system by siRNAs as well as the unintended knockdown of nontargeted mRNAs through either Ago2-mediated mRNA cleavage or through

the miRNA pathway.<sup>99–102</sup> Historical experience using ASOs initially led researchers to expect that simple homology searches could be used to predict the risk of targeting unintended genes that share sequence similarity with the siRNA. While homology searches remain a necessary step to eliminate overt crossreactivity, screens of this stringency are inadequate to predict the actual risk of OTEs. Birmingham and colleagues demonstrated that high complementarity throughout the entire 21-nt guide strand is not required and that significant OTEs can be mediated by as little as the 7-nt domain that comprises the guide “seed region”—nucleotides 2–8 at the 5'-end of the guide strand.<sup>99,103</sup> Seven base sequence motifs are abundant in the transcriptome, and the number of mRNAs that contain potential seed-region binding sites for a given siRNA usually number in the thousands. Importantly, the presence of a “seed match” in the 3'-UTR of an mRNA does not necessarily correlate with the capability to be regulated by miRNA-like interactions with siRNAs; in fact, most sequence matches of this kind show no effect at all and predicting which sites are “real” versus which sites are short regions of homology of no consequence is difficult, making screening and prediction of OTEs difficult. Heptamer motifs are not uniformly expressed in the 3'-UTRs of mammalian genes and a correlation does exist between the frequency of expression of a motif and the relative risk that sequence bears as a trigger for OTEs.<sup>104</sup>

Recently, both chemical modification and variations in siRNA design have been successfully employed to limit the risk of OTEs. Jackson and colleagues found that placing a single 2'OMe residue at position 2 of the guide strand was sufficient to block OTEs due to seed region complementarity in many sequences tested.<sup>105</sup> Unfortunately, this modification pattern can reduce potency of the siRNA (sequence context dependent) and may not be a universal solution to the problem. OTEs resulting from seed homology have also been reduced by substituting DNA bases in the seed region and its complementary region on the passenger strand, along with the 5'-end of the guide strand and the 3'-overhang of the passenger strand.<sup>52</sup> Using luciferase expression from a psiCHECK2 plasmid reporter, four different, unmodified siRNAs known to have significant OTEs arising from the passenger strand had this unwanted activity blocked by modification with 10 DNA bases at the 3'-end of the passenger strand and 8 DNA bases at the 5'-end of the guide strand.

Selective placement of LNA residues may help reduce OTEs more efficiently than 2'OMe modifications.<sup>106</sup> Transfections with siRNAs containing various LNA and 2'OMe patterns were compared for their effects on 47,000 different genes by global gene profiling. Certain LNA modification patterns were capable of reducing the OTEs without reducing potency. Both LNA and 2'OMe modifications are stabilizing, *i.e.*, they increase the  $T_m$  of the siRNA duplex. More recently, Bramsen and colleagues demonstrated that placing a single UNA residue in the seed region (at position 7 from the 5'-end of the guide strand) was particularly effective in decreasing OTEs.<sup>57</sup> Incorporation of a UNA modification at position 7 was the most effective variant found for reducing OTEs compared to 10 other chemical modifications tested at various positions within a set of siRNAs specific for three different targets. The beneficial effects of a UNA base at position 7 of the guide strand were independently verified by Vaish and colleagues

who additionally found that adding UNA residues at the 3'-ends of both strands increased stability of the siRNA (presumably by reducing 3'-exonuclease attack). Placing a UNA residue at the 5'-end of the passenger strand blocked its ability to participate in RISC and thereby eliminated any OTEs originating from that strand.<sup>107</sup> As a general rule, modifications that eliminate the passenger strand from being functional in RISC will prevent OTEs that may arise from that strand and may also improve potency of the guide strand by reducing competition for RISC loading.

A variety of approaches can be used to block passenger strand participation in RISC. Ago2 recognizes the 5'-phosphate present on natural siRNAs. Chemically synthesized siRNAs can exhibit the same potency whether they have a 5'-phosphate or a 5'-hydroxyl group present because the 5'-hydroxyl is rapidly converted to the 5'-phosphate form in cells after transfection.<sup>108</sup> Groups that block the ability of the passenger strand to be phosphorylated, such as 5'-O-methylation, will reduce the ability of that strand to load into RISC and reduce OTEs which would otherwise arise from that strand.<sup>109</sup> Blocking the 5'-end of a strand is not always completely effective, however, so additional strategies may also need to be employed.<sup>110</sup> Small internally segmented interfering (sisi)-RNAs are a design variant where the passenger strand is synthesized as two separate oligos which anneal adjacent to each other on an intact guide strand, mimicking natural cleavage by Ago2.<sup>111</sup> The use of  $T_m$ -enhancing LNA modifications improves the stability of hybridization of the short passenger strand fragments and improves performance of this approach. The segmented passenger strand is inactive in RISC and therefore cannot contribute to any OTEs.

### Innate immunity

Mammals have evolved two active immune pathways to counter the wide range of biological threats encountered in the environment. The adaptive immune system employs receptor systems which have hundreds to thousands of gene elements that recombine and mutate to evolve antibody and T-cell responses having exquisite specificity. Adaptive immunity can take months to mount a maximal response. In contrast, the innate immune system relies on a small number of fixed receptors that identify and respond to the presence of known, potentially foreign molecules which are "high risk" for the host. Innate immunity is rapid but can only respond to a limited collection of predefined triggers. A subset of innate immune receptors recognize foreign DNA [Toll-like receptor 9 (TLR9), recognizes DNA with unmethylated CpG motifs] and foreign RNA (TLRs 3, 7, and 8, MDA5, RIG-I, PKR, OAS, and others), and it is important to understand the basis of these immune responses and have strategies to evade them when employing synthetic nucleic acids in any mammalian system. Many of these receptors can bind and respond to highly structured self RNAs and a mixture of endogenous chemical modification strategies and compartmentalization help restrict these responses (albeit not always successfully). It is critical to consider the potential for immune responses when designing and interpreting siRNA experiments, and it appears that some early siRNA successes, particularly in treating viral infections, may have had a large unrecognized immune component.<sup>112</sup> While one typically considers an innate immune response to a synthetic nucleic acid to be an

undesired OTE, there are circumstances where immune stimulation may be beneficial and could be exploited therapeutically.<sup>113,114</sup> A number of excellent reviews of this important subject have been published and readers are referred to recent work from Judge and MacLachlan,<sup>115</sup> Robbins *et al.*,<sup>116</sup> Krieg,<sup>117</sup> and Hennessy *et al.*<sup>118</sup> In spite of the existence of many publications that demonstrate the importance of immune effects, a surprisingly large percentage of *in vivo* studies seem to ignore this problem (including many of the manuscripts discussed in the present review) and readers are advised to consider this when evaluating all *in vivo* RNAi work.

Of the various receptors that perform surveillance for the innate immune system, TLR3 binds dsRNA and TLRs7/8 bind single-stranded RNA; all three of these receptors can detect synthetic siRNAs. Due to their primary localization in the endosomal compartment, these receptors most readily recognize and bind ligands during internalization of siRNAs complexed with cationic lipids and polymers. Other modes of delivery such as electroporation, hydrodynamic delivery, or peptide transduction can bypass transit through this compartment and often evade detection by these receptors.<sup>119</sup> Likewise, shRNAs endogenously synthesized within the cell from a viral template are less likely to trigger an interferon response than when the same sequences are chemically synthesized and exogenously transfected with lipid-based reagents.<sup>120</sup> Several cytoplasmic localized receptors recognize foreign RNAs, including PKR, OAS, MDA5, and RIG-I. Fortunately these receptors primarily recognize dsRNAs which are longer than traditional siRNAs (PKR >30, OAS >60–70)<sup>121,122</sup> or have different end structures than standard siRNAs. For example, RIG-I recognizes a 5'-triphosphate end, which is generated *in vivo* during viral replication or on *in vitro* transcription products but is not triggered by the 5'-cap structure present on mammalian mRNAs.<sup>123–125</sup> RIG-I may also be activated by blunt ends in longer dsRNAs.<sup>126</sup>

Strategies exist to enable synthetic siRNAs to evade detection by the innate immune system through design and chemical modification. As mentioned above, most of these receptors preferentially recognize long RNAs better than short RNAs, and siRNA designs which employ shorter sequences (such as asymmetric siRNAs) will generally have a lower risk of triggering an immune response than longer sequences (such as DsiRNAs). Long dsRNAs naturally exist within mammalian cells and these usually do not elicit an immune response; this is achieved by compartmentalization (exclusion of these RNAs from endosomal TLRs) and endogenous chemical modification. Sugar modifications, such as 2'OMe RNA, and some base modifications, such as pseudouridine, are common in mammalian tRNAs and rRNAs and help these large, highly structured species to evade initiating an autoimmune response. In contrast, foreign RNAs (such as viral RNAs or exogenous synthetic species), which do not bear such modifications, typically trigger immune responses.<sup>127</sup> Of the various chemical modifications that can be employed to help synthetic siRNAs evade immune detection, 2'OMe RNA is the most commonly used. It is a naturally occurring RNA variant that is relatively inexpensive and also improves nuclease stability. Extensive modification is not necessary and fewer than 20% of residues can be modified and still block immune responses.<sup>128</sup> Furthermore, 2'OMe-modified siRNAs function as competitive antagonists of TLR7 that can act in *cis* or in *trans* and retain inhibitory efficacy when dosed as

either single- or dsRNAs.<sup>129</sup> In fact, 2'OMe-modified siRNAs can block TLR7 activation induced by the small molecule agonist loxoribine. Other 2'-modifications, such as 2'F and LNA, also help to evade immune detection.

When critically evaluating work done using siRNAs *in vivo* for the various complications that can arise from immune responses, it is important to keep some basic facts in mind. Studies done *in vitro* that employ cell lines such as HeLa or HEK293, which do not express TLR7 or 8, do not support conclusions that the compounds under investigation do not have immunostimulatory potential. Ideally, *in vitro* studies should be performed using a mixed population of primary immune cells, such as fresh peripheral blood mononuclear cells. Most importantly, signs of immune activation should be tested *in vivo*. It is important to look for immune activation at 4 and 24 hours postadministration to catch both the early and late phase responses. Studies that only examine cytokine levels or look for activation of inflammatory pathway genes at 24 hours can easily miss important signs of immune stimulation.

## OVERVIEW OF STUDIES USING siRNAs IN MAMMALS

### Pharmacokinetic and pharmacodynamic evaluation

**Whole animal imaging and reporter systems.** The challenges to systemic use of siRNAs in animals are well-known: nuclease instability, poor bioavailability, and lack of tissue-targeting. The issues associated with pharmacokinetics (PK) and pharmacodynamics (PD) cumulatively represent the most significant hurdle to therapeutic application of this technology. siRNA sequences that mediate potent knockdown for any gene of interest can readily be obtained today. For this reason, there is an emphasis on developing suitable delivery vehicles to make functional siRNAs available in the desired tissue. Many *in vivo* siRNA studies have been done without any therapeutic target with the objective of characterizing the capabilities of various delivery systems and studying PK/PD. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are imaging technologies that have been applied to define the PK and biodistribution of siRNA nanoplexes. Use of whole-animal imaging modalities is beneficial because measurements do not require animal sacrifice to harvest tissue for a biochemical assay. Rather, these assay methods allow for facile, rapid, quantitative, and serial data collection from the same cohort of animals over an extended time course.

Several proof-of-principle experiments have been done using PET or SPECT imaging of injected siRNAs. In the first example, siRNA biodistribution following i.v. administration in Balb/c mice was measured by dual isotope SPECT (<sup>111</sup>In-labeling of siRNAs and <sup>99</sup>Tc-labeling of bone for anatomical orientation), and was found to correlate reliably with results obtained by tissue harvesting and scintillation counting of dissected tissue.<sup>130</sup> Next, the PK of <sup>111</sup>In-labeled free siRNAs was compared to that of polyethyleneimine (PEI)-complexed siRNAs. The two formulations showed different distribution patterns at 2 hours following i.v. administration at which time the PEI-complexed siRNAs showed significantly greater accumulation in the stomach compared to the free siRNAs. The key finding was that the endpoint data for free siRNAs and

PEI-siRNAs was well-correlated when assayed by either SPECT or by tissue harvest followed by scintillation counting. Finding the same result using both assays validated the use of whole-animal SPECT as a viable method for siRNA quantification.

The positron-emitting isotope <sup>18</sup>F can be conjugated to siRNAs and used for PET imaging.<sup>131,132</sup> Dynamic and quantitative PET imaging performed following i.v. administration of <sup>18</sup>F-labeled siRNAs to rats indicated that native 2'OH-siRNAs, 2'OMe-siRNAs, and 2'F-siRNAs were all rapidly eliminated by renal excretion ( $t_{1/2}$  = 1.9, 1.9, and 6.7 minutes, respectively). 2'F-modified siRNAs had a slightly higher bioavailability, but none of the modified siRNAs showed significant luciferase knockdown in a xenograft tumor model expressing the reporter gene. Gary and colleagues also used PET imaging to compare siRNA uptake in a murine tumor model via polyethyleneglycol-conjugated (PEGylated) polyplexes with poly(dimethylaminoethyl methacrylate) (PDMAEMA) and PEGylated micelleplexes (triblock copolymer).<sup>133</sup> A 6-hour biodistribution analysis showed a predominance of the remaining signal in the gastrointestinal tract and gall bladder, with 10–15% of injected dose seen in each tissue for both delivery systems. The micelleplexed siRNAs did show slightly higher tissue retention in lung and tumor tissue when compared to polyplexed siRNAs, likely a result of the larger particle size. In summary, PET imaging is a useful method to noninvasively quantify the biodistribution and PK of siRNA delivery. The results of the study further underscore the importance of a functional delivery system for i.v.-administered siRNAs.

Mudd and colleagues recently reported a PK study<sup>134</sup> that suggests tissue-specific targeting could be achieved using siRNA-containing “dynamic polyconjugates (DPCs)”<sup>135</sup> This group employed a hybrid PET plus computed tomography (CT) imaging method to gain further insights into their synthetic siRNA delivery system. Both components of the delivery system, siRNAs stabilized by 2'OMe- and PS-modifications and the endosomolytic, amphipathic polymer of butyl and amino vinyl ethers, were modified with Cu-chelating DOTA and subsequently labeled with the positron-emitting isotope <sup>64</sup>Cu. The CT contrast agent, eXIA 160 was employed to accurately define the liver. As expected, free siRNAs administered i.v. to mice was rapidly cleared with >60% of the injected dose lost in the urine after 25 minutes. PET-CT imaging showed that 60% percent of the injected dose of the siRNA-polymer complex accumulated in the liver after just 5 minutes. The total accumulation of siRNA-DPC in the liver was 70% over the course of 1 hour following i.v. administration. Polymer-alone had a slower onset of accumulation, but >90% of the injected dose appeared in the liver after 1 hour.

Bioluminescence imaging (BLI) is commonly used to quantify luciferase expression from reporter systems in whole animals. As opposed to the PK of a siRNA nanoplex that can be measured by PET, BLI provides a reliable assay system for quantifying the functionality of siRNAs *in vivo*—or for assessing the PD. Work from the Davis lab in 2007 combined both imaging modalities to characterize the PK and PD of siRNA delivery.<sup>136</sup> They employed PET to track the biodistribution of <sup>64</sup>Cu-labeled siRNAs delivered by i.v. administration complexed with a cyclodextrin-based nanoparticle. siRNAs were shown to rapidly accumulate in the kidneys and subsequently in the bladder for excretion. This was true for



both transferrin (Tf)-targeted polyplexes and those that did not contain a targeting ligand. Tumor localization as measured by PET for targeted versus nontargeted polyplexes was also quite similar. BLI was used to quantify luciferase knockdown in a constitutively expressing murine tumor model. The functionality of the Tf-targeted siRNAs was improved by >50% compared to nontargeted formulations, suggesting that the Tf-targeting ligand enabled receptor-mediated endocytosis and promoted internalization necessary for siRNA function. Further work by Bartlett and Davis compared the PD of chemically modified (siSTABLE siRNA) and unmodified siRNAs.<sup>137</sup> Following hydrodynamic tail vein administration in mice, improved knockdown of luciferase activity in the liver was seen using the modified duplexes. Mathematical modeling of the data suggested that the main advantage of using modified siRNAs occurs before and during uptake into cells. Once the siRNAs were intracellular, kinetics were not predicted to be significantly affected by chemical modification.

Calando Pharmaceuticals (Pasadena, CA) used BLI to screen siRNAs for *in vivo* efficacy against the M2 subunit of ribonucleotide reductase, *RRM2*.<sup>138</sup> A lead siRNA sequence targeting *RRM2* was identified from an *in vitro* screen, and the anti-*RRM2* siRNA (2.5 mg/kg) was coadministered via hydrodynamic dosing with a plasmid expressing the *RRM2*-luciferase fusion protein (0.25 mg/kg). Luciferase expression in the liver was observed via BLI over the course of 17 days. Compared to controls dosed with the plasmid alone or plasmid plus control siRNAs, the anti-*RRM2* siRNA showed 90% knockdown on day 2 and ~85% on day 17. These values were very similar to hydrodynamic coadministration of the reporter plasmid and control siRNA targeting *Luciferase*. This study also serves to demonstrate how BLI can be a useful assay for validating the efficacy of siRNAs *in vivo*.

One of the challenges to using BLI as an assay for PD of systemically delivered siRNAs is achieving stable, consistent luciferase expression in a targeted tissue of interest. Svensson and colleagues developed a mouse which ubiquitously expresses luciferase via Cre-mediated recombination and removal of the stop codon from the *Rosa26-Lsl-Luc* allele. They demonstrated stable, uniform luciferase expression in all tissues in the new "Flash" mouse. Further, they were able to show luciferase knockdown via a novel lipidoid compound (98N<sub>12</sub>-5 from Alnylam Pharmaceuticals, Cambridge, MA) formulated with siRNA specific for the *Luciferase* gene. The siRNA, dosed i.v. at 5 mg/kg, had 2'OMe-modified pyrimidines in the sense strand, and the terminal 3'-linkages were PS-modified on both strands. Luciferase levels were evaluated after 72 hours by BLI which demonstrated an 80% decrease in luminescence compared to control animals dosed with siRNA targeting *F7* (factor VII). The knockdown was observed to be liver-specific. This type of animal model could facilitate rapid, high-throughput screening of delivery systems for siRNA delivery.<sup>139</sup>

Similar to the improved luciferase-expressing mouse, scientists at Sirna developed a mouse model with liver-specific luciferase expression that is induced by a liver-targeting adeno-associated virus (AAV) expressing recombinant Cre.<sup>140</sup> The group systematically studied animals over a 25-day time course for luciferase knockdown in the liver using various doses of lipid nanoparticle-formulated siRNAs. In addition to the PD effects, the authors quantified the total amount of siRNA in the liver

and the fraction of Ago2-associated siRNAs at each time point over the duration of the study. They demonstrated a direct relationship between *Luciferase* mRNA, protein, and Ago2-bound siRNAs; however, total siRNA levels in the liver were in vast abundance and did not correlate well with luciferase knockdown. This suggests that guide strand loading into Ago2 is the rate-determining step for *in vivo* RNAi. This model of tissue-specific luciferase expression is advantageous because it cannot be influenced by background expression from any neighboring tissue. BLI has been used in combination with hydrodynamic injection of a luciferase plasmid to achieve substantial expression in the liver which can also serve as a model to assess siRNA-mediated knockdown *in vivo*.<sup>137</sup>

Aside from bioluminescence, whole animal fluorescent imaging can detect the presence of near-infrared (NIR) dyes through mammalian tissue. Fluorescence has been used to compare the distribution patterns of cholesterol- and RGD-conjugated Cy5-siRNAs. Results from this study of PK suggest that liver-accumulating siRNAs are readily eliminated via the gall bladder and small intestine. This has been previously observed,<sup>133</sup> but a novel elimination pathway was validated here following bile duct ligation which blocked the appearance of Cy5-siRNA fluorescence in the gastrointestinal tract.<sup>141</sup> Also, work by Yagi and colleagues demonstrated that Cy5-labeled siRNA formulated as a cationic lipid complex could be delivered systemically to mice bearing s.c. tumors.<sup>142</sup> Cy5 fluorescence was observed in tumor tissue 11 days postinjection. Functionally, these same siRNAs targeting *Klf5* to inhibit tumor angiogenesis showed a 50% reduction in tumor volume 10 days following i.v. doses on days 2–8. Xiong and Lavasanifar recently described a multifunctional micelle delivery system for siRNAs.<sup>143</sup> They incorporated poly(ethylene oxide) and poly( $\epsilon$ -caprolactone) both functionalized with either poly(ethylene amine) or doxorubicin. Additionally, polymeric backbones were coupled to RGD or TAT peptides. Upon assembly, the polymer-peptide micellar "shell" surrounded the doxorubicin and anti-*Abcb1* siRNA. Cy5.5 labeling of the delivery vehicle, as well as Dy-677 labeling of siRNAs enabled whole-animal, NIR imaging, demonstrating that both components colocalized in the same multidrug resistant tumor xenografts in mice. Tumor localization was dependent on the presence of the RGD peptide for targeting. This particular study was a proof-of-principle delivery experiment which stopped short of demonstrating an increase in chemotherapeutic efficacy gained by doxorubicin delivery coupled with ABCB1 knockdown.

Whole-animal imaging experiments discussed to this point all employed i.v. dosing. Whole animal imaging techniques have also been used to study intraperitoneal (i.p.) dosed siRNAs. Huang and colleagues used CT and BLI to noninvasively assess the PD of lipidoid nanoparticles in a murine model for ovarian cancer.<sup>144</sup> Tumor-bearing mice were i.p.-dosed with 2'OMe-modified siRNA targeting *CLDN3* formulated with the lipidoid 98N<sub>12</sub>-5. Mice were dosed twice weekly over the course of 3 weeks and anti-*CLDN3*-treated mice showed no increase in ovarian cancer tumor load over 3 weeks; the same tumors grew more than fivefold in volume when treated with nontargeting siRNAs as measured by micro-CT. In the same way, a luciferase-expressing mouse tumor model was used to demonstrate that these same formulations and dosing regimen did



not show any significant increase in tumor volume over the course of 3 weeks as measured by BLI. Mice that were untreated or treated by a nontargeting siRNA did not survive the 3-week duration of the experiment due to rapidly increasing tumor volumes.

Abbott labs reported development of a novel, positive-readout assay system for monitoring the PD of siRNA delivery vehicles.<sup>145</sup> Tet Repressor (TetR) is a protein that binds the tet operon promoter sequence such that TetR homodimers block promoter function and prevent expression of any linked gene. Suppression of TetR removes this block, allowing expression, which in this case was either a  $\beta$ -galactosidase or luciferase gene. Potent siRNAs have been validated against *tetR* and successful delivery of these duplexes into cells bearing the *tetR*-reporter transgene results in the appearance of a detectable signal from the reporter. The positive-readout reporter system was used to test the efficiency of siRNA delivery by several common lipid and polymeric systems. Interestingly, upon testing 16 combinations of delivery systems by 3 routes of delivery, only 1,2-dioleoyl-3-(dimethylamino) propane (DODAP)-based liposomes and stable nucleic acid lipid particles (SNALPs) gave a positive readout with an i.v. dose (2.5 mg/kg dosed twice) targeting a liver tumor. This novel reporter system greatly reduces background signal, and ubiquitous expression of TetR and the reporter gene allows the PD to be assayed in a tissue-specific manner.

**In vitro PK/PD assays.** Quantitative reverse transcription PCR (RT-qPCR) is a sensitive and robust method to quantify mRNA in harvested tissue to assess the PD of a siRNA polyplex. Since mRNA is the endogenous biomolecule targeted by siRNAs, this assay is not only relevant to proof-of-principle delivery experiments; determining mRNA levels is a much more direct measurement of siRNA function than phenotypic readouts usually employed in mouse models for a particular disease state. However, a recent manuscript identified a potential artifact encountered when using RT-qPCR on *in vivo* samples.<sup>146</sup> When high doses of siRNAs were given locally to a tissue, the siRNA guide strand was retained in the isolated cellular RNA. If the qPCR assay primers flanked the siRNA target site, the retained 2'OMe-modified guide strand inhibited the reverse transcription (RT) reaction and to a lesser extent qPCR, resulting in a false positive result (*i.e.*, incorrectly observing reduced levels of the target gene of interest).

RT-qPCR is the most widely used method to quantify knock-down mediated by siRNAs. A recent report on the biodistribution and kinetics of (lipid nanoparticle) LNP201-siRNA delivery system used stem-loop RT-qPCR to quantify the amount of siRNAs in various tissues following i.v. administration (3 mg/kg via tail vein).<sup>147</sup> Organ accumulation of siRNAs was greatest in the liver > spleen > kidney; whereas, the duodenum, lung, heart and brain showed minimal accumulation. Fluorescence microscopy of tissue sections showed very similar biodistribution results of siRNAs containing a 5'-Cy5 label on the passenger strand. Further, the authors used immunofluorescence staining to characterize uptake in different cell types within the liver. LNP-siRNAs were delivered to both Kupffer Cells and hepatocytes in a time-dependent manner. Consideration of uptake by Kupffer cells may warrant greater attention, as clearance by the mononuclear phagocytic system in the liver may play an important role, especially when siRNAs are administered i.v.

5'RACE-PCR (rapid amplification and cloning of ends) is the definitive method to confirm that mRNA cleavage occurred via an Ago2 mechanism of action following siRNA transfection. The 5'RACE protocol places an oligonucleotide linker at the newly formed 5'-end of an mRNA following Ago2 cleavage. When mediated by RISC, cleavage occurs precisely 10 bases from the 5'-end of the siRNA guide strand. The linker provides a forward PCR primer binding site and PCR is done using a gene-specific reverse primer located 3'-to the cut site. Demonstrating the existence of a cleavage product at this precise location is diagnostic that mRNA cleavage occurred via an RNAi mechanism of action. Note, however, that showing a positive 5'-RACE result does not exclude the possibility that coexisting immune or other OTEs may still contribute to any observed phenotype. Judge and colleagues used 5'RACE-PCR to demonstrate cleavage of the *PLK1* target in regressing tumors in mice treated with an anti-*PLK1* siRNA delivered in SNALPs.<sup>148</sup> Using RNA isolated from the treated tumor cells, RT was performed using gene-specific primers followed by PCR, which resulted in an amplicon of the expected size. Sequencing of this amplicon confirmed the position of the cleavage site. This cleaved sequence was found in tumors of all mice treated with the anti-*PLK1* siRNAs and was not found in mice treated with nontargeting, control siRNAs. 5'RACE-PCR has been employed by many investigators as part of their evaluation of siRNA experiments performed *in vivo* and is the "gold standard" to identify RNAi mechanism of action.<sup>64,148-152</sup>

## Systemic delivery

***i.v. administration*** *i.v.* administration is generally the most effective way to achieve systemic delivery of a large molecule drug. For nucleic acids, serum is a relatively hostile environment and the various proteins and nucleases present in circulation require that the siRNAs be protected by the delivery system and/or by chemical modifications. Ideally, the delivery system should also include some type of targeting component that leads to preferential accumulation of the siRNAs in the organ/tissue of interest. Compared to local delivery, *i.v.* dosing requires a significantly larger amount of siRNAs in order to achieve the same bioavailability at the site of action, especially in the absence of any targeting ligands. A variety of different strategies have been employed to try to achieve these goals.

***Liposomes and other lipid-based nanoparticles.*** Liposomes and other lipid nanoparticles are commonly employed to deliver siRNAs *in vivo*. siRNAs can be formulated in liposomes from several commercial sources with proprietary lipid compositions. Likewise, the use of dioleoylphosphotidylethanolamine (DOPE), 1,2-dioleoyl-3-(trimethylammonium) propane (DOTAP) and cholesterol to form cationic liposomes via solvent-emulsion methods is commonly used to "generically" formulate particles. Toxicity of these vehicles can be limiting and a variety of different chemical modification strategies have been employed to mitigate the problem.<sup>153-155</sup>

Atu027 is a 23-nt, 2'OMe-modified blunt design siRNA<sup>156</sup> that is now in clinical trials as part of the Silence Therapeutics program. This siRNA targets protein kinase N3 (*PKN3*). It is formulated as a lipid nanoparticle AtuFECT01 and has been studied using *i.v.* administration in two mouse models of induced lung

metastasis.<sup>74</sup> The AtuFECT01 lipid has previously been shown to target vascular endothelium, so mechanism of action will likely be vascular and not in the tumor cells themselves.<sup>157,158</sup> Tail vein injection of either B16 melanoma cells or Lewis lung carcinoma cells results in rapid tumor growth in the lungs and is a good model for metastatic disease. Mice were treated with Atu027 (1.88 mg/kg) beginning one day after tumor cell injection and were dosed i.v. every other day for 16 days. At day 16, the mean lung weight in Atu027-treated mice was less than half that of the negative control group (treatment with a vehicle dose of 270 mmol/l sucrose, not a control siRNA-lipid formulation). Upon macroscopic evaluation, there was a significant reduction in tumor colonization in lungs for both models of induced metastasis.

Yokota and colleagues reported a study in nonhuman primates treating the hepatitis virus GB virus-B (a flavivirus) as a model for hepatitis C virus infection.<sup>159</sup> An unmodified, 21-nt siRNA targeting the 5'UTR of *GBVB* was formulated with a cationic lipid and dosed i.v. at 5 mg/kg daily for 3 days. Viral titers were undetectable for the anti-*GBVB* siRNA-treated cohort; however, administration of a 5 mg/kg dose of a control siRNA also suppressed viral load. An evaluation of interferon levels suggested there may be a nonspecific response of the immune system that reduced *GBVB* levels, but the induction was much lower for the anti-*GBVB*-dosed group. This is taken to indicate that an i.v. dose of the cationic liposome-formulated siRNAs induced an interferon response; yet, anti-*GBVB* siRNA still mediated some target-specific knockdown of the infecting virus. Infectious disease and oncology indications may be areas of siRNA use where the combined effects of immune stimulation plus specific gene target knockdown could combine to give improved results over either effect alone.

Using an arthritis model system, an unmodified 21-nt siRNA targeting *Tnf* was delivered by i.v. injection in mice using a formulation of DOPE combined with the cationic lipid RPR209120.<sup>160</sup> Weekly administration of 10 µg of the formulated siRNAs led to a significant decrease in tumor necrosis factor (TNF) levels as measured by ELISA and resulted in complete regression of the induced arthritis. This work was later expanded to include formulations with siRNAs targeting *Il1*, *Il6*, and *Il18*; wherein, a weekly dosing regimen (2 mg/kg) improved the reduction of all rheumatoid arthritis pathological features to a greater extent than did the anti-*Tnf* siRNA monotherapy.<sup>161</sup>

Delivery of 2'OMe- and PS-modified 21-nt siRNAs to the lung has been demonstrated with a methoxypolyethylene glycol (mPEG)-functionalized lipopolyamine (Staramine) delivery system following i.v. administration (40 µg siRNA).<sup>162</sup> Biodistribution studies showed the lung retained the greatest amount of siRNA at 24 and 48 hours when compared to liver, kidney and spleen on a per gram of tissue basis. Staramine functionalized with a monodisperse (mPEG) (515 Da), as opposed to the polydisperse form, further improved lung targeting. In an attempt to identify the lung cell type targeted by these i.v.-dosed nanocomplexes, the authors demonstrated knockdown of endothelial cell-specific transcripts (*Pecam1* and *Tek*) with the Star-mPEG515 delivery system; whereas, knockdown of epithelial cell-, fibroblast- or leukocyte-specific targets was absent.

The SNALPs from Tekmira Pharmaceuticals (Burnaby, British Columbia, Canada; formerly Protiva Biotherapeutics) have been

employed in multiple studies to deliver siRNAs *in vivo* to hepatic targets. The first large *in vivo* study performed using SNALPs was reported by Morrissey and colleagues in 2005 where unmodified and modified siRNAs were compared for efficacy in reducing hepatitis B virus infection.<sup>163</sup> Using this cationic lipid nanoparticle system, unmodified siRNAs provoked a strong immune response but highly modified siRNAs (including 2'-O-methyl, 2'-F, DNA, and PS bonds) were well tolerated. Without the aid of a delivery tool, the circulating half-life of unmodified siRNAs were only 2 minutes which increased to 6.5 hours when using highly modified siRNAs formulated in SNALPs. Mice given a dose of 3 mg/kg daily for 3 days saw a 10–100 fold reduction in detectable hepatitis B virus DNA levels. The presence of 2'OMe-modified residues was later identified as being the primary modification which blocked immune responses for siRNAs delivered using cationic lipid vehicles, especially on uridine bases.<sup>128</sup>

The SNALP vehicle was employed in the first study of siRNAs delivered to nonhuman primates. A chemically modified anti-*ApoB* siRNA, which was similar to a version previously reported to suppress *APOB* expression in rodents using a cholesterol delivery approach,<sup>149</sup> was administered i.v. to cynomolgus monkeys at doses of 1 or 2.5 mg/kg.<sup>64</sup> An 80% reduction in *ApoB* mRNA levels was seen following a single 1 mg/kg dose, which represents fully a 100-fold increase in potency over the efficacy observed in rats using cholesterol-mediated delivery. At higher doses, significant reductions in serum cholesterol were observed which were sustained for at least 11 days following the end of treatment. RNAi mechanism of action was confirmed by demonstrating the expected Ago2 cut-site in the *ApoB* mRNA using 5'RACE techniques. The treatments were well tolerated, and this study was widely viewed as validation that siRNA compounds might be suitable for drug development in humans.

MacLachlin and colleagues studied use of combined anti-*PLK1* and anti-*KIF11* (KSP1) siRNAs in SNALPs as a potential antitumor therapy. The siRNAs were 2'OMe modified and administered i.v. at a dose of 2 mg/kg. Treatment reduced growth and induced apoptosis in xenogeneic human Hep3B tumor cells implanted in the livers of nude mice or syngeneic Neuro2A tumor cells implanted in the livers of immune-competent A/J mice.<sup>148</sup> Evaluation of serum cytokine levels confirmed the absence of an immune response against the 2'OMe-modified siRNAs in SNALPs. Target-specific cleavage of *PLK1* and *KIF11* mRNA was demonstrated using 5' RACE-PCR, confirming an RNAi mechanism of action. A separate oncology study involving another cell-cycle protein, *COPS5* (CSN5), further demonstrated the effectiveness of SNALPs for systemically delivered siRNAs.<sup>164</sup> In an orthotopic tumor model of hepatocellular carcinoma generated with human Huh7-luc<sup>+</sup> cells, four doses (2 mg/kg/dose) of SNALP-formulated siRNA targeting *COPS5* were given i.v. over the course of 12 days. BLI was used to monitor tumor growth, and the luciferase signal obtained was 50-fold lower in mice receiving the anti-*COPS5* siRNA compared with the cohort that received negative control siRNA targeting β-galactosidase.

siRNAs formulated in SNALPs are also under development as a therapy for infection with hemorrhagic fever viruses, like the Zaire Ebola virus. Following pilot studies in guinea pigs,<sup>165</sup> Geisbert and colleagues reported good results using anti-Ebola

siRNAs to prevent death in nonhuman primates postexposure to a lethal dose of Zaire Ebola virus.<sup>166</sup> A cocktail of three 2'OMe-modified siRNAs targeting the Zaire Ebola virus L polymerase, viral protein 24, and viral protein 35 were administered to macaque monkeys as a 2 mg/kg i.v. infusion at 30 minutes and daily for 6 days postexposure to the virus. All animals given this 7 dose regimen survived infection, while animals given fewer doses showed a mixed response. This offers the first hope of treatment for a disease which otherwise shows as high as a 90% mortality rate.

Improvements to lipid-based formulations are ongoing, and the Anderson and Langer labs described the use of a combinatorial library to create novel lipid compositions and tested these in a high-throughput fashion for improved characteristics as a nucleic acid delivery aid.<sup>167</sup> Some promising new candidates, called "lipidoids," were found; their performance *in vivo* was tested in mice, rats, and cynomolgus monkeys. Additional improvements resulted in nanoparticle formulations with ED<sub>50</sub> values below 0.03 mg/kg in cynomolgus monkeys [using siRNA specific for transthyretin (*TTR*), a gene target of interest for one form of human amyloidosis].<sup>168</sup> Using a different approach, Semple and colleagues used rational design strategies to specifically alter the properties of lipids used in earlier generations of SNALPs to create lipid particles using dimethylaminopropane (DLinDMA) analogs in a search for compounds with improved properties for siRNA delivery. One variant, DLin-KC2-DMA, showed particularly favorable behavior and was tested for performance in mice and in nonhuman primates. In contrast to earlier generations of lipid particles, the performance in mice showed an ED<sub>50</sub> as low as 0.01 mg/kg and in cynomolgus monkeys as low 0.3 mg/kg, at least a tenfold improvement over previous best results.<sup>169</sup> These new highly potent lipid formulations primarily target liver; finding formulations that provide similar high potency delivery to other tissues remains an area of active investigation.

DLinKC2-DMA-based nanoparticles have been recently shown to mediate gene silencing in splenic antigen-presenting cells (APCs).<sup>170</sup> Biodistribution studies following i.v. administration of Cy3-labeled siRNAs delivered by lipid nanoparticles demonstrated uptake by the liver (as noted above) as well as in APCs of the spleen and peritoneal cavity. Additionally, mice were dosed with LNPs (5 mg/kg) containing siRNA targeting *Gapdh*. APCs were harvested and western analysis showed GAPDH expression decreased by 60% relative to a negative control siRNA in F4-80/CD11b- and CD11c-enriched cell populations. Silencing was confirmed to be RNAi-mediated by 5'RACE, and the specificity of LNPs for APCs was shown to be dependent on nanoparticle size—a variable controllable by the ratio of lipid components. Specifically, 80 nm LNPs target siRNAs to hepatocytes as well as APCs whereas 360 nm LNPs show a marked decrease of RNAi in the liver while maintaining potency in APCs.

In a related study, LNPs were used to i.v. deliver siRNA targeting *Ccr2* to inflammatory monocytes.<sup>171</sup> Fluorescence molecular tomography-CT was used in biodistribution imaging of LNPs containing siRNAs labeled with AF-647 (1 mg/kg) and showed peak fluorescence in the spleen on a per gram of tissue basis. Further analysis using flow cytometry specifically identified splenic Ly-6C<sup>high</sup> monocytes as having the highest uptake. RNAi-mediated knockdown of *Ccr2* in Ly-6C<sup>high</sup> monocytes was

confirmed by qPCR, western blot and 5'RACE in mice treated with i.v.-dosed LNPs and on a dosing schedule of 0.5 mg/kg/day for up to 7 days. Importantly, *Ccr2* knockdown resulted in greatly decreased migration of Ly-6C<sup>high</sup> monocytes which led to decreased accumulation at sites of infection given a biweekly dosing regimen (0.5 mg/kg/day). Specifically, there was a decrease in adverse function of monocytes observed in mouse models of atherosclerotic plaques, coronary artery occlusion, pancreatic islet transplantation and tumor volume.

Adami and colleagues at Marina Biotech recently described synthesis of a novel lipid-based amphoteric nanoparticle delivery system based on dialkylated arginine (DiLA<sup>2</sup> compounds).<sup>172</sup> The final optimized particles are ~100 nm in diameter and undergo a pH-dependent phase transition that assists in escape of the particles from endosomes to the cytoplasm. Following i.v. injection, the particles are rapidly cleared with a half-life ( $t_{1/2}$ ) of 20 minutes in mice, becoming undetectable by 4 hours postinjection. Uptake was primarily hepatic (80%), followed by spleen, kidneys, lung, and jejunum. No uptake was detectable in skeletal muscle. Using anti-*ApoB* siRNAs, an ED<sub>50</sub> of 0.1 mg/kg was observed for mRNA suppression in the livers of mice. This same delivery tool was also used with good results in bladder, employing a local administration approach (see below).

Liposomes and lipid nanoparticles can also be conjugated with a targeting ligand to improve or alter their biodistribution and tissue-targeting patterns. Sato and colleagues conjugated vitamin A to liposomes as a means to improve delivery to hepatic stellate cells to treat hepatic fibrosis following chemical injury.<sup>173</sup> Liposomes were made using the Lipotrust reagent system containing *O,O'*-ditradecanoyl-*N*-( $\alpha$ -trimethylammonioacetyl)diethanolamine chloride (DC-6-14) with cholesterol and DOPE. The vitamin A-conjugated liposomes were loaded with siRNA targeting the collagen chaperone heat shock protein 47 gene (*Serpinh1*, gp46) and administered i.v. at a dose of 0.75 mg/kg two or three times weekly. The vitamin A-derivatized liposomes with anti-*Serpinh1* siRNA reduced collagen secretion by the hepatic stellate cells, preventing fibrosis and subsequent cirrhosis of rats treated with chemical toxins (dimethylnitrosamine or carbon tetrachloride) or bile duct ligation.

Peer and colleagues described an antibody-based approach to produce targeted lipid nanoparticles as a carrier for siRNAs.<sup>174</sup> While researchers traditionally have favored the use of PEG-based coatings to provide "stealth" character to nanoparticles, this group employed hyaluronan, a naturally occurring biopolymer in mammals that does not generate an immune response and has minimal toxicity. The siRNAs were condensed with protamine and complexed with a shell made of neutral lipids with hyaluronan attached via dipalmitoylphosphatidylethanolamine (DPPE). Targeting was provided by covalent attachment of FIB504, a monoclonal antibody specific for the  $\beta_7$ -integrins, which are cell surface markers expressed on mononuclear leukocytes. The final particles, which were called  $\beta_7$ I-tsNPs, each carried ~4,000 siRNA molecules as cargo, equating to ~100 siRNAs per attached surface antibody molecule. The  $\beta_7$ I-tsNPs were loaded with control siRNA or siRNA targeting cyclin D1 (*Ccnd1*), an important cell cycle regulator. CCND1 is essential for cell division, so leukocytes receiving the anti-*Ccnd1* siRNA via  $\beta_7$ I-tsNPs should show impaired proliferation, thereby



limiting their potential to mount an immune response. This system was used to treat a mouse model of inflammatory bowel disease, dextran sulfate-induced colitis (DSS-colitis). The anti-*Ccnd1* and control  $\beta_7$ I-tsNPs were administered i.v. at a dose of 2.5 mg/kg every other day for a total of four doses. Treatment reduced levels of expression of mRNA encoding the inflammatory cytokines TNF and IL12 in the gut, but not the immunosuppressive cytokine IL10. Anti-*Ccnd1* siRNA-treated animals showed a marked reduction in gut inflammation and tissue damage, less weight loss, and improved hematocrit compared with control animals.

In studying the mechanisms of uptake of siRNAs formulated in lipid nanoparticles, Akinc and colleagues found that pathways varied with certain characteristics of the lipids.<sup>175</sup> Specifically, apolipoprotein E (APOE) was found to play a significant role in the uptake of ionizable lipid nanoparticles but not cationic lipid nanoparticles. Incorporation of N-acetylgalactosamine (GalNAc) into the lipid nanoparticle resulted in binding and uptake mediated by the hepatic asialoglycoprotein receptor (ASGRI) without APOE or low-density lipoprotein (LDL) receptor dependence.

**Clinical trials—liposomes and lipid particles, i.v.** Several clinical trials have been completed or are currently in progress using some of the previously discussed lipid formulations, all of which employ i.v. administration. Tekmira Pharmaceuticals (formerly Protiva Biotherapeutics) opened a phase I dose-escalation trial for PRO-040201 (<http://clinicaltrials.gov/ct2/show/NCT00927459>) in June of 2009 to evaluate SNALP-delivered anti-*APOB* siRNA in patients with hypercholesterolemia (the program is now called TKM-APOB). A total of 23 patients were enrolled in this trial, of which 17 received a single dose of the SNALP-formulation. In spite of extensive prior testing of these formulations in rodents and nonhuman primates with little evidence for immunostimulatory potential, one of two patients receiving the highest dose developed flu-like symptoms that indicated development of a significant innate immune response. The trial was stopped and will resume pending reformulation of both the SNALP carrier and siRNA cargo to limit the likelihood of recurrence of immune-related side effects. In addition, Tekmira Pharmaceuticals has a phase I trial in the recruitment stage for dose-escalation of TKM-080301 (siRNA targeting *PLK1* delivered by SNALP—TKM-PLK1) for patients with solid tumors (<http://clinicaltrials.gov/ct2/show/NCT01262235>). Tekmira Pharmaceuticals hopes to file an IND with the US Food and Drug Administration to begin a phase I trial for their anti-Ebola siRNA (TKM-Ebola).

Alnylam Pharmaceuticals initiated a phase I dose-escalation trial for a pair of SNALP-formulated, siRNA-based drugs—both of which are in the recruitment phase. The first is openly recruiting participants for ALN-VSP02, a drug containing siRNAs targeting *VEGF* and *KIF11* (KSP1) for treatment of solid tumors (<http://clinicaltrials.gov/ct2/show/NCT01158079>). Results of this trial were recently discussed at the June 2011 meeting for the American Society of Clinical Oncology ([http://abstract.asco.org/AbstView\\_102\\_80216.html](http://abstract.asco.org/AbstView_102_80216.html)). A total of 41 patients were given doses of ALN-VSP02 ranging from 0.1 to 1.5 mg/kg, with 1–28 doses per patient. The drug's safety profile was deemed acceptable, and Alnylam is recommending a 1.0 mg/kg dose every 2 weeks for efficacy evaluation in the planned phase II trial. There is a

second, but currently inactive phase 1 trial for ALN-VSP02 that would expand the number of patients enrolled into a 16-week study (<http://clinicaltrials.gov/ct2/show/NCT00882180>). Another drug, ALN-TTR01, targets *TTR* in hepatocytes for the treatment of TTR-mediated amyloidosis (<http://clinicaltrials.gov/ct2/show/NCT01148953>). The anti-*TTR* siRNA is formulated in a SNALP in partnership with Tekmira Pharmaceuticals. Participants are still being recruited for this trial which opened in July 2010. A second program for this disease is being developed by Alnylam in parallel which employs a different lipid formulation, but this compound is still in preclinical phase. Silence Therapeutics is targeting *PKN3* in solid tumors by a lipid-formulated (AtuPLEX) siRNA, Atu027 (<http://clinicaltrials.gov/ct2/show/NCT00938574>). This study was opened in 2009. Results of this trial were recently discussed at the June 2011 ASCO meeting ([http://abstract.asco.org/AbstView\\_102\\_80541.html](http://abstract.asco.org/AbstView_102_80541.html)). A favorable safety profile was reported with no dose-limited toxicities or obvious evidence of cytokine activation. A single-patient phase I safety study sponsored by the University of Duisburg–Essen tested administration of siRNAs in an anionic lipid (Lipovenös) formulation.<sup>176</sup> Unmodified siRNA targeting the fusion oncogene *BCR-ABL* was delivered at doses of 10–30  $\mu$ g/kg to a patient that had previously received allogeneic hematopoietic stem cell transplantation for imatinib-resistant chronic myeloid leukemia. siRNA treatment (coupled i.v. plus s.c. dosing) was initiated +426 days following transplant. The therapy resulted in detectable inhibition of *BCR-ABL*, which led to chronic myeloid leukemia cell apoptosis without any associated adverse effects that could be ascribed to the siRNA drug.

**Polyplex delivery systems.** Several nonlipid cationic polymers have been used to systemically deliver siRNAs. Due to complications caused by electrostatic interactions of positively charged nanoparticles with negatively charged serum proteins, improved performance of both cationic lipid and cationic polyplex formulations is usually seen with conjugation to some uncharged, hydrophilic group, such as PEG. This creates a “stealth” coating that helps to prevent binding and clumping with the serum proteins when administered i.v. Accumulation of cationic nanoparticles can lead to micron-sized aggregates that become lodged in capillary beds and can trigger a complement cascade or other inflammatory responses, especially in the lungs.<sup>130</sup>

PEI is a cationic polymer that has been widely used in nucleic acid delivery due to its ability to condense DNA and RNA as well as for the abundance of protonatable secondary amines that are thought to aid in endosomal escape (via the “proton sponge” effect<sup>177</sup>). Although unmodified PEI can be very toxic, the newer generation of chemically-altered PEI-based vehicles have been more widely used as an *in vivo* delivery tool. It has been suggested that mitochondrial membrane depolarization is the basis for much of the observed PEI-related toxicity.<sup>178</sup> Progress in using PEI derivatives as delivery tools for siRNAs was recently reviewed by Gunther and colleagues.<sup>179</sup>

Kamlah and colleagues employed the commercially available product jetPEI (PolyPlus), which is a linear PEI derivative. Unmodified siRNAs targeting both *Hif1a* and *Epas1* (*Hif2a*) were complexed with the PEI reagent at an N:P ratio of 1:10 and



delivered i.v. (25 µg of siRNAs per dose, or about 1.25 mg/kg) in mice bearing Lewis lung carcinoma implants.<sup>180</sup> Survival was prolonged with combination therapy and a HIF1A-dependent marker, SLC2A1, was found to be markedly reduced in the anti-*Hif1a/Epas1* siRNA-treated animals but not in the control animals. The authors also attempted other routes of delivery, including: PEI-siRNA dosed i.p., PEI- and lipofectamine-siRNA dosed intratracheally, or lipofectamine-siRNA dosed i.v. Use of a Cy5-labeled siRNA demonstrated that PEI-condensed siRNA dosed i.v. was the most efficient at targeting the pulmonary tumor implants. It is uncertain if any nonspecific effects relating to the aforementioned nanoparticle aggregation and lung capillary entrapment contributed to these findings.

Work from Buhjwalla and colleagues employed PEI as the chief condensing-agent for siRNAs in a novel bioconjugate nanoparticle.<sup>181</sup> The “nanoplex” contained PEG-PEI-condensed siRNA targeting *Chka*, Gd-labeled poly-L-lysine and the prodrug-activating enzyme cytosine deaminase. The siRNA- and protein-containing nanoplex was dosed i.v. in tumor-bearing mice (300 mg/kg for the entire nanoplex). 5-Fluorocytosine was dosed i.v. 24 hours following injection of the nanoplex, allowing sufficient time for particle accumulation in the tumors. Tumor doubling time for various treatment groups was 5.5 days for negative control animals, 10 days for those animals receiving the siRNA-nanoplex alone, 18 days for those receiving the enzyme-prodrug alone and 35 days for those receiving the siRNA-nanoplex-enzyme-prodrug combination therapy. The combination therapy of siRNA targeting *Chka* and the prodrug 5-fluorocytosine converted to the active drug, 5-fluorouracil, significantly decreased tumor progression.

Poly(amidoamine) (PAMAM) is a dendrimer that forms nanoplexes with siRNAs via electrostatic interactions, much like PEI. Recently published results describe an anti-HIV-1 effect following i.v. administration of a generation-5 PAMAM dendrimer complexed with a cocktail of DsiRNAs in “combinatorial delivery”—that is, DsiRNAs targeting *tat/rev* (viral transcript) as well as *TNPO3* and *CD4* (host transcripts).<sup>182</sup> Humanized mice (Rag2<sup>-/-</sup>γc<sup>-/-</sup>) were infected with HIV-1, and weekly antiviral treatment (0.15 mg/kg total DsiRNAs) began 3 weeks postinfection and continued for 5 weeks. Viral load was monitored by qPCR. Mice dosed with the DsiRNA cocktail/PAMAM delivery system displayed viral loads reduced by approximately three orders of magnitude when compared to various negative controls. Preliminary work with 5'RACE confirmed that target knockdown was mediated by Ago2 in a site-dependent manner. Further experiments demonstrated that a rebound in viral titers could be ablated with retreatment at 24.5 and 25.5 weeks postinfection and complete suppression continued through week 28. Biodistribution of DsiRNAs via PAMAM nanoplexes was confirmed to peripheral blood mononuclear cells as well as to the liver, and there was no demonstration of obvious toxicity.

Other polymers have been successfully employed in the construction of siRNA-nanoparticles including chitosan, polypeptides, and cyclodextrin. Chitosan, a natural product derived from crustacean shells, is a linear, cationic polysaccharide made by the deacetylation of chitin—polymeric *N*-acetylglucosamine with β-1-4 linkages. In one recent study, imidazole-modified chitosan was incorporated into PEGylated polyplexes for i.v. dosing of anti-

*Gapdh* siRNA in mice.<sup>183</sup> siRNA dosed with this formulation at 1 mg/kg gave significant knockdown of GAPDH protein in the lungs and the liver when compared to imidazole-modified chitosan with a control siRNA or with unmodified chitosan with the anti-*Gapdh* siRNA. Pille and colleagues employed a chitosan-based nanoparticle to deliver siRNAs via i.v. injection (retroorbital vein) in nude mice bearing implants of the human breast carcinoma cell line MDA-MB-231.<sup>184</sup> An unmodified control siRNA or a siRNA targeting the *Rhoa* gene was administered once every 3 days for 30 days. Tumor growth for the anti-*Rhoa*-treated animals was significantly inhibited compared to animals receiving the control siRNA for both the 0.15 and 1.5 mg/kg dose cohorts. Other studies have employed chitosan nanoparticles using intratracheal or i.p. delivery routes, which will be discussed in other sections of this review.

A significant body of work has been published by the Davis Laboratory and Calando Pharmaceuticals relating to the use of cyclodextrin-containing polycations<sup>185</sup> as a siRNA delivery vehicle which is suitable for *in vivo* use with i.v. delivery;<sup>186</sup> the work from these groups was well covered in an earlier review.<sup>186</sup> A recent pre-clinical trial in nonhuman primates was a dose-escalation study of i.v.-administered cyclodextrin particles containing Tf-targeting ligands.<sup>187</sup> An unmodified, 21-nt siRNA targeting the M2 subunit of ribonucleotide reductase (*Rrm2*) was dosed multiple times at 3, 9, and 27 mg/kg. Cytokine assays showed increased IL6 in the 27 mg/kg dosing group. There were no signs of immunostimulation in the other treatment groups receiving lower doses. In a set of experiments to define the optimal dosing schedule, cyclodextrin nanoparticles containing siRNA against *Rrm2* (2.5 mg/kg) were dosed for 3 consecutive days to mice containing 100 mm<sup>3</sup> Neuro2A tumors s.c.<sup>188</sup> Tf-targeted nanoparticles showed reduced tumor volume over 17 days and survival of these mice was extended significantly beyond untreated mice and marginally beyond nontargeted treatments. The preferred embodiment of the cyclodextrin vehicle was used in the first clinical trial where a siRNA/polyplex formulation was administered i.v. to humans (see below).

Atelocollagen, a water-soluble, pepsin digestion product of collagen, is another biopolymer that has been successfully used as a siRNA delivery vehicle. In one study, *Ccl2*-targeted siRNA administered i.v. as a single 50 µg dose complexed with atelocollagen reduced the symptoms of contact hypersensitivity in mice.<sup>189</sup> CCL2 (MCP1) is known to initiate the inflammatory response associated with contact hypersensitivity. In this study, ear-swelling was used as the functional assay to quantify the degree of contact hypersensitivity. Atelocollagen-formulated siRNA targeting *Ccl2* decreased the recruitment of immune cells and resulted in a significant decrease in the ear-swelling as compared to the same siRNAs delivered using liposomes. Kinouchi and colleagues described use of atelocollagen to deliver unmodified siRNA targeting myostatin either by local intramuscular (i.m.) injection or systemically by i.v. (retroorbital) injection to increase muscle mass in both wild-type and *dmx* mice, a model of Duchenne muscular dystrophy. In both the local- and i.v.-injected cohorts, muscle mass and myofibril diameter was increased, suggesting that a treatment of this kind may eventually offer some therapeutic benefit for any of the muscle-wasting diseases, such as Duchenne muscular dystrophy.<sup>190</sup>

PepFect6 is a novel cell-penetrating peptide (CPP) (AGYL LGKINLKALAALALLIL) containing a sterylated N-terminus and

multiple chloroquine analogs conjugated to the lysine at position 7.<sup>191</sup> PepFect6 polyplexes with a siRNA targeting *Hprt1* were administered as a single i.v. dose at 1 mg/kg in mice. After 72 hours, mRNA levels of *Hprt1* were measured in the kidney. PepFect6 showed a ~60% decrease in *Hprt1* levels compared to a control siRNA. *Hprt1* knockdown in the lung was similar to that observed in the kidney, while liver knockdown was even better at ~75%. No toxicity was reported for the PepFect6 formulations. In general, most peptides that mediate cell uptake are cationic and, when complexed with anionic nucleic acids, form tight electrostatic complexes. Charge neutralization can block the cell-penetrating properties of these peptide reagents, reducing functional performance. Direct conjugation or complexation of siRNAs with peptides has therefore not been met with general, widespread success.

The blood-brain barrier (BBB) normally presents an obstacle to large molecule drug entry into the central nervous system (CNS).<sup>192,193</sup> Kumar and colleagues described use of a peptide delivery tool to facilitate uptake of i.v.-administered siRNAs into the CNS. A 29-amino-acid peptide derived from the rabies virus glycoprotein (RVG) was fused with a poly-arginine cationic domain (9R) and electrostatically complexed with a siRNA cargo.<sup>194</sup> The RVG specifically binds the nicotinic acetylcholine receptor and siRNAs complexed with this vehicle were shown to be delivered into neuronal cells. Functional performance was validated by using i.v. administration of anti-*JEV* siRNA complexed with RVG-9R to protect mice from encephalitis caused by infection with the JEV flavivirus. This same strategy was later employed to deliver anti-*Thf* siRNA to the CNS, specifically targeting microglia/macrophage cells which also express the nicotinic acetylcholine receptor.<sup>195</sup> i.v. administration of the anti-*Thf* RVG-9R complex was protective against neuronal inflammation following administration of bacterial lipopolysaccharide. Although it was published 4 years ago, independent validation of this potentially exciting approach has not appeared from other groups. The use of synthetic peptides to facilitate transit of the BBB of either small or large molecule drugs following i.v. administration remains an intense area of investigation. Angiochem is developing a suite of engineered peptides that bind the LDL receptor-related protein-1, which is highly expressed throughout the CNS and directs transport of over 40 natural ligands across the BBB. The properties of one peptide, Angiopep-2, was studied in detail and properties appeared to be favorable for development of a CNS-drug delivery aid.<sup>196</sup>

In general, lipoplex delivery and polyplex delivery vehicles share several characteristics. They typically employ cationic polymers to condense the nucleic acid cargo, have similar submicron particle sizes and often require chemical modification (such as PEGylation) to confer “stealth” characteristics. Some recent manuscripts describe use of novel delivery systems that are quite different from the rest of this class. Shahzad and colleagues formulated siRNAs in reconstituted high-density lipoprotein (HDL) nanoparticles that were taken-up by the scavenger receptor type-B1, which is overexpressed on many tumor cells.<sup>197</sup> Alvarez-Erviti and colleagues exploited endogenous nanovesicles, called exosomes that were derived from dendritic cells (DCs). The DCs were engineered to express Lamp2b (an exosome membrane protein) fused with RVG, which is thought to direct CNS targeting (see above). The modified exosomes were loaded *ex vivo* with siRNA targeting

*Bace1*, a target which has received much attention for its potential involvement in the pathophysiology of Alzheimer’s disease.<sup>198</sup> The Lampe2b-RVG anti-*Bace1* loaded exosomes were injected i.v. in normal mice and successfully delivered their cargo to the CNS, where *Bace1* mRNA and protein levels were reduced, with no evidence of delivery to other tissues.

*Clinical trials—polyplex delivery systems, i.v.* CALAA-01 is a siRNA targeting *RRM2* complexed in an amantadine-cyclodextrin vehicle that contains PEG-shielding and employs Tf as a targeting ligand. A phase I trial opened by Calando Pharmaceuticals in May of 2008 with patients having solid tumors that were refractory to standard therapy (<http://clinicaltrials.gov/ct2/show/NCT00689065>). 5’RACE-PCR data were generated using RNA obtained from a tumor biopsy from one treated patient demonstrating that the *RRM2* target mRNA was cleaved at the expected location, providing the first proof of RNAi mechanism of action in humans.<sup>151</sup> This report was also significant in that it represented the first use of siRNAs in humans with i.v. administration using a synthetic polyplex delivery vehicle.

*Ligand-siRNA conjugates and naked delivery.* A variety of different ligands or functional groups have been covalently attached to siRNAs to direct delivery, usually in a tissue-specific fashion. For this approach, the siRNAs must be chemically modified to confer sufficient nuclease resistance to survive naked exposure to serum or other environments. Aptamers are highly folded single-stranded nucleic acid molecules having conformations that bind a target molecule with high affinity and specificity in a fashion similar to antibodies. Aptamers have been employed to facilitate delivery of siRNAs both *in vitro* and *in vivo*. Rossi and colleagues described development of an aptamer specific for the HIV-1 gp120 protein which is expressed on the surface of HIV-infected cells.<sup>199,200</sup> An anti-gp120 aptamer was fused with a 27-nt DsiRNA specific for the HIV *tat/rev* gene. The aptamer-siRNA chimera was made using *in vitro* transcription with modified bases so that the entire strand was made of RNA purine and 2’F pyrimidine bases. An unmodified RNA complement was hybridized to the siRNA-component of this fusion construct to constitute a functional siRNA duplex. The final compound had good relative nuclease stability and could survive naked incubation in serum. Following uptake into infected cells, the siRNA was cleaved from the aptamer by Dicer, resulting in a 21-nt mature anti-*tat/rev* siRNA which suppressed *HIV* mRNA. RNAi mechanism of action was demonstrated by 5’RACE-PCR. Studies were performed using the gp120-DsiRNA fusion molecule with i.v. administration in a humanized mouse model of HIV infection. Although the anti-gp120 aptamer alone had some anti-HIV activity, the gp120-DsiRNA fusion product showed the greatest efficacy and reduced HIV viral titers by several logs, preventing the decline of CD4<sup>+</sup> T-cells which is characteristic of advancing HIV infection.<sup>152</sup> The antiviral protection extended for several weeks after the last dose.

McNamara, Giangrande, and colleagues used an aptamer (A10) that specifically binds the prostate-specific membrane antigen (PSMA, which is expressed only on prostate cells and in many prostate cancers) conjugated to an anti-*PLK1* siRNA to treat human prostate cancer xenografts in nude mice.<sup>201</sup> The

A10-siRNA was taken up by prostate tumors lines which express PSMA, such as LNCaP cells, but not by prostate tumor lines which do not express PSMA, such as PC3 cells. Uptake of the A10-siRNAs led to reduction in *PLK1* expression and induced tumor cell apoptosis. In this study, direct intratumor injection led to regression of the tumor. Subsequent work demonstrated a similar ability to prevent growth of PSMA-expressing human prostate tumors in nude mice using i.v. administration.<sup>202</sup> Like lipid nanoparticles and polyplexes, PEGylation of the A10-siRNA chimeras resulted in improved circulation half-life and reduced rates of clearance.

A variety of lipophilic moieties can be conjugated to siRNAs to improve uptake *in vivo*, the best studied of which is cholesterol. Cholesterol was one of the first ligands employed to directly facilitate uptake of siRNAs following i.v. administration. Soutschek and colleagues described direct i.v. injection of an anti-*Apob* siRNA in mice to lower APOB levels and reduce serum cholesterol.<sup>149</sup> The siRNAs employed were modified with 2'OMe RNA and PS linkages. Addition of the cholesterol group extended serum half-life by 15-fold compared with control siRNAs. Uptake was primarily seen in liver and heart, but was also detectable in kidney, adipose tissue, and lung. Although effective, very high doses of siRNAs were needed and administration of 50 mg/kg daily for 3 days was required to achieve a 65% reduction in APOB levels. Similarly, cholesterol has been used to improve uptake of anti-miRNA oligonucleotides (AMOs, or "antagomirs") following i.v. administration.<sup>203</sup> Mechanistically, cholesterol-modified siRNAs interact with serum lipoprotein particles and uptake is dependent upon cellular lipoprotein and other transmembrane receptors.<sup>204</sup> LDL receptor expression is necessary for uptake of LDL-associated cholesterol-siRNA, which primarily targets liver. In contrast, the scavenger receptor SCARB1 is involved in uptake of HDL-associated siRNAs. Interestingly, the transmembrane protein SID1 is also involved in cholesterol-siRNA uptake; this gene product was originally identified as being essential for siRNA uptake in *Caenorhabditis elegans* in 2003.<sup>205</sup> In addition, Kuwahara and colleagues recently demonstrated a role for APOE and the LDL receptor in the uptake of cholesterol-modified siRNAs by brain capillary endothelial cells following i.v. administration in mice.<sup>206</sup>

Vitamin E is a lipid-soluble antioxidant found in plasma and all mammalian cells. Like cholesterol,  $\alpha$ -tocopherol is usually associated with serum lipoproteins and both the LDL receptor and SCARB1 scavenger receptor are involved in cellular uptake.<sup>207</sup> Interestingly, vitamin E was first produced as an activated phosphoramidite for conjugation in oligonucleotide synthesis in 1999 for use as a lipophilic capture tag.<sup>208</sup> Nishina and colleagues conjugated vitamin E to a 27/29-nt DsiRNA at the 5'-end of the guide strand in a position which would be removed by Dicer processing following delivery into the cytoplasm.<sup>65</sup> The duplex was modified using 2'OMe RNA residues and PS linkages to sufficiently stabilize the compound for direct i.v. administration, leaving an unmodified domain positioned to permit Dicer cleavage. A dose response study was performed using a vitamin E-modified siRNA targeting murine *Apob* and reductions in *Apob* mRNA levels were measured in the liver. For a single i.v. administration, an ED<sub>50</sub> of 2 mg/kg was seen, with 80% knockdown of *Apob* observed after a 32 mg/kg dose. Vitamin E-conjugated

siRNAs have also been successfully employed in the CNS following direct intraventricular injection (see below).<sup>209</sup>

Although it is desirable in most settings to avoid immune stimulation following injection of synthetic siRNAs, activation of the immune system may be beneficial when treating certain malignancies or viral infections.<sup>113</sup> Kortylewski and colleagues described a system where a single-stranded DNA oligonucleotide (CpG1688), which is a known potent TLR9 agonist, was covalently attached using an aliphatic linker to a DsiRNA targeting *Stat3* and was used to treat mice in a metastatic melanoma model.<sup>210</sup> STAT3 is an interesting oncology target as it is upregulated in some cancers and promotes tumor cell proliferation and survival. It also reduces Th-1 responses and may blunt the magnitude of local antitumor immune responses. Thus *Stat3* silencing could have antitumor effects at several levels. TLR9 recognizes CpG motifs in DNA when the cytosine is not methylated (most mammalian DNAs have 5-methyl-cytosine in the context of a CpG dinucleotide, while bacterial genomes are not modified in this way). TLR9 is expressed on a subset of immune cells including B cells and plasmacytoid DCs. Mice, but not humans, also express TLR9 on monocytes and myeloid DCs. TLR9 is primarily located in the endosomal compartment and cells expressing it will take up CpG-motif DNAs and internalize them even though TLR9 is not present on the cell surface (*i.e.*, TLR9 is not directly involved in internalization). Kortylewski demonstrated that the CpG oligonucleotide plus the linked siRNA cargo was taken up by TLR9-expressing cells and a fraction of this material escaped endosomal sequestration into the cytoplasm and was effective at suppressing STAT3 expression. While most cells will take up DNA whether a CpG motif is present or not, the combination of CpG-motif nucleic acid and TLR9 seemed to improve delivery of the siRNA cargo into the cytoplasm. Direct peritumor injection of the CpG-*Stat3*-siRNA conjugates reduced the size of s.c. tumor implants. Furthermore, direct i.v. administration of the CpG-*Stat3*-siRNA conjugates significantly reduced both the size and number of pulmonary implants which developed following i.v. injection of B16 melanoma cells in syngeneic C57BL/6 mice.

Although not commonly used with i.v. administration in the absence of a delivery aid, Tammali and colleagues injected naked, chemically-stabilized (siSTABLE) anti-*ALDR1* siRNA in mice and demonstrated a role for aldose reductase (*ALDR1*) in colon cancer metastasis.<sup>211</sup> EGFP-expressing human KM20 colon cancer cells were injected intrasplenically in nude mice to generate a model of colon cancer. The number of implants were reduced by >65% after i.v. administration of the anti-*ALDR1* siRNA. Three 200  $\mu$ g doses were delivered i.v. to mice once every 10 days. *ALDR1* knockdown was measured by RT-qPCR, and the mice dosed with anti-*ALDR1* siRNA demonstrated 90% knockdown of *ALDR1* mRNA in the livers of treated mice compared to negative controls. Overall, *ALDR1* inhibition led to decreased cell adhesion to epithelial cells, invasion, and migration.

**Clinical trials—conjugates or naked siRNA, i.v.** There are currently no clinical trials ongoing using direct siRNA-ligand conjugates in humans. However, one siRNA drug is being studied which employs naked i.v. administration without any targeting ligand or vehicle to facilitate delivery. I5NP is a siRNA drug in clinical



trials sponsored by Quark Pharmaceuticals. The first phase I dose-escalation trial evaluated the *p53* inhibitor as a means of preventing acute kidney and renal injury in patients that had undergone major cardiovascular surgery (<http://clinicaltrials.gov/ct2/show/NCT00554359>). I5NP is currently being evaluated in a phase I/II dose-escalation study to determine its efficacy as a prophylactic treatment for delayed graft function in kidney transplant patients (<http://clinicaltrials.gov/ct2/show/NCT00802347>). I5NP is a blunt siRNA that is heavily modified with 2'OMe residues and is administered i.v. in naked form without a delivery aid, taking advantage of the observation that high doses of nucleic acids in the serum will achieve entry into cells in the proximal convoluted tubules of the kidney where they are highly concentrated during urinary excretion.<sup>212</sup>

**Inorganic particles.** Gold nanoparticles are amenable to surface functionalization that permits loading with various biomolecules and are finding a growing number of applications for *in vivo* use, including delivery of nucleic acids such as ASOs and siRNAs.<sup>213–215</sup> Methods have been developed to trigger release of siRNAs attached to gold particles following exposure to NIR light, taking advantage of the surface-plasmon resonance properties of this material.<sup>216</sup> NIR light in the 700–850 nm wavelength range has excellent tissue penetration and is easily adapted to *in vivo* use. Lu and colleagues employed hollow gold nanospheres (HAuNS) with NIR irradiation to deliver siRNAs in nude mice bearing HeLa cell implants in their hind limbs.<sup>217</sup> Using a thiocytic acid-terminated PEG linker, folic acid was coupled to the gold particles as a targeting ligand to increase particle uptake by the tumor cells. Unmodified 21-nt siRNAs targeting *RELA* (nuclear factor- $\kappa$ B p65 subunit) were attached to the particles via a sulfhydryl linker that connected the 5'-end of the siRNA passenger strand to the gold surface, resulting in a final "F-PEG-HAuNS-siRNA" particle. Particle uptake and biodistribution was studied using PET imaging following i.v. injection of the F-PEG-HAuNS-siRNAs labeled with DOTA/<sup>64</sup>Cu. Both folate-conjugated and nontargeted particles showed significant uptake in liver and spleen; however, folate targeting conferred selectivity as shown by fivefold increase in tumor implant uptake. Mice were administered a single 3 mg/kg i.v. dose of the F-PEG-HAuNS-siRNAs and one hind limb received NIR irradiation at 6 hours postinjection (50 mW/cm<sup>2</sup>). Tumor implants were removed 48 hours later and western blot and immunohistochemical evaluation indicated that the NF $\kappa$ B p65 subunit was suppressed by 75% in the tumors treated with F-PEG-HAuNS-anti-*RELA*-siRNAs plus NIR but not without NIR treatment or when using control siRNA particles. Combination therapy using a single dose of the F-PEG-HAuNS-anti-*RELA*-siRNA nanoparticles (with NIR treatment) and two doses of irinotecan, a topoisomerase 1 inhibitor, led to complete inhibition of tumor implant growth over 30 days.

**i.p. administration.** i.p. administration of siRNAs represents another route to achieve local or even systemic effects *in vivo* which may have fewer toxicity issues than direct i.v. injection. Dosing by this route does not allow for direct transport of injected nanoparticles via the circulatory system in the same way that i.v. dosing does. Rather, systemic distribution by i.p. administration

is dependent upon indirect distribution initiated by movement of the organism as well as migration via the lymphatic system. i.p. administration is advantageous compared to i.v. delivery in that serum proteins that can contribute to polyplex aggregation are not prevalent. Since i.p.-dosed particles need not extravasate from venous fenestrae in order to reach the targeted tissue of interest, there is less of a requirement that particles have a small diameter (as are needed for i.v. delivery). Several systemic siRNA experiments have utilized the i.p. delivery route due to some of these advantages. In particular, the following studies address siRNA delivery to ovarian cancer or other cancer models.

i.p. delivery has been commonly used for treating ovarian cancer in murine models. A study described above in the "whole animal imaging" section demonstrated tumor regression with lipidoid-formulated nanoparticles carrying siRNA against *CLDN3*.<sup>144</sup> An i.p. dose of siRNA targeting *CLDN3* was delivered twice weekly (175  $\mu$ g per injection). This treatment reduced the incidence of metastases and gave no detectable immune response after multiple doses. Ovarian cancer was treated with siRNA against *STAT3* or *PTK2* (FAK) formulated by reconstituted HDL nanoparticles.<sup>197</sup> As discussed previously, siRNAs (0.2 mg/kg) dosed in combination with chemotherapeutic agents led to a significant decrease in tumor weight and the number of tumor nodules present following i.p. as well as i.v. delivery. Additionally, i.p. delivery showed potential for ovarian cancer treatment using neutral, 1,2-dioleoyl-sn-glycerol-3-phosphatidylcholine (DOPC) liposomes containing siRNA targeting *EPHA2*.<sup>218</sup> Liposome-siRNA (150  $\mu$ g/kg) was i.p.-dosed in a mouse model of advanced ovarian cancer twice weekly for 3 weeks. Compared with mice receiving paclitaxel and control siRNA-DOPC liposomes, 50–80% reduction in tumor growth was observed in mice treated with paclitaxel and anti-*EPHA2* siRNA-DOPC liposomes. Halder and colleagues again targeted *PTK2* (FAK), a protein known to play a role in ovarian cancer metastasis, with a similar neutral lipid/siRNA formulation and dosing regimen as was used in the *Epha2* study.<sup>219</sup> The results here were very similar to those observed from the HDL nanoparticle experiments. There was a decrease in tumor growth when mice were dosed with anti-*PTK2* siRNA compared to negative controls, and the reduction was even more significant when the RNAi therapy was combined with a known chemotherapeutic agent. Given the propensity for metastasis to spread throughout the peritoneal cavity in advanced ovarian cancer, i.p. methods of treatment (including i.p. chemotherapy) are common medical practice today.

In another study using i.p. delivery for the treatment of ovarian cancer in mice, anti-*Parp1* siRNA was formulated with the lipidoid NC100, which was identified from a compound library screen to be highly effective in transfecting ovarian cancer cells *in vitro*.<sup>220</sup> The siRNAs were 2'OMe-modified, and three doses at 5 mg/kg were delivered i.p. in two mouse models of ovarian cancer using BRCA1-deficient cells and BRCA1 wild-type cells. RNA isolated from tumors showed *Parp1* knockdown, but survival was extended only in the BRCA1-deficient tumor model and not in the BRCA1 wild-type model. This confirmed a specific mechanism of lethality requiring a deficiency in both PARP1 and BRCA1 to induce apoptosis. Similarly, PEI-formulated, unmodified siRNA targeting *MAD2L1* was dosed i.p. (7 doses of 10  $\mu$ g over the course of 2 weeks) in mice-bearing human xenograft tumors.<sup>221</sup> Tumor



regression was observed which suggests that the mitotic spindle checkpoint may be a therapeutic target for i.p. delivery in ovarian cancer.

Aside from ovarian cancer, other xenograft cancer models have been effectively targeted by i.p. delivery of siRNAs. Interestingly, siRNA against tissue factor (*F3*) was able to reduce the metastatic colonization of lung tissue by B16 melanoma when cells were injected i.v. as a metastatic challenge at the same time or immediately following i.p. delivery of the siRNA.<sup>222</sup> The unmodified siRNAs were complexed with Lipofectamine-2000 and mice were dosed three times. The initial dose (100 µg) was delivered 24 hours before tumor challenge and subsequent doses (50 µg each) were given on days 3 and 6 post-tumor challenge. The number of lung tumors present 7 days after B16 cells were i.v.-injected decreased from ~350 in the control group to <100 in mice treated with the anti-*F3* siRNA.

Tesniere and colleagues reported use of siRNAs targeting *Gata3* and T-BET (*Tbx21*) (transcription factors required for the development of helper T1 and T2 cells, respectively) in immunomodulation as it relates to anti-tumor vaccination.<sup>223</sup> A naked, unmodified anti-*Gata3* siRNA (2 µg; 3 doses in 5 days) was delivered i.p. to a vaccinated, tumor-bearing mouse model leading to immunostimulation and reduced tumor growth. However, simultaneous treatment with the anti-*Tbx21* siRNA resulted in uninhibited tumor growth, demonstrating the antagonistic effects of sub-populations of helper T cells on anticancer immune responses.

While absorption and systemic distribution of small molecule drugs following i.p. injection is well accepted, small nanoparticles can be rapidly cleared from the peritoneal cavity and absorbed into the lymphatic circulation or cleared by the spleen which may limit efficient systemic delivery,<sup>224</sup> although work from Gao and co-workers with chitosan-siRNA nanoparticles indicates the presence of siRNAs in blood 15 minutes following an i.p. dose.<sup>225</sup> One way to circumvent this potential problem is to target a mobile population of cells, like macrophages, which reside in the peritoneal cavity reservoir. Such cells can be transfected with siRNAs and are free to migrate systemically, effectively bringing the siRNA cargo with them. Approaches like this have been used to target macrophages as a means to modulate diseases with an inflammatory component. The use of siRNAs targeting TNF production by macrophages with i.p. delivery has been exploited in several recent studies.

A study by Lundberg and colleagues employed an anti-*Tnf* 27-nt DsiRNA to study the role of TNF in the pathophysiology of herpes simplex virus-induced encephalitis.<sup>226</sup> TransIT-TKO was used to formulate the DsiRNAs for i.p. delivery (2 and 4 µg doses; six injections over 8 days). Interestingly, i.p. injection of DsiRNAs in a cationic lipid complex was able to influence a disease process in the CNS. Presumably, this result was not due to direct CNS delivery of the DsiRNAs but rather by transfection of peritoneal macrophages with the anti-*Tnf* DsiRNA, which later migrated to the site of inflammation in the CNS. This study highlights the complex role that TNF plays in survival of herpes encephalitis and suggested the existence of an unknown third TNF receptor in mice which, in this experiment, were double-knockouts for the two known TNF receptors (p55 and p75).

Howard, Kjems, and colleagues have developed a chitosan nanoparticle which can be employed *in vivo* using intratracheal, i.p., or other routes of administration.<sup>227</sup> This group employed the same anti-*Tnf* DsiRNA previously used by Lundberg<sup>226,228</sup> to moderate the severity of murine collagen-induced arthritis.<sup>229</sup> Anti-*Tnf* DsiRNA-chitosan complexes were administered by i.p. injection at doses of 0.125 to 0.25 mg/kg every other day for a total of 5 doses, starting at the onset of overt arthritis (4 weeks after collagen immunization). Unmodified anti-*Tnf* DsiRNA showed some improvement in arthritic score; however, 2'-OMe-modified duplexes performed better and subsequent histological evaluation of joints showed no evidence for erosive destruction of the articular surface in this cohort of animals. This same group later employed the same anti-*Tnf*-chitosan formulation to prevent development of radiation-induced fibrosis following high-dose gamma irradiation of a hind limb.<sup>230</sup> Anti-*Tnf*-chitosan was administered i.p. to mice given 45 Gy irradiation to a single hind limb. The development of contractures and radiation-induced fibrosis was monitored compared with the non-irradiated contralateral control limb. The DsiRNA-chitosan treatment was given by i.p. injection 2 days prior to irradiation and twice weekly for a variable period of time thereafter. All control mice and those treated with the anti-*Tnf* DsiRNA for only 10 days developed radiation-induced fibrosis. Mice treated for 22 days, 34 days, or 258 days, however, showed no evidence for fibrosis, offering hope for a potential treatment to prevent this morbidity associated with radiation therapy.

There are currently no clinical trials ongoing using synthetic siRNA with i.p. delivery in humans.

### Local delivery

Clinical application of tissue-specific dosing routes are attractive due to the increase in target tissue bioavailability, selectivity, and the reduced dose of siRNAs required compared to systemic routes of administration, especially i.v. delivery. Direct injection of siRNAs into the intended site of action reduces considerations that might otherwise be needed for tissue-specific targeting. In addition, the need for extensive nuclease stabilization—whether by means of modified nucleotides or by formulation with a carrier molecule—is not as high of a priority as it is in systemic delivery where the siRNAs are exposed to serum. In this section, we discuss several types of formulations, siRNA modifications, etc. that have been successfully used in mediating gene knockdown and relief of disease-associated phenotypes via direct local administration.

**Direct CNS administration.** Large molecule and some small molecule drugs are routinely administered to the CNS by direct injection because the BBB normally prevents their entry from the arterial circulation. Unlike serum, cerebrospinal fluid is a relatively nuclease poor environment, which can reduce the extent of chemical modification needed to protect the siRNAs from degradation during delivery. CNS delivery options include intrathecal, intraventricular, epidural, and direct intratissue or intratumoral injection. Compounds can be administered as a single bolus or by slow, continuous, long-term infusions using mini pumps. Reports vary on the need for delivery aids in the CNS, with some researchers reporting seemingly successful results

using very high-dose naked infusion and others reporting significant benefit from employing lipids, polymers, peptides, or other delivery vehicles. The use of delivery aids will certainly reduce the amount of siRNA needed for each administration.

Altier and colleagues used bolus intrathecal (i.t.) delivery to suppress a specific calcium channel to define its role in nociception.<sup>231</sup> Rats were dosed three times over 2 days with 60 µg of unmodified 21-nt siRNA in 10 µl of water (0.3 mg/kg using no delivery aid) targeting exon 37a of the N-type calcium channel (*Cacna1b*). Results from pain tests in rats indicated that the voltage-gated calcium channel containing transmembrane protein 37a plays a role in thermal nociception and developing thermal and mechanical hyperalgesia following formalin injection or sciatic nerve constriction. The effects of pain-related stimuli were decreased upon treatment with siRNA targeting exon 37a of the N-type calcium channel which helped identify the role of the transmembrane protein in these types of responses. Taishi and colleagues also employed direct bolus injection of unmodified 21-nt siRNAs in saline into brain tissue, in this case to study if TNF plays a role in sleep regulation.<sup>232</sup> Rats were administered 0.05 nmoles of anti-*Tnf* siRNA twice a week (~0.03 mg/kg) via direct microinjection into the somatosensory cortex, with one side of the brain receiving the anti-*Tnf* siRNA and the contralateral side receiving control siRNAs. RT-qPCR indicated a 37% reduction in *Tnf* mRNA in the anti-*Tnf* treated tissue compared to control tissue. Electrophysiological studies showed that reduction in TNF levels correlated with reduced electroencephalogram delta wave power, suggesting a role for this cytokine in sleep regulation.

Chronic intraventricular dosing was used to deliver siRNA targeting the amyloid precursor protein gene (*App*) in adult mice to investigate the effects of this gene product in Alzheimer's-related functions as an alternative to using APP knockout mice, which are totally devoid of APP throughout development.<sup>233</sup> Mini-osmotic pumps were implanted s.c. in mice and delivered 400 µg of unmodified anti-*App* 21-nt siRNA by direct intraventricular infusion daily (~15 mg/kg direct infusion into the brain) for 2 weeks with the anti-*App* siRNA at a concentration of 67 µg/µl in an isotonic buffer with no delivery aid. Via *in-situ* hybridization, the most potent siRNA sequence was shown to reduce *App* mRNA in the CA2 and CA3 regions of the hippocampus. This knockdown correlated with impaired hippocampus-dependent spatial working memory via locomotion and maze testing.

Also using naked, unassisted delivery in buffered saline, McCormack and colleagues employed chronic infusion of chemically-stabilized siRNAs in nonhuman primates (squirrel monkeys) to suppress levels of  $\alpha$ -synuclein; overexpression of this protein is correlated with several neurodegenerative disorders, including Parkinson's disease.<sup>234</sup> Direct infusion into the substantia nigra was achieved using an implanted Alzet mini-osmotic pump at a flow rate of 5.4 µg/hour over the course of 4 weeks. The 21-nt siRNA had 2'OMe-modified pyrimidines and terminal PS linkages at the 3'-ends of each strand.  $\alpha$ -Synuclein (*Snca*) mRNA levels were evaluated by qPCR and were shown to be reduced 25-50% relative to treatment with a nontargeting control siRNA. Likewise, immunohistochemistry of tissue sections showed that  $\alpha$ -synuclein protein was decreased ~40% in the substantia nigra, however no phenotypic changes were observed. Likewise, Wang and colleagues

employed chronic infusion of a chemically-modified 21-nt siRNA into the CNS of mice with an Alzet osmotic infusion pump in a SOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis (ALS).<sup>235</sup> In this case, anti-*Sod1* siRNA was selectively modified with PS linkages and 2'F-pyrimidine residues near the ends of each strand. Following infusion of the siRNAs over the course of one week, northern blotting showed that a 100 µg dose of siRNAs decreased *Sod1* mRNA levels in the spinal cord to near-undetectable levels as compared to a negative control. In the transgenic mouse model for ALS, a 28-day infusion of the siRNAs significantly slowed disease progression, and the siRNAs were shown to be stable over the course of 28 days.

Most studies where siRNAs are administered to the CNS are targeting neurons. In a recent study, Querbes and colleagues demonstrated that chronic infusion of chemically-modified siRNAs in phosphate-buffered saline (PBS) can also target oligodendrocytes.<sup>236</sup> An oligodendrocyte specific gene, 2',3'-cyclic nucleotide 3'-phosphodiesterase (*Cnp*), was targeted using 21-nt siRNAs that had 2'OMe-modified pyrimidines and terminal PS linkages at the 3'-ends of each strand (similar to the design employed by McCormick above). siRNAs were administered using an implanted Alzet osmotic pump in both rats (dosed at a rate of 6 mg/kg/day over 7 days) and rhesus monkeys (dosed at 1.2 mg/kg/day for 10 days). Reduction in *Cnp* mRNA was shown using RT-qPCR and an RNAi mechanism of action was proven using 5'RACE-PCR.

Two recent studies demonstrated use of ligand-coupled siRNAs within the CNS. DiFiglia and colleagues employed cholesterol-conjugated 21-nt siRNAs with terminal PS linkages using direct intrastratial injection to target mutant *Htt* and evaluate its role in Huntington's disease.<sup>237</sup> Administration of a single 0.5 nmole dose of cholesterol-siRNA led to a decrease in the mutant HTT protein with improved viability of striatal neurons, smaller inclusion size, and reduced signs of motor disturbance in gait testing. Uno and colleagues conjugated 2'OMe-modified 27/29-nt DsiRNAs with 3'-PS linkages to vitamin E as a delivery ligand.<sup>209</sup> The siRNA targeted *Bace1*, a target of interest for treatment of Alzheimer's disease. The modified anti-*Bace1* siRNA was delivered either in PBS or as a mixture with purified HDL using continuous intracerebroventricular infusion with an osmotic mini-pump for 7 days. Uptake of vitamin E by cells normally involves complexation with LDL (entry into liver) or HDL (entry into other tissues). The authors compared the performance of unconjugated siRNAs with vitamin E-conjugated siRNAs and vitamin E-conjugated siRNAs plus HDL. The vitamin E-conjugated siRNAs mixed with purified HDL significantly outperformed the other formulations, showing a maximal 40% and 60% knockdown of *Bace1* in the hippocampus and parietal cortex, respectively, as measured by RT-qPCR. Without the addition of HDL, the unconjugated siRNAs performed nearly as well as the vitamin E-conjugated siRNAs, and neither was significantly different than the negative controls, highlighting the benefit of adding purified HDL when using vitamin E conjugates.

A number of groups have employed cationic lipid-assisted delivery in the CNS. For example, LaCroix-Fralish and colleagues established a role for the  $\beta_3$  subunit of the Na<sup>+</sup>,K<sup>+</sup>-ATPase pump (*Atp1b3*) as a source of inter-strain variability in the early phase

of the pain response to formalin (chemical burn).<sup>238</sup> The mouse strain A/J exhibits a less pronounced pain response to formalin injections into the foot pad than the mouse strain C57BL/6. Genetic mapping and quantitative trait locus analysis tentatively identified the *Atp1b3* gene as being implicated in the differences in pain responses between mouse strains; this gene had heretofore not been considered important in nociception. To test this hypothesis, anti-*Atp1b3* DsiRNA was administered into the lumbar spinal cord of mice from both strains by i.t. injection at a dose of 0.5  $\mu$ g (~0.025 mg/kg) in the cationic lipid iFECT at 24 hour intervals for a total of 3 injections. Mice were then studied for formalin pain response. Mice receiving vehicle alone or control DsiRNAs injections showed the expected behavioral differences between strains, however mice given anti-*Atp1b3* DsiRNA showed identical behavior between strains for the early phase of the pain response. This pattern was identical for two different anti-*Atp1b3* DsiRNAs, confirming a role for this gene product in nociception.

Also using lipid-assisted delivery of siRNAs into CNS, Dore-Savard and colleagues studied the role of a GPCR, the neurotensin receptor 2 (*Nts2*), in rat thermal nociception.<sup>239</sup> Stimulation of *Nts2* by the synthetic agonist JMV-431 results in analgesia, so suppression of the receptor by RNAi should block the analgesic effects expected from this compound. Anti-*Nts2* DsiRNA was administered as two i.t. injections between the L5 and L6 vertebrae 24 hours apart at a dose of only 1  $\mu$ g (~0.005 mg/kg) in the cationic lipid iFECT. The agonist JMV-431 was given on days 1-4 and rats were tested for thermal nociception. Analgesic responses were totally blocked on days 1 and 2 (following the last DsiRNA injection) and gradually returned to baseline thereafter. Both *Nts2* mRNA and protein levels were demonstrated to be significantly reduced in the L5/6 dorsal root ganglia at day 2, consistent with the observed phenotypic responses. Two different anti-*Nts2* DsiRNAs were demonstrated to result in the same effects, both in suppressing *Nts2* expression and altering nociceptive responses to JMV-431. While the iFECT lipid greatly improved delivery of the DsiRNAs to rat spinal cord and dorsal root ganglia, use of the lipid/siRNA cocktail was limited to acute pain studies as vehicle alone altered animal behavior in attempts to perform similar studies using tonic and chronic pain model systems (Nicolas Beaudet, University of Sherbrooke, personal communication). This problem was solved by shifting to use of the peptide delivery tool Transductin (see discussion below).

Dong and colleagues also employed the iFECT cationic lipid to deliver siRNAs into rat lumbar spinal cord using an epidural catheter in a pain model employing sciatic nerve ligation.<sup>240</sup> Unmodified 21-nt siRNA targeting  $\text{Na}_v1.8$  (tetrodotoxin resistant sodium channel; *Scn10a*) was administered at a dose of 4  $\mu$ g (~0.02 mg/kg) four times over 17 days. Mechanical allodynia was significantly reversed in animals receiving the anti-*Scn10a* siRNA but not the control siRNAs, which correlated with a ~40% decrease in *Scn10a* mRNA as confirmed by RT-qPCR. In one additional study of lipid-formulated siRNAs delivered to CNS tissue, a DOTAP/cholesterol carrier was used to deliver anti-*Jun* siRNA to the striatum in mice and showed 40% knockdown of reporter gene expression.<sup>241</sup> These results were observed 48 hours following a single 3  $\mu$ g dose of the siRNAs.

CPPs or peptide transduction domains (PTDs) have been employed to deliver a variety of cargoes into cells. Their success

with direct conjugation to nucleic acids has been more problematic than expected, possibly because the cationic peptides electrostatically complex with anionic nucleic acids and the resulting charge neutralization blunts the effectiveness of the PTD to mediate transduction.<sup>242</sup> Eguchi and colleagues recently described development of a novel chimeric peptide delivery tool which fused a TAT PTD with the dsRNA-binding domain (DRBD) from a mammalian RNA-binding protein.<sup>243</sup> The resulting peptide was called "PTD-DRBD" and was shown to direct functional delivery of siRNAs to a wide variety of cell types *in vitro* with markedly reduced OTEs compared with traditional cationic lipid mediated transfection (the PTD-DRBD construct is commercially available as Transductin). Michiue and colleagues established a mouse glioblastoma model by stereotactic implantation of human U87MG-EGFRvIII cells into the right corpus striatum of nude mice.<sup>244</sup> Mice were dosed with direct intratumoral CNS injection of various unmodified 21-nt siRNAs complexed with the PTD-DRBD at a dose of 600 pmoles (~0.3 mg/kg) at days 3, 8, and 13 postimplantation. siRNAs targeting *EGFR*, *AKT1*, *AKT2*, and *AKT3* were tested; treatment with any single siRNA sequence did not result in tumor regression. However, treatment with a combination of the anti-*EGFR* siRNA plus the anti-*AKT2* siRNA (but not the anti-*AKT1* or the anti-*AKT3* siRNAs) resulted in apoptosis of tumor cells and markedly improved survival.

Carbon nanotubes are a new material that has the potential to be used for nucleic acid delivery. Carbon nanotubes derivatized with siRNA targeting caspase-3 (*Casp3*) were employed for CNS delivery by Al-Jamal and colleagues, which were delivered to the cortex of rats by stereotactic injection either prior to or following induction of stroke by administration of endothelin1 (ET1), a potent vasoconstrictor.<sup>245</sup> When the siRNA-carbon nanotubes were delivered 24 hours prior to ET1 administration, the anti-*Casp3* siRNA treatment group showed a significant decrease in apoptotic cells as measured by a TUNNEL assay. Carbon nanotubes which were dosed 1 hour following stroke induction showed decreased apoptosis, but the difference compared to negative controls was not as significant.

There are currently no clinical trials ongoing using synthetic siRNAs with CNS delivery in humans.

**Topical administration.** The topical administration section will include both transdermal and mucosal use of siRNAs in animals. Transdermal delivery of siRNAs has been used to knockdown a variety of disease-related targets in skin. An excellent review of the use of lipid-based agents for topical delivery of nucleic acids was recently published by Geusens.<sup>246</sup> Some of the most notable work in this field has come from the Kaspar lab working on treatments for Pachyonychia congenita (PC), a rare skin disorder caused by mutations in one of the many keratin genes which is characterized by thickened nails with painfully disabling palmo-plantar hyperkeratosis. Thus far, 55 different mutations associated with PC have been identified, the most common of which affects amino-acid position 171 in the keratin *KRT6A* gene. For more details, see a recent review of this field by Leachman.<sup>247</sup> Early work from the lab indicated that unmodified 21-nt siRNAs may be suitable for naked delivery in skin<sup>248</sup> and successful uptake of siRNAs in targeted cells was shown using confocal microscopy.<sup>249</sup>



Empiric screening of a set of siRNAs that were tiled through the site of the N171K mutation identified a potent allele-specific siRNA sequence which selectively suppressed the mutant form of the *KRT6A* gene.<sup>43</sup> The lead candidate from this work (TD101) was taken into a phase 1 clinical trial (see below), utilizing direct injection of unmodified, naked siRNA in saline into the plantar hyperkeratotic lesions. Results from studies performed in a single patient were reported last year.<sup>250</sup> While encouraging (transient improvement was observed at the site of the injection), severe pain associated with direct injection proved limiting to the study. As a result, the group has since shifted to study the use of a transdermal delivery cream (GeneCream, TransDerm) or highly modified “self-delivering” siRNAs which could potentially be applied as a topical formulation for therapeutic applications.<sup>251</sup>

Peptides have also been used to facilitate transdermal delivery of siRNAs in mice.<sup>252</sup> Uchida and colleagues studied the use of two different peptides as delivery aids, AT1002 (FCIGRLCG, which was recently identified as a modulator of intracellular tight junctions and directs “paracellular transport”<sup>253</sup>), and Tat (GRKKRRNRRCG), a well-known CPP. These two peptides were complexed with fluorescein-labeled siRNAs and a small volume was applied to the backs of shaved mice. The combination of both peptides complexed with the siRNA led to the deepest and most widely dispersed dye signal as observed by confocal microscopy. These results suggested that a complex which mediates both transcellular and intracellular delivery is optimal for transdermal delivery of siRNAs.

Takanashi and colleagues describe use of a lipid/alcohol-based formulation called “GeneCream”, obtained from TransDerm.<sup>254</sup> This group employed unmodified 21-nt siRNA targeting osteopontin (*Spp1*), an extracellular matrix Th1 cytokine known to be involved in the pathogenesis of autoimmune inflammatory arthritis, to reduce the severity of collagen-induced arthritis in mice. The siRNA was administered topically as 2 mg/day in GeneCream to the paws of mice. A marked reduction in joint swelling was observed in mice receiving the anti-*Spp1* siRNA/GeneCream formulation but not those receiving the scrambled siRNAs or vehicle-only controls. Joint histology showed a significant reduction in inflammation, reminiscent of the images seen in collagen-induced arthritis mice using i.p. injected anti-*Tnf* DsiRNA with a chitosan vehicle previously discussed above.<sup>229</sup>

Cholesterol-conjugated siRNAs having 3'-PS linkages were directly administered to the intravaginal epithelium of mice.<sup>255</sup> Two siRNAs were employed; a siRNA sequence targeting the *UL29* gene of the herpes simplex virus type-2 (HSV-2) was combined with a siRNA sequence targeting the HSV-2 host factor, nectin-1 (*Pvr11*). Use of the anti-*UL29* siRNA alone gave about 24 hours of protection from the time of application while use of the anti-*Pvr11* siRNA showed delayed but longer lasting activity. Topical administration of both siRNAs together provided protection from HSV-2 viral challenge over the course of 1 week. Previous work from this group showed slight but significant inflammation when unmodified siRNAs were applied to vaginal mucosa in a cationic lipid formulation.<sup>256</sup> In the present study, combined use of the cholesterol and PS modifications resulted in stable molecules that could be used with naked delivery, eliminating toxicity associated with the delivery vehicle.

**Clinical trials—transdermal delivery.** As discussed above, TD101 was tested in a phase I clinical trial for the treatment of PC in a single patient having a known N171K mutation in the *KRT6A* gene. This trial represented the first time a mutation-specific siRNA sequence was evaluated in humans.<sup>250</sup> The 26-week study was completed late in 2008 and was sponsored by the PC Project in association with TransDerm, Inc. (<http://clinicaltrials.gov/ct2/show/NCT00716014>). Patient assessment and physician-determined clinical efficacy metrics revealed regression of callus on the siRNA-treated lesions, but not on the vehicle-treated foot. Pain associated with direct injection into the callus was limiting and other routes of administration are being investigated. No side effects were observed that could be directly ascribed to the siRNA drug itself.

In a clinical study performed in China, a CPP siRNA formulation using the peptide TD1-R8 (ACSSSPSKHCGGRRRRRRRR) was used in the topical administration of siRNA targeting microphthalmia-associated transcription factor (*MITF*).<sup>257</sup> TD1-R8 and anti-*MITF* siRNA was formulated in a cream to treat hyperpigmented (hypermelanin) facial lesions, a disorder known as melasma. *MITF* (microphthalmia-associated transcription factor) is a major regulator of melanocyte development and is a possible target to treat conditions involving hyperpigmentation. A total of 56 patients were enrolled with moderate to severe facial lesions. A study group of 31 received the 0.005% anti-*MITF* siRNA cream and a control group of 26 received a 10% magnesium-L-ascorbyl-2-phosphate cream. Clinical evaluation at the end of the 12 week study showed a significant lightening of the skin as expected with *MITF* inhibition for those patients who received the anti-*MITF*-siRNA cream.

A clinical trial (<http://clinicaltrials.gov/ct2/show/NCT00672542>) sponsored by Duke University is in the recruitment phase and involves *ex vivo* siRNA transfection in DCs to be used as a vaccine in patients with confirmed metastatic melanoma. Preclinical results demonstrated that siRNA targeting the immunoproteasome in DCs and subsequent transfection with RNA encoding melanoma antigens led to improved induction of cytotoxic T lymphocytes targeting melanoma cells.<sup>258</sup> In this phase 1 study, DCs with optimized antigen presentation are administered via intradermal injection. Toxicity and clinical response following vaccination are currently being evaluated.

**Direct intratumoral administration.** Intratumoral injection is a commonly used strategy to query the role of specific oncogenes in s.c. tumor models in rodents. This route of dosing does not necessarily require as much protection of the siRNAs from nuclease degradation by chemical modification or complexation with a delivery vehicle as does i.v. administration. Removal of issues associated with systemic delivery is advantageous, and local delivery usually requires significantly lower total doses of siRNAs.

Subcutaneous implants of B16 melanoma cells in syngeneic C57BL/6 mice were used to test the role of RALBP1 (Rlip76) in tumor growth.<sup>259</sup> A single intratumoral injection of 100 µg of naked, unmodified anti-*Ralbp1* siRNA in 100 µl PBS targeting the stress-response membrane protein Rlip76 resulted in tumor regression out to almost 30 days. The same results were seen with treatment using an anti-RALBP1 antibody or a PS antisense DNA



oligonucleotide directed to RALBP1, further validating use of this target as a treatment for melanoma. Also using naked delivery, Suo and colleagues treated gastric cancer *in vivo* with unmodified 21-nt siRNA targeting the anion exchanger 1 (*SLC4A1*).<sup>260</sup> Established s.c. tumors (SGC7901 cells) were directly injected with 7 doses of 13.3 µg of anti-*SLC4A1* siRNA every 3 days. After 18 days, Western blot analysis showed almost complete knock-down of *SLC4A1* protein expression and tumor volume was 50% less than in negative control mice.

Formulation of siRNAs with cationic lipids is a common approach used to improve delivery following direct local injection; several reports using these methods will be discussed. Dharmapuri and colleagues used 21-nt siRNAs targeting the cell cycle regulators *KIF11* and *PLK1* formulated in lipid nanoparticles provided by Sirna/Merck to suppress growth of s.c. xenogeneic tumor implants in nude mice.<sup>261</sup> siRNAs were directly injected into the tumor mass at a dose of 60 µg in 50 µL volume using variable dosing regimens. On average, the rate of tumor growth was reduced by 50% using this approach. Malignant glioblastoma is a cancer with high mortality and with no effective treatments. Liu and colleagues postulated that disrupting iron homeostasis in glioma cells using siRNA targeting the heavy chain of ferritin (*FTH1*) would impair energy metabolism and reduce cell growth rate or make the cells more susceptible to traditional chemotherapeutic agents.<sup>262</sup> Anti-*FTH1* siRNA was formulated in cholesterol/DOPE liposomes and delivered by intratumoral injection (1.5 µg) once weekly into s.c. implants of U251 glioma cells in nude mice. BCNU (bis-chloroethylnitrosourea, a standard chemotherapeutic agent for treatment of glioblastoma) was administered 24 hours after the siRNA treatment. Tumor volume in siRNA-treated mice was half that observed in control animals, indicating that the anti-*FTH1* treatments sensitized the tumors to chemotherapy.

A high percentage of human cervical cancers are linked to infection by the human papilloma virus (HPV), particularly strains HPV16 and HPV18. The viral E7 gene product directs degradation of the retinoblastoma protein (pRb, an endogenous tumor-suppressor) by targeting it for ubiquitination. Reducing pRb levels leads to derepression of certain transcription factors, which in turn leads to cell division. At the same time, the viral E6 gene product blocks the compensatory upregulation of p53 that normally occurs as a regulatory response to uncontrolled cell division. Thus the combined actions of the viral E6 and E7 gene products are needed to produce the malignant phenotype. The E6 and E7 genes are therefore ideal targets for nucleic acid-based therapies for the treatment of HPV-derived tumors.<sup>263</sup> Direct intratumoral injection of naked, highly modified (siSTABLE) siRNAs targeting the HPV E6/E7 genes was studied by Jonson and colleagues.<sup>264</sup> s.c. tumor implants of ovarian cancer cells in mice (CaSki cells, which are HPV 16+) were treated every 3 days (4 pmole/dose in saline, ~0.0025 mg/kg/dose) for 35 days. The size of anti-E6/E7 siRNA-treated tumors was significantly smaller than the saline-treated or the control siRNA-treated implants. Yamato and colleagues took a similar approach, studying the use of carefully optimized unmodified 21-nt anti-E6/E7 siRNAs directly injected into s.c. tumors in mice derived from SiHa cells (a HPV16+ cervical cancer line).<sup>265</sup> In this case, the siRNAs were complexed with atelocollagen and

dosed at 500 pmoles per injection once every 7 days for 35 days. Dramatic regression of tumors was observed only in the anti-E6/E7 siRNA-treated animals. A number of researchers have employed nucleic acid-based anti-HPV treatments for the treatment of cervical cancer, including expressed anti-E6/E7 shRNAs delivered in a lentiviral vector<sup>266</sup> and anti-E6/E7 siRNAs delivered i.v. using a lipid-based nanoparticle.<sup>267</sup>

Seth and colleagues described use of siRNAs formulated in DiLA<sup>2</sup> lipid nanoparticles with direct intravesicular infusion as a local treatment for bladder cancer implants in mice.<sup>268</sup> The siRNAs employed were UNA-modified 21-nt duplexes targeting the survivin (*BIRC5*) and polo like kinase 1 (*PLK1*) genes. Human KU-7 bladder cancer cells engineered to express a luciferase reporter were grown as intravesicular implants in nude mice. The siRNA/lipid nanoparticles were administered as an intravesicular infusion at doses of 0.5–1.0 mg/kg on days 2, 4, 7 and 10 after tumor implantation. Tumor growth was assessed by *in vivo* BLI which showed reductions in tumor growth rates in treated animals compared with controls. This correlated with 70–90% reductions in *BIRC5* and *PLK1* mRNA by RT-qPCR assays. RNAi mechanism of action was confirmed by 5'RACE-PCR analysis.

A number of researchers have reported success using PEI as a siRNA delivery tool with direct local injection. This route of administration bypasses some toxicity concerns which sometimes limit PEI use following systemic i.v. injection. In a s.c. murine glioma model, unmodified 21-nt anti-*HIF1A* siRNA was formulated with JetPEI and dosed every third day for up to 60 days using direct intratumoral injection (~0.4 mg/kg/dose).<sup>269</sup> The anti-*HIF1A* siRNA treatment significantly reduced the size of established tumors and almost totally prevented growth of smaller tumors. Similarly, Chen and colleagues used unmodified, 21-nt siRNA targeting *KLF6-SV1* formulated with PEI for direct injection into s.c. tumor implants in mice.<sup>270</sup> *KLF6-SV1* is a dominant-negative splice variant of the Kruppel-like factor 6 gene which is thought to play a role in development of some gastric carcinomas. Proliferation of two different gastric cancer cell lines (BGC-823 and SGC-7901 cells) was reduced following treatment with even a single 20 µg dose (1 mg/kg) of the anti-*KLF6-SV1* siRNA compared to control siRNAs.

Electroporation is commonly used *in vitro* to promote cellular uptake of DNA or RNA, particularly in cell lines that are difficult to transfect with cationic lipids. It can also be applied to *in vivo* local delivery of nucleic acids. Golzio and colleagues reported the use of unmodified 22-nt anti-*EGFP* siRNA to suppress fluorescence in B16F10-EGFP melanoma cells growing in syngeneic C57BL/6 mice as s.c. implants.<sup>271</sup> The B16F10-EGFP cells stably express EGFP and offer a convenient reporter system. A single 12 µg dose of siRNAs in PBS was injected into the tumors followed by electroporation at the site of injection using 4 pulses of 480V/cm at 5 ms duration with 1 Hz frequency. EGFP fluorescence was suppressed for 4 days post-treatment and whole-body imaging showed a significant decrease in fluorescence between the siEGFP-treated mice and negative control animals. Nakai and colleagues also employed electroporation to deliver naked, unmodified 25–27-nt siRNAs in mice.<sup>272</sup> The gene target, microphthalmia-associated transcription factor (*Mitf*) regulates melanocyte differentiation and is involved

in melanin synthesis. In this case, suppression of *Mitf* was tested as a means to reduce growth of B16 melanoma cells in syngeneic C57BL/6 mice. Consecutive 2 x 20 µg doses of the siRNAs were administered daily for the first 10 days of the study. Following direct injection of the siRNAs in PBS into the tumor mass, local electroporation was performed using 4 pulses at 175V/cm at 50 ms duration with 1 Hz frequency. Mice receiving anti-*Mitf* siRNA via electroporation showed no tumor growth through the first 20 days while the anti-*GFP* siRNA, PBS alone and nontreated control mice all showed tumor growth by day 8. After 35 days, tumor volume was more than double for all of the negative control cohorts relative to the anti-*Mitf* siRNA-treated animals.

Peptide carriers for siRNAs are often perceived as having lower toxicity because biodegradation of the delivery system results in amino-acid monomers. Recently, disulfide-linked, polyarginines were demonstrated to have *in vivo* utility in delivering siRNAs using direct injection into s.c. tumors.<sup>273</sup> Unmodified 21-nt siRNA targeting *VEGF* were condensed in the presence of the cysteine-flanked peptide, Cys-Arg<sub>5</sub>-Cys, to discrete particles with a mean size of 100 nm. *In vitro* studies showed that the polyplexes were readily reduced in the cytoplasm when cells contained a relatively high cytoplasmic concentration of glutathione. *In vivo*, the growth rate of a s.c. tumor was reduced when two intratumoral doses (3.5 µg/dose) were delivered weekly.

**Clinical trials—intratumoral delivery.** Silenseed launched a Phase 0/I Trial in patients with operable adenocarcinoma of the pancreas in a safety and tolerability study of siG12D LODER (<http://clinicaltrials.gov/ct2/show/NCT01188785>). The siRNA sequence targets the *KRAS*-G12D mutation and is delivered with a biodegradable polymeric matrix, LODER. The formulation is dosed directly to the adenocarcinoma via a biopsy needle.

**Intranasal/inhaled administration.** Inhaled sprays are a common method of delivering small molecule drugs to the respiratory system. Direct nasal or intratracheal administration was one of the early routes employed for *in vivo* siRNA delivery. Often the target tissue is the epithelial lining of the lungs; however, trafficking siRNA nanoparticles through the mucous layer which lines the epithelium is a significant barrier for this method of delivery. Nevertheless, some favorable results have been reported using this approach. Yueksekdag and colleagues employed intranasal administration of naked, unmodified 21-nt siRNAs in mice.<sup>274</sup> This group studied suppression of the amiloride-sensitive epithelial Na<sup>+</sup> channel (*Scnn1a*), a target of interest in treatment of cystic fibrosis. A single 80 µg perfusion of the anti-*Scnn1a* siRNA in water did not lead to a detectable reduction of *Scnn1a* mRNA; however, 3 doses of anti-*Scnn1a* siRNA over the course of 8 days resulted in a 60% decrease in expression when assayed by RT-qPCR.

The use of siRNA to treat respiratory viruses has been an area of particular focus as few small molecule drugs exist which are effective in treating these pathogens. siRNA-based treatments for influenza virus or SARS corona virus infections were discussed in previous reviews,<sup>7,275</sup> and improved methods to treat respiratory infections using modified siRNAs were recently reviewed by Barik.<sup>276,277</sup> In a mouse model of equine herpes virus type-1

(EHV-1) infection, siRNAs targeting a key viral envelope glycoprotein and helicase were delivered 0.5 hours prior to infection or up to 12 hours following infection by intranasal infusion using doses ranging from 6.25 to 37.5 pmoles (~0.02 mg/kg or less) in either PBS or the cationic lipid Lipofectamine.<sup>278</sup> A large reduction in plaque-forming units per mg of lung tissue was seen, and combination therapy of more than one anti-*EHV-1* siRNA sequence was more effective than use of a single agent. Interestingly, the siRNAs delivered in PBS were generally more effective than when delivered in a cationic lipid formulation. When studying treatments for viral infection, it is important to consider and control for the effects of immune stimulation by dsRNAs as this side effect may contribute to observed antiviral effects.<sup>112</sup>

**Clinical trials—intranasal/inhaled delivery.** ALN-RSV01 is an unmodified 21-nt siRNA from Alnylam Pharmaceuticals which is currently under study for the treatment of respiratory syncytial virus (RSV) via intranasal/inhaled administration. ALN-RSV01 is administered without a delivery aid; disruption of the integrity of the normal air/tissue interface mucus barrier during viral infection may facilitate delivery in lung, a tissue that is normally well defended against the entry of foreign material. A phase I dose-escalation and tolerability study was completed in 2007.<sup>279</sup> A total of 101 healthy adults were treated with placebo (normal saline) or ALN-RSV01 and no adverse effects were observed for doses of up to 150 mg administered five times daily. Any side effects seen were moderate and occurred with similar frequency in the ALN-RSV01 treatment group and the placebo group. A Phase 2 study evaluated ALN-RSV01 in 88 healthy human volunteers inoculated with RSV.<sup>280</sup> ALN-RSV01 was delivered intranasally (75 or 150 mg) 2 days prior to and 3 days following RSV infection. The placebo-treated group showed 71.4% RSV infections; whereas, the ALN-RSV01 recipients had only 44.2% culture-defined RSV infections. Further evaluation of ALN-RSV01 in naturally infected patients was recently completed in 24 lung-transplant patients infected with RSV.<sup>281</sup> Three daily treatments with aerosolized ALN-RSV01 (0.6 mg/kg) resulted in an improvement of RSV symptoms as reflected by “cumulative daily total symptom scores.” In addition, ALN-RSV01 treatments lead to a reduction in the incidence of bronchiolitis obliterans (BOS)—fibrosis/inflammation of the bronchioles following RSV infection. A further Phase IIb clinical trial was opened in February of 2010 to evaluate the efficacy and safety of aerosolized ALN-RSV01 as well as standard of care in lung-transplant patients infected with RSV (<http://www.clinicaltrials.gov/ct2/show/NCT01065935>). The primary outcome measure of this study which is currently recruiting patients will be the occurrence of new or progressive BOS.

ZaBeCor Pharmaceuticals reported the completion of a Phase I clinical trial for Excellair, a siRNA drug targeting spleen tyrosine kinase (SYK) for the treatment of asthma (<http://www.zabecor.com/news/news092209.php>). Patients received Excellair by inhalation daily over 21 days. No serious side effects were reported and 75% indicated an improvement in breathing. In addition, ZaBeCor announced the launch of a Phase II clinical trial in 2009. The details of these trials from this Pennsylvania-based company have not been published.

**Optical administration.** Due to the unique ability to deliver drugs using direct local intravitreal injection, ocular diseases were among the first indications investigated for siRNA-based therapeutics. Ocular delivery of nucleic acid-based drugs was recently reviewed by Fattal<sup>282</sup> and Campochiaro.<sup>283</sup> While the earliest studies reported in the literature employed direct intravitreal injection of naked siRNAs, work by Murata and colleagues used lipid-facilitated delivery with subconjunctival injection. Large sets of siRNAs targeting a particular gene can be made using PCR, *in vitro* transcription, and Dicer. A pooled collection of anti-*Vegf* diced-siRNAs (1 µg) were formulated in Lipofectamine and administered by subconjunctival injection in rats in a suture-induced corneal angiogenesis model system.<sup>284</sup> Treatment with the pooled anti-*Vegf* siRNAs significantly reduced angiogenesis. Any therapy which reduces neovascularization is of interest in the treatment of wet age-related macular degeneration (AMD) or diabetic retinopathy. In another study using lipid-assisted delivery, fluorescently labeled siRNAs were formulated in Transit-KO and administered by direct intravitreal injection in mice.<sup>285</sup> As little as 5 ng of siRNAs showed robust uptake in the retina by histological sectioning and fluorescent microscopy 24 hours following injection.

Enthusiasm for direct ocular administration of siRNAs to treat diseases like AMD grew from the number of favorable early reports from many groups and led to the initiation of several clinical trials (see below) of RNAi therapies targeting genes involved in choroidal neovascularization in the eye, such as vascular endothelial growth factor (*VEGF*) or its receptor (*FLT1*). While ocular siRNA drugs still have promise, enthusiasm for this approach waned following reports that cell-surface TLR3 receptors recognized 21-nt siRNAs and that downstream effects of a TLR3-mediated innate immune response were responsible for some of the early successes reported in preventing neovascularization.<sup>286</sup> A recent report showed that subretinal injections of 21-nt siRNAs triggered TLR3 and induced retinal degeneration which further complicates optical delivery of siRNAs in clinical trials.<sup>287</sup>

**Clinical trials—optical delivery.** Bevasiranib was first introduced into a clinical trial in 2005 by Opko Health, Inc. Since then, a Phase II trial has been completed and this siRNA against *VEGF* became the first Phase III drug in this class of therapeutics. However, the study was terminated in 2009 based on a recommendation from the Independent Data Monitoring Committee (<http://clinicaltrials.gov/ct2/show/NCT00499590>). This study was aimed at the treatment of wet AMD. In addition, a Phase II study for Bevasiranib was completed for the treatment of diabetic macular edema (DME), but no Phase III trial has been announced (<http://clinicaltrials.gov/ct2/show/NCT00306904>). Wet AMD has been the most studied disease for siRNA drugs in clinical trials. Sirna-027 (now AGN-745 in the Phase II study sponsored by Allergan) is a chemically-modified siRNA that targets *VEGF* and was tested in a dose-escalation study by intravitreal injection in 26 patients with choroidal neovascularization from wet AMD.<sup>288</sup> Single doses ranged from 100 to 1600 µg and were well-tolerated. Mean foveal thickness was reduced two weeks following Sirna-027 dosing, and the decrease was most pronounced in the 100 and 200 µg doses. Like Bevasiranib, Sirna-027 was shown to be well-tolerated from

a safety standpoint, but the trial was terminated as a result of lack of improvement of visual acuity.

PF-655, from Pfizer and Quark Pharmaceuticals, was studied in a phase I and two phase II clinical trials for the treatment of AMD. This siRNA sequence targets a different proangiogenic factor, *RTP801*. As with the other intravitreal-delivered siRNAs, the phase I trial (<http://clinicaltrials.gov/ct2/show/NCT00725686>) indicated that PF-655 was well-tolerated; however, the objectives of the study were deemed to be not achievable and the trial was terminated (<http://clinicaltrials.gov/ct2/show/NCT00701181>). The drug, now termed PF-04523655, is being evaluated in a Phase II trial to treat wet AMD in combination with Lucentis, an anti-VEGF antibody (<http://clinicaltrials.gov/ct2/show/NCT00713518>). US Food and Drug Administration-approved therapies for wet AMD include Macugen (pegaptanib) and Lucentis (ranibizumab). Treatment with these drugs is extremely effective and it will be challenging for new siRNA-based therapies to show better performance.

Quark Pharmaceuticals initiated a phase I dose-escalation study to study siRNAs with intravitreal administration as therapy for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (<http://clinicaltrials.gov/ct2/show/NCT01064505>). QPI-1007 is a chemically-modified siRNA sequence targeting *CASP2*. Sylentis is developing a therapy for ocular hypertension using a siRNA (SYL040012) that targets the  $\beta$ -2 adrenergic receptor (*ADRB2*) (<http://clinicaltrials.gov/ct2/show/NCT00990743>). A phase I trial tested the safety and the effect on intraocular pressure using topical administration (eye drops) and showed no adverse effects. A phase II trial opened in 2010 to evaluate the tolerance and therapeutic effect of the siRNA in patients with elevated intraocular pressure (<http://clinicaltrials.gov/ct2/show/NCT01227291>).

***i.m. administration.*** The protein atelocollagen (see above) has been used in *i.m.* delivery of unmodified 21-nt siRNA targeting myostatin (*Gdf8*) in the treatment of muscular dystrophy.<sup>190</sup> The anti-*Gdf8* siRNA (10 µmol/l in 0.5% atelocollagen) was injected into the biceps femoris muscle of C57BL/6 mice, with injection of a scrambled siRNA/atelocollagen formulation in the contralateral muscle serving as a negative control. The anti-*Gdf8* siRNA-treated muscle showed a significant increase in muscle mass over two weeks following the single *i.m.* injection.

Morgan and colleagues reported direct injection of siRNAs to cardiac muscle.<sup>289</sup> A single 20 µg dose of naked unmodified 21-nt siRNA targeting the sodium/hydrogen exchanger (*Nhe1*) was injected into the left ventricle. NHE1 protein and mRNA were reduced after 48 hours by 33% and 20%, respectively. Additionally, RT-qPCR results from cardiac tissue 72 hours following siRNA delivery suggested the presence of a bystander effect. Examination of tissue from locations other than the site of injection (left ventricle) in the heart also showed some *Nhe1* knockdown, which suggests that the anti-*Nhe1* siRNA may have spread to neighboring cells/tissue via gap junctions.

**Oral administration.** Most compounds suitable for oral administration are small molecule drugs formulated to release the active agent in the stomach or small intestine for absorption by the gut mucosa and eventual release into the circulatory system.



This environment is quite harsh, and any drug delivered this way experiences wide swings in pH with prolonged exposure to a variety of nucleases, as well as proteases and lipases. While oral administration of siRNAs remains a lofty goal, it seems unlikely that true systemic delivery will be easily achieved, although Tillman and colleagues have reported some success with oral delivery of single-stranded ASOs.<sup>290</sup> Double-stranded siRNAs have a very high molecular weight and, even if such compounds survived the harsh gastrointestinal environment, they would be largely excluded from uptake by the gut epithelia and subsequent escape into the circulatory system. Therefore, this discussion of a common route of systemic delivery for small molecules is more appropriately highlighted under the heading of “local delivery” since oral administration of siRNAs may more easily find application to treat local diseases within the gastrointestinal system itself. Wilson and colleagues designed a thioketal delivery system that is selectively degraded in the presence of reactive oxygen species produced in the intestinal epithelium.<sup>291</sup> In this case, the orally-delivered siRNA targets *Tnf*, a proinflammatory cytokine which induces the intestinal inflammation required to release the siRNA from the thioketal delivery system. Colitis-induced mice were dosed by oral gavage with 0.23 or 2.3 mg/kg of siRNAs daily for 6 days and sacrificed on the 7th day to determine siRNA uptake and function in target tissue. The induced colon inflammation coupled with thioketal-formulated particles led to increased release of Cy5-labeled siRNAs selectively in regions of inflammation. Also, colonic *Tnf* levels were significantly reduced based on RT-qPCR analysis of mRNA in harvested tissue. In addition to the thioketal work, the same group also developed a PEI-condensed siRNA and PLGA nanoparticle delivery system for reducing TNF in inflamed colon tissue.<sup>292</sup> Anti-*Tnf*-siRNA nanoparticles showed a tenfold decrease in colonic TNF expression when dosed orally over the course of 4 days compared to control siRNAs.

By exploiting the mobility of immune cells, Aouadi and colleagues demonstrated systemic effects from oral delivery of siRNAs encapsulated in  $\beta$ 1,3-D-glucan shells (GeRPs, essentially porous shells extracted from yeast).<sup>293</sup> Oral gavage of GeRPs containing an anti-*Map4k4* siRNA in mice resulted in suppression of *Map4k4* mRNA in macrophages isolated from a variety of tissues, including lung, liver, spleen, as well as a decrease in *Tnf* from the peritoneal cavity following lipopolysaccharide stimulation. It was thought that the GeRPs were taken up by resident macrophages in the gut-associated lymphoid tissue after which normal immune cell trafficking resulted in systemic spread of macrophages bearing the orally dosed anti-*Map4k4* siRNA. The same group later reported an improvement in this technology where the siRNA cargo was complexed with the peptide delivery tool Endo-Porter. The new formulation showed improved delivery and was particularly effective in macrophage-specific targeting with i.p. administration.<sup>294</sup>

There are currently no clinical trials ongoing using chemically synthesized siRNAs with oral delivery in humans. However, an oral “transkingdom” expressed shRNA (tkRNAi) drug targeting *CTNNB1* ( $\beta$ -catenin) called CEQ508 is currently recruiting patients for a Phase 1 trial by Marina Biotech for the treatment of familial adenomatous polyposis.<sup>295</sup>

## Other delivery routes

Sellick and colleagues employed direct cochlear administration of naked siRNAs to elucidate the function of inner ear proteins. In a proof-of-principle study, this group demonstrated that direct cochlear delivery was possible while still preserving auditory function.<sup>296</sup> Fluorescein-tagged siRNAs were administered using a micropipette directly into the endolymphatic compartment of the cochlear duct. The dye-labeled siRNAs entered into the stria vascularis, where several ion transport channels involved in hearing are localized.

Nakamura and colleagues developed an octa-arginine-modified multifunctional envelope-type nanoparticle device (R8-MEND) for siRNA delivery.<sup>297</sup> When complexed with siRNAs, R8-MEND formed particles under 100 nm in diameter which efficiently delivered siRNAs *in vitro* with minimum toxicity. Akita and colleagues coupled the fusogenic peptide GALA to this particle and employed it for *ex vivo* delivery of siRNA targeting *Socs1* to bone marrow-derived DCs (BMDCs).<sup>298</sup> *Ex vivo* silencing of *Socs1* led to an increase in STAT1 production in BMDCs as confirmed by Western blot. Likewise, the cytokines TNF and IL6 were both increased in the anti-*Socs1*-treated BMDCs compared to use of a control siRNA. The *ex vivo* treated BMDCs were injected into the footpads of mice and subsequent s.c. tumor challenge showed that *Socs1*-silenced BMDCs lead to a dramatic decrease in the rate of tumor growth over the course of 35 days. CD40 plays a key role in immune recognition of foreign tissue and may be involved in kidney allograft rejection. Ripoll and colleagues delivered unmodified 21-nt anti-*Cd40* siRNA to rat kidneys *ex vivo* via intra-arterial infusion of 30  $\mu$ g siRNAs in water.<sup>299</sup> The treated kidneys were subsequently transplanted, and the rats were monitored for 100 days post-transplant. Histological analysis showed that transplanted kidneys treated with the anti-*Cd40* siRNA had reduced features characteristic of humoral rejection, suggesting successful intervention in the graft rejection process.

## CONCLUDING REMARKS

Methods that selectively suppress the expression of a targeted gene are remarkably useful tools in studying the role that gene function has in normal and pathological states. The past five years have seen an explosion in the use of siRNAs as a research tool in animal models. While such experiments are not yet routine, the use of gene knockdown technology *in vivo* has almost become expected in some journals. The technology exists to suppress the level of any gene target desired. Delivery technology has not fully caught up, and safe, efficient delivery of the nucleic acid effector molecules to the desired tissue remains the greatest limitation to more widespread adoption of this technology.

As *in vitro* use of RNAi methods has become more widespread, a variety of potential problems emerged that complicated interpretation of experiments: OTEs from immune stimulation and from suppression of nontargeted genes by the unintended interaction of the siRNAs with miRNA-pathway processes (via seed-region homology). Over time, the underlying mechanisms for these unwanted OTEs have been elucidated and methods to prevent or circumvent them are now widely available. In particular, selective use of chemical modifications (such as 2'OMe and UNA residues) can reduce or eliminate many of the miRNA-pathway

class of OTEs and can help to evade stimulation of the innate immune system. While many cell lines adapted to growth *in vitro* no longer have the capacity to respond to dsRNAs as foreign molecules, stimulation of the innate immune system is a significant concern *in vivo* and it is prudent to modify all siRNAs used in animal work, especially when using polymer- and lipid-based delivery tools that maximize exposure of the siRNA cargo to the endosomal compartments where TLRs 7 and 8 reside. All *in vivo* studies should include monitoring for immune stimulation by the siRNAs and/or the delivery tool, even if the appropriate chemical modification strategies are employed.

As crucial as use of a delivery system is to the success of most *in vivo* siRNA experiments, the delivery vehicle itself can be a source of toxicity and/or OTEs. New delivery tools are constantly under development that hopefully will address these concerns, and breakthroughs in delivery technology will pave the way to finally make animal experimentation commonplace. The “final frontier” of siRNA technology is use as a drug in humans. A number of clinical trials are already in progress and additional new trials are planned to begin in the next few years. Local administration avoids many of the complications seen with systemic delivery; therefore ocular and topical therapies have the greatest potential to move forward quickly. Recent advances in lipid nanoparticle chemistry look particularly favorable for liver delivery, and it seems likely that hepatic diseases may be the first area widely approachable using systemic/i.v. routes of administration. As a final note: as with all branches of science, novel methods in the RNAi field are quickly published and rapidly generate widespread enthusiasm; it is prudent to recall that many of the exciting reports discussed herein have not yet been reproduced by outside groups and that independent validation is a necessary step.

## SUPPLEMENTARY MATERIAL

**Table S1.** Important features of 134 reports employing synthetic siRNA *in vivo*.

## ACKNOWLEDGMENTS

The authors gratefully acknowledge the assistance of Kim A. Lennox and Scott D. Rose for helpful discussions and in preparing the manuscript. The authors are employed by Integrated DNA Technologies, Inc., (IDT) which offers oligonucleotides for sale similar to some of the compounds described in the manuscript. IDT is, however, not a publicly traded company and neither author owns any shares/equity in IDT. M.A.B. is on the scientific advisory board of Dicerna Pharmaceuticals.

## REFERENCES

1. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**: 806–811.
2. Meister, G and Tuschl, T (2004). Mechanisms of gene silencing by double-stranded RNA. *Nature* **431**: 343–349.
3. Pham, JW and Sontheimer, EJ (2004). The Making of an siRNA. *Mol Cell* **15**: 163–164.
4. Tiemann, K and Rossi, JJ (2009). RNAi-based therapeutics-current status, challenges and prospects. *EMBO Mol Med* **1**: 142–151.
5. Zamore, PD, Tuschl, T, Sharp, PA and Bartel, DP (2000). RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* **101**: 25–33.
6. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**: 494–498.
7. Behlke, MA (2006). Progress towards *in vivo* use of siRNAs. *Mol Ther* **13**: 644–670.
8. Davidson, BL and McCray, PB, Jr (2011). Current prospects for RNA interference-based therapies. *Nat Rev Genet* **12**: 329–340.
9. Burnett, JC, Rossi, JJ and Tiemann, K (2011). Current progress of siRNA/shRNA therapeutics in clinical trials. *Biotechnol J* **6**: 1130–1146.
10. Schwarz, DS, Hutvagner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. *Cell* **115**: 199–208.
11. Khvorova, A, Reynolds, A and Jayasena, SD (2003). Functional siRNAs and miRNAs exhibit strand bias. *Cell* **115**: 209–216.
12. Ui-Tei, K, Naito, Y, Takahashi, F, Haraguchi, T, Ohki-Hamazaki, H, Juni, A *et al.* (2004). Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. *Nucleic Acids Res* **32**: 936–948.
13. Reynolds, A, Leake, D, Boese, Q, Scaringe, S, Marshall, WS and Khvorova, A (2004). Rational siRNA design for RNA interference. *Nat Biotechnol* **22**: 326–330.
14. Pei, Y and Tuschl, T (2006). On the art of identifying effective and specific siRNAs. *Nat Methods* **3**: 670–676.
15. Peek, AS and Behlke, MA (2007). Design of active small interfering RNAs. *Curr Opin Mol Ther* **9**: 110–118.
16. McQuisten, KA and Peek, AS (2009). Comparing artificial neural networks, general linear models and support vector machines in building predictive models for small interfering RNAs. *PLoS ONE* **4**: e7522.
17. Huesken, D, Lange, J, Mickanin, C, Weiler, J, Asselbergs, F, Warner, J *et al.* (2005). Design of a genome-wide siRNA library using an artificial neural network. *Nat Biotechnol* **23**: 995–1001.
18. Shabalina, SA, Spiridonov, AN and Ogurtsov, AY (2006). Computational models with thermodynamic and composition features improve siRNA design. *BMC Bioinformatics* **7**: 65.
19. Wang, X, Wang, X, Varma, RK, Beauchamp, L, Magdaleno, S and Sendra, TJ (2009). Selection of hyperfunctional siRNAs with improved potency and specificity. *Nucleic Acids Res* **37**: e152.
20. Westerhout, EM and Berkhout, B (2007). A systematic analysis of the effect of target RNA structure on RNA interference. *Nucleic Acids Res* **35**: 4322–4330.
21. Gredell, JA, Berger, AK and Walton, SP (2008). Impact of target mRNA structure on siRNA silencing efficiency: A large-scale study. *Biotechnol Bioeng* **100**: 744–755.
22. Schubert, S, Grünweller, A, Erdmann, VA and Kurreck, J (2005). Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. *J Mol Biol* **348**: 883–893.
23. Mückstein, U, Tafer, H, Hacker Müller, J, Bernhart, SH, Stadler, PF and Hofacker, IL (2006). Thermodynamics of RNA-RNA binding. *Bioinformatics* **22**: 1177–1182.
24. Shao, Y, Chan, CY, Malyekkel, A, Lawrence, CE, Roninson, IB and Ding, Y (2007). Effect of target secondary structure on RNAi efficiency. *RNA* **13**: 1631–1640.
25. Lu, ZJ and Mathews, DH (2008). Efficient siRNA selection using hybridization thermodynamics. *Nucleic Acids Res* **36**: 640–647.
26. Tafer, H, Ameres, SL, Obernosterer, G, Gebeshuber, CA, Schroeder, R, Martinez, J *et al.* (2008). The impact of target site accessibility on the design of effective siRNAs. *Nat Biotechnol* **26**: 578–583.
27. Peek, AS (2007). Improving model predictions for RNA interference activities that use support vector machine regression by combining and filtering features. *BMC Bioinformatics* **8**: 182.
28. Tilesi, F, Fradiani, P, Socci, V, Willems, D and Ascenzioni, F (2009). Design and validation of siRNAs and shRNAs. *Curr Opin Mol Ther* **11**: 156–164.
29. Hofacker, IL and Tafer, H (2010). Designing optimal siRNA based on target site accessibility. *Methods Mol Biol* **623**: 137–154.
30. Ebalunode, JO, Jagun, C and Zheng, W (2011). Informatics approach to the rational design of siRNA libraries. *Methods Mol Biol* **672**: 341–358.
31. Behlke, MA (2008). Chemical modification of siRNAs for *in vivo* use. *Oligonucleotides* **18**: 305–319.
32. Gaglione, M and Messere, A (2010). Recent progress in chemically modified siRNAs. *Mini Rev Med Chem* **10**: 578–595.
33. Bramsen, JB and Kjems, J (2011). Chemical modification of small interfering RNA. *Methods Mol Biol* **721**: 77–103.
34. Watts, JK, Deleavey, GF and Damha, MJ (2008). Chemically modified siRNA: tools and applications. *Drug Discov Today* **13**: 842–855.
35. Hoerter, JA and Walter, NG (2007). Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. *RNA* **13**: 1887–1893.
36. Choung, S, Kim, YJ, Kim, S, Park, HO and Choi, YC (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. *Biochem Biophys Res Commun* **342**: 919–927.
37. Kraynack, BA and Baker, BF (2006). Small interfering RNAs containing full 2'-O-methylribose nucleotide-modified sense strands display Argonaute2/elf2C2-dependent activity. *RNA* **12**: 163–176.
38. Turner, JJ, Jones, SW, Moschos, SA, Lindsay, MA and Gait, MJ (2007). MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNase A-like activity. *Mol Biosyst* **3**: 43–50.
39. Haupenthal, J, Baehr, C, Zeuzem, S and Piiper, A (2007). RNase A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1. *Int J Cancer* **121**: 206–210.
40. Haupenthal, J, Baehr, C, Kiermayer, S, Zeuzem, S and Piiper, A (2006). Inhibition of RNase A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. *Biochem Pharmacol* **71**: 702–710.
41. Lennox, KA and Behlke, MA (2010). A direct comparison of anti-microRNA oligonucleotide potency. *Pharm Res* **27**: 1788–1799.
42. Hong, J, Huang, Y, Li, J, Yi, F, Zheng, J, Huang, H *et al.* (2010). Comprehensive analysis of sequence-specific stability of siRNA. *FASEB J* **24**: 4844–4855.
43. Hickerson, RP, Smith, FJ, Reeves, RE, Contag, CH, Leake, D, Leachman, SA *et al.* (2008). Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. *J Invest Dermatol* **128**: 594–605.
44. Zhou, J and Rossi, JJ (2011). Cell-specific aptamer-mediated targeted drug delivery. *Oligonucleotides* **21**: 1–10.
45. Bidner, RA, Hammer, RP, Lopez, MJ, Robinson, SO and Monroe, WT (2007). Fully 2'-deoxy-2'-fluoro substituted nucleic acids induce RNA interference in mammalian cell culture. *Chem Biol Drug Des* **70**: 113–122.
46. Dowler, T, Bergeron, D, Tedeschi, AL, Paquet, L, Ferrari, N and Damha, MJ (2006). Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA). *Nucleic Acids Res* **34**: 1669–1675.
47. Mook, OR, Baas, F, de Wissel, MB and Fluitcr, K (2007). Evaluation of locked nucleic acid-modified small interfering RNA *in vitro* and *in vivo*. *Mol Cancer Ther* **6**: 833–843.

48. Glud, SZ, Bramsen, JB, Dagnaes-Hansen, F, Wengel, J, Howard, KA, Nyengaard, JR *et al.* (2009). Naked siRNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. *Oligonucleotides* **19**: 163–168.
49. Swayze, EE, Siwkowski, AM, Wanciewicz, EV, Migawa, MT, Wyrzykiewicz, TK, Hung, G *et al.* (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. *Nucleic Acids Res* **35**: 687–700.
50. Hogrefe, RI, Lebedev, AV, Zon, G, Pirollo, KF, Rait, A, Zhou, Q *et al.* (2006). Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery *in vitro* and *in vivo* for RNAi of HER-2. *Nucleosides Nucleotides Nucleic Acids* **25**: 889–907.
51. Pirollo, KF, Rait, A, Zhou, Q, Hwang, SH, Dagata, JA, Zon, G *et al.* (2007). Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. *Cancer Res* **67**: 2938–2943.
52. Ui-Tei, K, Naito, Y, Zenno, S, Nishi, K, Yamato, K, Takahashi, F *et al.* (2008). Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. *Nucleic Acids Res* **36**: 2136–2151.
53. Odadzic, D, Bramsen, JB, Smicic, R, Bus, C, Kjems, J and Engels, JW (2008). Synthesis of 2'-O-modified adenosine building blocks and application for RNA interference. *Bioorg Med Chem* **16**: 518–529.
54. Langkjaer, N, Pasternak, A and Wengel, J (2009). UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. *Bioorg Med Chem* **17**: 5420–5425.
55. Werk, D, Wengel, J, Wengel, SL, Grunert, HP, Zeichhardt, H and Kurreck, J (2010). Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3. *FEBS Lett* **584**: 591–598.
56. Laursen, MB, Pakula, MM, Gao, S, Fluiter, K, Mook, OR, Baas, F *et al.* (2010). Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance *in vitro* and *in vivo*. *Mol Biosyst* **6**: 862–870.
57. Bramsen, JB, Pakula, MM, Hansen, TB, Bus, C, Langkjaer, N, Odadzic, D *et al.* (2010). A screen of chemical modifications identifies position-specific modification by UNA to most potentially reduce siRNA off-target effects. *Nucleic Acids Res* **38**: 5761–5773.
58. Levin, AA (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. *Biochim Biophys Acta* **1489**: 69–84.
59. Geary, RS, Watanabe, TA, Truong, L, Freier, S, Lesnik, EA, Sioufi, NB *et al.* (2001). Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. *J Pharmacol Exp Ther* **296**: 890–897.
60. Geary, RS (2009). Antisense oligonucleotide pharmacokinetics and metabolism. *Expert Opin Drug Metab Toxicol* **5**: 381–391.
61. Geary, RS, Wanciewicz, E, Matson, J, Pearce, M, Siwkowski, A, Swayze, E *et al.* (2009). Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. *Biochem Pharmacol* **78**: 284–291.
62. Yu, RZ, Lemonidis, KM, Graham, MJ, Matson, JE, Crooke, RM, Tribble, DL *et al.* (2009). Cross-species comparison of *in vivo* PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. *Biochem Pharmacol* **77**: 910–919.
63. Detzer, A and Szczakiel, G (2009). Phosphorothioate-stimulated uptake of siRNA by mammalian cells: a novel route for delivery. *Curr Top Med Chem* **9**: 1109–1116.
64. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN *et al.* (2006). RNAi-mediated gene silencing in non-human primates. *Nature* **441**: 111–114.
65. Nishina, K, Unno, T, Uno, Y, Kubodera, T, Kanouchi, T, Mizusawa, H *et al.* (2008). Efficient *in vivo* delivery of siRNA to the liver by conjugation of alpha-tocopherol. *Mol Ther* **16**: 734–740.
66. Hohjoh, H (2002). RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells. *FEBS Lett* **521**: 195–199.
67. Boutla, A, Delidakis, C, Livadaras, I and Tabler, M (2003). Variations of the 3' protruding ends in synthetic short interfering RNA (siRNA) tested by microinjection in *Drosophila* embryos. *Oligonucleotides* **13**: 295–301.
68. Strapps, WR, Pickering, V, Muir, GT, Rice, J, Orsborn, S, Polisky, BA *et al.* (2010). The siRNA sequence and guide strand overhangs are determinants of *in vivo* duration of silencing. *Nucleic Acids Res* **38**: 4788–4797.
69. Schmitz, JC and Chu, E (2011). Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors. *Silence* **2**: 1.
70. Sano, M, Sierant, M, Miyagishi, M, Nakanishi, M, Takagi, Y and Souto, S (2008). Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. *Nucleic Acids Res* **36**: 5812–5821.
71. Chang, CI, Kim, HA, Dua, P, Kim, S, Li, CJ and Lee, DK (2011). Structural diversity repertoire of gene silencing small interfering RNAs. *Nucleic Acid Ther* **21**: 125–131.
72. Czauderna, F, Fechtner, M, Ayygun, H, Arnold, W, Klippel, A, Giese, K *et al.* (2003). Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. *Nucleic Acids Res* **31**: 670–682.
73. Czauderna, F, Fechtner, M, Dames, S, Ayygun, H, Klippel, A, Pronk, GJ *et al.* (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. *Nucleic Acids Res* **31**: 2705–2716.
74. Santel, A, Aleku, M, Röder, N, Möpert, K, Durieux, B, Janke, O *et al.* (2010). Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. *Clin Cancer Res* **16**: 5469–5480.
75. Patel, R, T'wallant, NC, Herbert, MH, White, D, Murison, JG and Reid, G (2009). The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. *Oligonucleotides* **19**: 317–328.
76. Salomon, W, Bulcock, K, Lapiere, J, Pavco, P, Woolf, T and Kamens, J (2010). Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. *Nucleic Acids Res* **38**: 3771–3779.
77. Chendrimada, TP, Gregory, RI, Kumaraswamy, E, Norman, J, Cooch, N, Nishikura, K *et al.* (2005). TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature* **436**: 740–744.
78. Haase, AD, Jaskiewicz, L, Zhang, H, Lainé, S, Sack, R, Gatignol, A *et al.* (2005). TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. *EMBO Rep* **6**: 961–967.
79. Rossi, JJ (2005). Mammalian Dicer finds a partner. *EMBO Rep* **6**: 927–929.
80. Sontheimer, EJ (2005). Assembly and function of RNA silencing complexes. *Nat Rev Mol Cell Biol* **6**: 127–138.
81. Wang, HW, Noland, C, Sirdedachidok, B, Taylor, DW, Ma, E, Felderer, K *et al.* (2009). Structural insights into RNA processing by the human RISC-loading complex. *Nat Struct Mol Biol* **16**: 1148–1153.
82. Matranga, C, Tomari, Y, Shin, C, Bartel, DP and Zamore, PD (2005). Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. *Cell* **123**: 607–620.
83. Rand, TA, Petersen, S, Du, F and Wang, X (2005). Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. *Cell* **123**: 621–629.
84. Kim, DH, Behlke, MA, Rose, SD, Chang, MS, Choi, S and Rossi, JJ (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. *Nat Biotechnol* **23**: 222–226.
85. Rose, SD, Kim, DH, Amarzguioui, M, Heidel, JD, Collingwood, MA, Davis, ME *et al.* (2005). Functional polarity is introduced by Dicer processing of short substrate RNAs. *Nucleic Acids Res* **33**: 4140–4156.
86. Noland, CL, Ma, E and Doudna, JA (2011). siRNA repositioning for guide strand selection by human Dicer complexes. *Mol Cell* **43**: 110–121.
87. Collingwood, MA, Rose, SD, Huang, L, Hillier, C, Amarzguioui, M, Wiiger, MT *et al.* (2008). Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. *Oligonucleotides* **18**: 187–200.
88. Kubo, T, Zhelev, Z, Ohba, H and Bakalova, R (2007). Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity. *Oligonucleotides* **17**: 445–464.
89. Kubo, T, Zhelev, Z, Ohba, H and Bakalova, R (2008). Chemically modified symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect. *Biochem Biophys Res Commun* **365**: 54–61.
90. Siolas, D, Lerner, C, Burchard, J, Ge, W, Linsley, PS, Paddison, PJ *et al.* (2005). Synthetic shRNAs as potent RNAi triggers. *Nat Biotechnol* **23**: 227–231.
91. Ge, Q, Ilves, H, Dallas, A, Kumar, P, Shorenstein, J, Kazakov, SA *et al.* (2010). Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. *RNA* **16**: 106–117.
92. Ge, Q, Dallas, A, Ilves, H, Shorenstein, J, Behlke, MA and Johnston, BH (2010). Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. *RNA* **16**: 118–130.
93. Sun, X, Rogoff, HA and Li, CJ (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. *Nat Biotechnol* **26**: 1379–1382.
94. Chang, CI, Yoo, JW, Hong, SW, Lee, SE, Kang, HS, Sun, X *et al.* (2009). Asymmetric shorter-duplex siRNA structures triggers efficient gene silencing with reduced nonspecific effects. *Mol Ther* **17**: 725–732.
95. Sierant, M, Kazmierczak-Baranska, J, Padaszyska, A, Sobczak, M, Pietkiewicz, A and Nawrot, B (2010). Longer 19-base pair short interfering RNA duplexes rather than shorter duplexes trigger RNA interference. *Oligonucleotides* **20**: 199–206.
96. Petrova Kruglova, NS, Meschaninova, MI, Venyaminova, AG, Zenkova, MA, Vlassov, VV and Chernolovskaya, EL (2010). 2'-O-methyl-modified anti-MDR1 fork-siRNA duplexes exhibiting high nuclease resistance and prolonged silencing activity. *Oligonucleotides* **20**: 297–308.
97. Ohnishi, Y, Tokunaga, K and Hohjoh, H (2005). Influence of assembly of siRNA elements into RNA-induced silencing complex by fork-siRNA duplex carrying nucleotide mismatches at the 3'- or 5'-end of the sense-stranded siRNA element. *Biochem Biophys Res Commun* **329**: 516–521.
98. Hohjoh, H (2004). Enhancement of RNAi activity by improved siRNA duplexes. *FEBS Lett* **557**: 193–198.
99. Birmingham, A, Anderson, EM, Reynolds, A, Illesly-Tyree, D, Leake, D, Fedorov, Y *et al.* (2006). 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. *Nat Methods* **3**: 199–204.
100. Vickers, TA, Lima, WF, Wu, H, Nichols, JG, Linsley, PS and Crooke, ST (2009). Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 "Slicer" independent and can be mediated by Ago1. *Nucleic Acids Res* **37**: 6927–6941.
101. Jackson, AL and Linsley, PS (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. *Nat Rev Drug Discov* **9**: 57–67.
102. Olejniczak, M, Galka, P and Krzyzosiak, WJ (2010). Sequence-non-specific effects of RNA interference triggers and microRNA regulators. *Nucleic Acids Res* **38**: 1–16.
103. Jackson, AL, Burchard, J, Schelter, J, Chau, BN, Cleary, M, Lim, L *et al.* (2006). Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. *RNA* **12**: 1179–1187.
104. Anderson, EM, Birmingham, A, Baskerville, S, Reynolds, A, Maksimova, E, Leake, D *et al.* (2008). Experimental validation of the importance of seed complement frequency to siRNA specificity. *RNA* **14**: 853–861.
105. Jackson, AL, Burchard, J, Leake, D, Reynolds, A, Schelter, J, Guo, J *et al.* (2006). Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. *RNA* **12**: 1197–1205.
106. Puri, N, Wang, X, Varma, R, Burnett, C, Beauchamp, L, Batten, DM *et al.* (2008). LNA incorporated siRNAs exhibit lower off-target effects compared to 2'-OMethoxy in cell phenotypic assays and microarray analysis. *Nucleic Acids Symp Ser (Oxf)* **25**–26.
107. Vaish, N, Chen, F, Seth, S, Fosnaugh, K, Liu, Y, Adami, R *et al.* (2011). Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. *Nucleic Acids Res* **39**: 1823–1832.
108. Weitzer, S and Martinez, J (2007). The human RNA kinase hClp1 is active on 3' transfer RNA exons and short interfering RNAs. *Nature* **447**: 222–226.
109. Chen, PY, Weinmann, L, Gaidatzis, D, Pei, Y, Zavolan, M, Tuschl, T *et al.* (2008). Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. *RNA* **14**: 263–274.
110. Shah, S and Friedman, SH (2007). Tolerance of RNA interference toward modifications of the 5' antisense phosphate of small interfering RNA. *Oligonucleotides* **17**: 35–43.



111. Bramsen, JB, Laursen, MB, Damgaard, CK, Lena, SW, Babu, BR, Wengel, J *et al.* (2007). Improved silencing properties using small internally segmented interfering RNAs. *Nucleic Acids Res* **35**: 5886–5897.
112. Robbins, M, Judge, A, Ambegia, E, Choi, C, Yaworski, E, Palmer, L *et al.* (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. *Hum Gene Ther* **19**: 991–999.
113. PoECK, H, Besch, R, Maihofer, C, Renn, M, Tormo, D, Morskaya, SS *et al.* (2008). 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. *Nat Med* **14**: 1256–1263.
114. Alshamsan, A, Hamdy, S, Haddadi, A, Samuel, J, El-Kadi, AO, Uludag, H *et al.* (2011). STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response *In Vitro* and *In Vivo*. *Transl Oncol* **4**: 178–188.
115. Judge, A and MacLachlan, I (2008). Overcoming the innate immune response to small interfering RNA. *Hum Gene Ther* **19**: 111–124.
116. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. *Oligonucleotides* **19**: 89–102.
117. Krieg, AM (2006). Therapeutic potential of Toll-like receptor 9 activation. *Nat Rev Drug Discov* **5**: 471–484.
118. Hennessy, EJ, Parker, AE and O'Neill, LA (2010). Targeting Toll-like receptors: emerging therapeutics? *Nat Rev Drug Discov* **9**: 293–307.
119. Fedorov, Y, King, A, Anderson, E, Karpilow, J, Ilsey, D, Marshall, W *et al.* (2005). Different delivery methods-different expression profiles. *Nat Methods* **2**: 241.
120. Robbins, MA, Li, M, Leung, I, Li, H, Boyer, DV, Song, Y *et al.* (2006). Stable expression of siRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs *in vitro*. *Nat Biotechnol* **24**: 566–571.
121. Manche, L, Green, SR, Schmedt, C and Mathews, MB (1992). Interactions between double-stranded RNA regulators and the protein kinase DAI. *Mol Cell Biol* **12**: 5238–5248.
122. Minks, MA, West, DK, Benven, S and Baglioni, C (1979). Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. *J Biol Chem* **254**: 10180–10183.
123. Kim, DH, Longo, M, Han, Y, Lundberg, P, Cantin, E and Rossi, JJ (2004). Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. *Nat Biotechnol* **22**: 321–325.
124. Pichlmair, A, Schulz, O, Tan, CP, Näslund, TI, Liljestrom, P, Weber, F *et al.* (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* **314**: 997–1001.
125. Hornung, V, Ellegast, J, Kim, S, Brzózka, K, Jung, A, Kato, H *et al.* (2006). 5'-Triphosphate RNA is the ligand for RIG-I. *Science* **314**: 994–997.
126. Marques, JT, Devosse, T, Wang, D, Zamanian-Daryoush, M, Serbinowski, P, Hartmann, R *et al.* (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. *Nat Biotechnol* **24**: 559–565.
127. KariKó, G, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* **23**: 165–175.
128. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing *in vivo*. *Mol Ther* **13**: 494–505.
129. Robbins, M, Judge, A, Liang, L, McClintock, K, Yaworski, E and MacLachlan, I (2007). 2'-O-methyl-modified RNAs act as TLR7 antagonists. *Mol Ther* **15**: 1663–1669.
130. Malek, A, Merkel, O, Fink, L, Czubayko, F, Kissel, T and Aigner, A (2009). *In vivo* pharmacokinetics, tissue distribution and underlying mechanisms of various PEI-(PEG)/siRNA complexes. *Toxicol Appl Pharmacol* **236**: 97–108.
131. Viel, T, Kuhnast, B, Hinnen, F, Boisgard, R, Tavitian, B and Dolle, F (2007). Fluorine-18 labelling of small interfering RNAs (siRNAs) for PET imaging. *J Label Compounds Radiopharm* **50**: 1159–1168.
132. Viel, T, Boisgard, R, Kuhnast, B, Jego, B, Siquier-Pernet, K, Hinnen, F *et al.* (2008). Molecular imaging study on *in vivo* distribution and pharmacokinetics of modified small interfering RNAs (siRNAs). *Oligonucleotides* **18**: 201–212.
133. Gary, DJ, Lee, H, Sharma, R, Lee, JS, Kim, Y, Cui, ZY *et al.* (2011). Influence of nanocarrier architecture on *in vitro* siRNA delivery performance and *in vivo* biodistribution: polyplexes vs micelleplexes. *ACS Nano* **5**: 3493–3505.
134. Mudd, SR, Trubetskoy, VS, Blokhin, AV, Weichert, JP and Wolff, JA (2010). Hybrid PET/CT for noninvasive pharmacokinetic evaluation of dynamic PolyConjugates, a synthetic siRNA delivery system. *Bioconjug Chem* **21**: 1183–1189.
135. Rozema, DB, Lewis, DL, Wakefield, DH, Wong, SC, Klein, JJ, Roesch, PL *et al.* (2007). Dynamic PolyConjugates for targeted *in vivo* delivery of siRNA to hepatocytes. *Proc Natl Acad Sci USA* **104**: 12982–12987.
136. Bartlett, DW, Su, H, Hildebrandt, IJ, Weber, WA and Davis, ME (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality *in vivo* imaging. *Proc Natl Acad Sci USA* **104**: 15549–15554.
137. Bartlett, DW and Davis, ME (2007). Effect of siRNA nuclease stability on the *in vitro* and *in vivo* kinetics of siRNA-mediated gene silencing. *Biotechnol Bioeng* **97**: 909–921.
138. Heidel, JD, Liu, JY, Yen, Y, Zhou, B, Heale, BS, Rossi, JJ *et al.* (2007). Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation *in vitro* and *in vivo*. *Clin Cancer Res* **13**: 2207–2215.
139. Svensson, RU, Shey, MR, Ballas, ZK, Dorkin, JR, Goldberg, M, Akinc, A *et al.* (2008). Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. *Mol Ther* **16**: 1995–2001.
140. Wei, J, Jones, J, Kang, J, Card, A, Krimm, M, Hancock, P *et al.* (2011). RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice. *Mol Pharmacol* **79**: 953–963.
141. Huang, Y, Hong, J, Zheng, S, Ding, Y, Guo, S, Zhang, H *et al.* (2011). Elimination pathways of systemically delivered siRNA. *Mol Ther* **19**: 381–385.
142. Yagi, N, Manabe, I, Tottori, T, Ishihara, A, Ogata, F, Kim, JH *et al.* (2009). A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth *in vivo*. *Cancer Res* **69**: 6531–6538.
143. Xiong, XB and Lavasanifar, A (2011). Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. *ACS Nano* **5**: 5202–5213.
144. Huang, YH, Bao, Y, Peng, W, Goldberg, M, Love, K, Bumcrot, DA *et al.* (2009). Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. *Proc Natl Acad Sci USA* **106**: 3426–3430.
145. Lin, X, Li, L, Wang, R, Wilcox, D, Zhao, X, Song, J *et al.* (2011). A robust *in vivo* positive-readout system for monitoring siRNA delivery to xenograft tumors. *RNA* **17**: 603–612.
146. Herbert, M, Coppieters, N, Lasham, A, Cao, H and Reid, G (2011). The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. *BMC Res Notes* **4**: 148.
147. Shi, B, Keough, E, Matter, A, Leander, K, Young, S, Carlini, E *et al.* (2011). Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. *J Histochem Cytochem* **59**: 727–740.
148. Judge, AD, Robbins, M, Tavakoli, I, Levi, J, Hu, L, Fronza, A *et al.* (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. *J Clin Invest* **119**: 661–673.
149. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M *et al.* (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* **432**: 173–178.
150. Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A *et al.* (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. *Proc Natl Acad Sci USA* **105**: 11915–11920.
151. Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA *et al.* (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. *Nature* **464**: 1067–1070.
152. Neff, CP, Zhou, J, Remling, L, Kuruvilla, J, Zhang, J, Li, H *et al.* (2011). An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. *Sci Transl Med* **3**: 66ra6.
153. Tousignant, JD, Gates, AL, Ingram, LA, Johnson, CL, Nietupski, JB, Cheng, SH *et al.* (2000). Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. *Hum Gene Ther* **11**: 2493–2513.
154. Dass, CR (2002). Cytotoxicity issues pertinent to lipoplex-mediated gene therapy *in vivo*. *J Pharm Pharmacol* **54**: 593–601.
155. Simberg, D, Weisman, S, Talmon, Y and Barenholz, Y (2004). DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. *Crit Rev Ther Drug Carrier Syst* **21**: 257–317.
156. Aleku, M, Schulz, P, Keil, O, Santel, A, Schaeper, U, Dieckhoff, B *et al.* (2008). Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. *Cancer Res* **68**: 9788–9798.
157. Santel, A, Aleku, M, Keil, O, Endruschat, J, Esche, V, Durieux, B *et al.* (2006). RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. *Gene Ther* **13**: 1360–1370.
158. Santel, A, Aleku, M, Keil, O, Endruschat, J, Esche, V, Fisch, G *et al.* (2006). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. *Gene Ther* **13**: 1222–1234.
159. Yokota, T, Iijima, S, Kubodera, T, Ishii, K, Katakai, Y, Agetama, N *et al.* (2007). Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. *Biochem Biophys Res Commun* **361**: 294–300.
160. Khoury, M, Louis-Plence, P, Escriou, V, Noel, D, Largeau, C, Cantos, C *et al.* (2006). Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. *Arthritis Rheum* **54**: 1867–1877.
161. Khoury, M, Escriou, V, Courties, G, Galy, A, Yao, R, Largeau, C *et al.* (2008). Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. *Arthritis Rheum* **58**: 2356–2367.
162. Polach, KJ, Matar, M, Rice, J, Slobodkin, G, Sparks, J, Congo, R *et al.* (2011). Delivery of siRNA to the Mouse Lung via a Functionalized Lipopolyamine. *Mol Ther* (epub ahead of print).
163. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W *et al.* (2005). Potent and persistent *in vivo* anti-HBV activity of chemically modified siRNAs. *Nat Biotechnol* **23**: 1002–1007.
164. Lee, YH, Judge, AD, Seo, D, Kitade, M, Gómez-Quiroz, LE, Ishikawa, T *et al.* (2011). Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. *Oncogene* **30**: 4175–4184.
165. Geisbert, TW, Hensley, LE, Kagan, E, Yu, EZ, Geisbert, JB, Daddario-DiCaprio, K *et al.* (2006). Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. *J Infect Dis* **193**: 1650–1657.
166. Geisbert, TW, Lee, AC, Robbins, M, Geisbert, JB, Honko, AN, Sood, V *et al.* (2010). Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. *Lancet* **375**: 1896–1905.
167. Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N *et al.* (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. *Nat Biotechnol* **26**: 561–569.
168. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR *et al.* (2010). Lipid-like materials for low-dose, *in vivo* gene silencing. *Proc Natl Acad Sci USA* **107**: 1864–1869.
169. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK *et al.* (2010). Rational design of cationic lipids for siRNA delivery. *Nat Biotechnol* **28**: 172–176.
170. Basha, G, Novobrantseva, TI, Rosin, N, Tam, YY, Hafez, IM, Wong, MK *et al.* (2011). Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. *Mol Ther* **19**: 2186–2200.
171. Leuschner, F, Dutta, P, Gorbato, R, Novobrantseva, TI, Donahoe, JS, Courties, G *et al.* (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. *Nat Biotechnol* **29**: 1005–1010.
172. Adami, RC, Seth, S, Harvie, P, Johns, R, Fam, R, Fosnaugh, K *et al.* (2011). An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. *Mol Ther* **19**: 1141–1151.

173. Sato, Y, Murase, K, Kato, J, Kobune, M, Sato, T, Kawano, Y *et al.* (2008). Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. *Nat Biotechnol* **26**: 431–442.
174. Peer, D, Park, EJ, Morishita, Y, Carman, CV and Shimaoka, M (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. *Science* **319**: 627–630.
175. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN *et al.* (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. *Mol Ther* **18**: 1357–1364.
176. Koldehoff, M, Steckel, NK, Beelen, DW and Elmaagacli, AH (2007). Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. *Clin Exp Med* **7**: 47–55.
177. Akinc, A, Thomas, M, Klibanov, AM and Langer, R (2005). Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. *J Gene Med* **7**: 657–663.
178. Grandinetti, G, Ingle, NP and Reineke, TM (2011). Interaction of poly(ethyleneimine)-DNA polyplexes with mitochondria: implications for a mechanism of cytotoxicity. *Mol Pharm* **8**: 1709–1719.
179. Günther, M, Lipka, J, Malek, A, Gutsch, D, Kreyling, W and Aigner, A (2011). Polyethylenimines for RNAi-mediated gene targeting *in vivo* and siRNA delivery to the lung. *Eur J Pharm Biopharm* **77**: 438–449.
180. Kamlah, F, Eul, BG, Li, S, Lang, N, Marsh, LM, Seeger, W *et al.* (2009). Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. *Cancer Gene Ther* **16**: 195–205.
181. Li, C, Penet, MF, Wildes, F, Takagi, T, Chen, Z, Winnard, PT *et al.* (2010). Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. *ACS Nano* **4**: 6707–6716.
182. Zhou, J, Neff, CP, Liu, X, Zhang, J, Li, H, Smith, DD *et al.* (2011). Systemic administration of combinatorial dsRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. *Mol Ther* **19**: 2228–2238.
183. Ghosh, B, Singh, A, Li, M, Vlassov, AV, Burnett, C, Puri, N *et al.* (2010). Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. *Oligonucleotides* **20**: 163–172.
184. Pillé, JY, Li, H, Blot, E, Bertrand, JR, Pritchard, LL, Opolon, P *et al.* (2006). Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. *Hum Gene Ther* **17**: 1019–1026.
185. Davis, ME and Brewster, ME (2004). Cyclodextrin-based pharmaceuticals: past, present and future. *Nat Rev Drug Discov* **3**: 1023–1035.
186. Davis, ME (2009). The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. *Mol Pharm* **6**: 659–668.
187. Heidel, JD, Yu, Z, Liu, JY, Rele, SM, Liang, Y, Zeidan, RK *et al.* (2007). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. *Proc Natl Acad Sci USA* **104**: 5715–5721.
188. Bartlett, DW and Davis, ME (2008). Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. *Biotechnol Bioeng* **99**: 975–985.
189. Ishimoto, T, Takei, Y, Yuzawa, Y, Hanai, K, Nagahara, S, Tarumi, Y *et al.* (2008). Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. *Mol Ther* **16**: 387–395.
190. Kinouchi, N, Ohswawa, Y, Ishimaru, N, Ohuchi, H, Sunada, Y, Hayashi, Y *et al.* (2008). Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. *Gene Ther* **15**: 1126–1130.
191. Andaloussi, SE, Lehto, T, Mäger, I, Rosenthal-Aizman, K, Oprea, II, Simonson, OE *et al.* (2011). Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically *in vivo*. *Nucleic Acids Res* **39**: 3972–3987.
192. Boado, RJ (2007). Blood-brain barrier transport of non-viral gene and RNAi therapeutics. *Pharm Res* **24**: 1772–1787.
193. Bellavance, MA, Blanchette, M and Fortin, D (2008). Recent advances in blood-brain barrier disruption as a CNS delivery strategy. *AAPS J* **10**: 166–177.
194. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL *et al.* (2007). Transvascular delivery of small interfering RNA to the central nervous system. *Nature* **448**: 39–43.
195. Kim, SS, Ye, C, Kumar, P, Chiu, I, Subramanya, S, Wu, H *et al.* (2010). Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. *Mol Ther* **18**: 993–1001.
196. Demeule, M, Currie, JC, Bertrand, Y, Ché, C, Nguyen, T, Régina, A *et al.* (2008). Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. *J Neurochem* **106**: 1534–1544.
197. Shahzad, MM, Mangala, LS, Han, HD, Lu, C, Bottsford-Miller, J, Nishimura, M *et al.* (2011). Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. *Neoplasia* **13**: 309–319.
198. Alvarez-Erviti, L, Seow, Y, Yin, H, Betts, C, Lakhal, S and Wood, MJ (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol* **29**: 341–345.
199. Zhou, J, Li, H, Li, S, Zaia, J and Rossi, JJ (2008). Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. *Mol Ther* **16**: 1481–1489.
200. Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, CP, Akkina, R *et al.* (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. *Nucleic Acids Res* **37**: 3094–3109.
201. McNamara, JO 2<sup>nd</sup>, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E *et al.* (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. *Nat Biotechnol* **24**: 1005–1015.
202. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR *et al.* (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. *Nat Biotechnol* **27**: 839–849.
203. Krützfeldt, J, Rajewsky, N, Braich, R, Rajeev, KG, Tuschl, T, Manoharan, M *et al.* (2005). Silencing of microRNAs *in vivo* with 'antagomirs'. *Nature* **438**: 685–689.
204. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK *et al.* (2007). Mechanisms and optimization of *in vivo* delivery of lipophilic siRNAs. *Nat Biotechnol* **25**: 1149–1157.
205. Feinberg, EH and Hunter, CP (2003). Transport of dsRNA into cells by the transmembrane protein SID-1. *Science* **301**: 1545–1547.
206. Kuwahara, H, Nishina, K, Yoshida, K, Nishina, T, Yamamoto, M, Saito, Y *et al.* (2011). Efficient *in vivo* delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. *Mol Ther* **19**: 2213–2221.
207. Rigotti, A (2007). Absorption, transport, and tissue delivery of vitamin E. *Mol Aspects Med* **28**: 423–436.
208. Sproat, BS, Rupp, T, Menhardt, N, Keane, D and Beijer, B (1999). Fast and simple purification of chemically modified hammerhead ribozymes using a lipophilic capture tag. *Nucleic Acids Res* **27**: 1950–1955.
209. Uno, Y, Piao, W, Miyata, K, Mizusawa, H and Yokota, T (2011). High-density lipoprotein facilitates *in vivo* delivery of a-tocopherol-conjugated short-interfering RNA to the brain. *Hum Gene Ther* **22**: 711–719.
210. Kortylewski, M, Swiderski, P, Herrmann, A, Wang, L, Kowolik, C, Kujawski, M *et al.* (2009). *In vivo* delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. *Nat Biotechnol* **27**: 925–932.
211. Tammali, R, Reddy, AB, Saxena, A, Rychahou, PG, Evers, BM, Qiu, S *et al.* (2011). Inhibition of aldose reductase prevents colon cancer metastasis. *Carcinogenesis* **32**: 1259–1267.
212. van de Water, FM, Boerman, OC, Wouterse, AC, Peters, JG, Russel, FG, and Masereeuw, R (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. *Drug Metab Dispos* **34**: 1393–1397.
213. Rosi, NL, Giljohann, DA, Thaxton, CS, Lyttton-Jean, AK, Han, MS and Mirkin, CA (2006). Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. *Science* **312**: 1027–1030.
214. Giljohann, DA, Seferos, DS, Prigodich, AE, Patel, PC and Mirkin, CA (2009). Gene regulation with polyvalent siRNA-nanoparticle conjugates. *J Am Chem Soc* **131**: 2072–2073.
215. Giljohann, DA, Seferos, DS, Daniel, WL, Massich, MD, Patel, PC and Mirkin, CA (2010). Gold nanoparticles for biology and medicine. *Angew Chem Int Ed Engl* **49**: 3280–3294.
216. Braun, CB, Pallaoro, A, Wu, G, Misirlis, D, Zasadzinski, JA, Tirrell, M *et al.* (2009). Laser-Activated Gene Silencing via Gold Nanoshell-siRNA Conjugates. *ACS Nano* **3**: 2007–2015.
217. Lu, W, Zhang, G, Zhang, R, Flores, LG 2<sup>nd</sup>, Huang, Q, Gelovani, JG *et al.* (2010). Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. *Cancer Res* **70**: 3177–3188.
218. Landen, CN, Merritt, WM, Mangala, LS, Sanguino, AM, Bucana, C, Lu, C *et al.* (2006). Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. *Cancer Biol Ther* **5**: 1708–1713.
219. Halder, J, Kamat, AA, Landen, CN Jr, Han, LY, Lutgendorf, SK, Lin, YG *et al.* (2006). Focal adhesion kinase targeting using *in vivo* short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. *Clin Cancer Res* **12**: 4916–4924.
220. Goldberg, MS, Xing, D, Ren, Y, Orsulic, S, Bhatia, SN and Sharp, PA (2011). Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. *Proc Natl Acad Sci USA* **108**: 745–750.
221. Kaestner, P, Aigner, A and Bastians, H (2011). Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth *in vivo*. *Cancer Lett* **304**: 128–136.
222. Amarguioi, M, Peng, Q, Wiiger, MT, Vasovic, V, Babaie, E, Holen, T *et al.* (2006). *Ex vivo* and *in vivo* delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. *Clin Cancer Res* **12**: 4055–4061.
223. Tesniere, A, Abernill, N, Schlemmer, F, Casares, N, Kepp, O, Pequignot, M *et al.* (2010). *In vivo* depletion of T lymphocyte-specific transcription factors by RNA interference. *Cell Cycle* **9**: 2830–2835.
224. Bajaj, G and Yeo, Y (2010). Drug delivery systems for intraperitoneal therapy. *Pharm Res* **27**: 735–738.
225. Gao, S, Dagnaes-Hansen, F, Nielsen, EJ, Wengel, J, Besenbacher, F, Howard, KA *et al.* (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. *Mol Ther* **17**: 1225–1233.
226. Lundberg, P, Welander, PV, Edwards, CK 3<sup>rd</sup>, van Rooijen, N and Cantin, E (2007). Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2. *J Virol* **81**: 1451–1460.
227. Howard, KA, Rahbek, UL, Liu, X, Damgaard, CK, Glud, SZ, Andersen, MØ *et al.* (2006). RNA interference *in vitro* and *in vivo* using a novel chitosan/siRNA nanoparticle system. *Mol Ther* **14**: 476–484.
228. Amarguioi, M, Lundberg, P, Cantin, E, Hagstrom, J, Behlke, MA and Rossi, JJ (2006). Rational design and *in vitro* and *in vivo* delivery of Dicer substrate siRNA. *Nat Protoc* **1**: 508–517.
229. Howard, KA, Paludan, SR, Behlke, MA, Besenbacher, F, Deleuran, B and Kjems, J (2009). Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. *Mol Ther* **17**: 162–168.
230. Nawroth, I, Alsnar, J, Behlke, MA, Besenbacher, F, Overgaard, J, Howard, KA *et al.* (2010). Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFalpha prevents radiation-induced fibrosis. *Radiother Oncol* **97**: 143–148.
231. Altier, C, Dale, CS, Kisilevsky, AE, Chapman, K, Castiglioni, AJ, Matthews, EA *et al.* (2007). Differential role of N-type calcium channel splice isoforms in pain. *J Neurosci* **27**: 6363–6373.
232. Taishi, P, Churchill, L, Wang, M, Kay, D, Davis, CJ, Guan, X *et al.* (2007). TNFalpha siRNA reduces brain TNF and EEG delta wave activity in rats. *Brain Res* **1156**: 125–132.
233. Senechal, Y, Kelly, PH, Cryan, JF, Natt, F and Dev, KK (2007). Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. *J Neurochem* **102**: 1928–1940.

234. McCormack, AL, Mak, SK, Henderson, JM, Bumcrot, D, Farrer, MJ and Di Monte, DA (2010). Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. *PLoS ONE* **5**: e12122.
235. Wang, H, Ghosh, A, Baigude, H, Yang, CS, Qiu, L, Xia, X *et al.* (2008). Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. *J Biol Chem* **283**: 15845–15852.
236. Querbes, W, Ge, P, Zhang, W, Fan, Y, Costigan, J, Charisse, K *et al.* (2009). Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. *Oligonucleotides* **19**: 23–29.
237. DiFiglia, M, Sena-Esteves, M, Chase, K, Sapp, E, Pfister, E, Sass, M *et al.* (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. *Proc Natl Acad Sci USA* **104**: 17204–17209.
238. LaCroix-Fralish, ML, Mo, G, Smith, SB, Sotocinal, SG, Ritchie, J, Austin, JS *et al.* (2009). The beta3 subunit of the Na<sup>+</sup>,K<sup>+</sup>-ATPase mediates variable nociceptive sensitivity in the formalin test. *Pain* **144**: 294–302.
239. Doré-Savard, L, Roussy, G, Dansereau, MA, Collingwood, MA, Lennox, KA, Rose, SD *et al.* (2008). Central delivery of Dicer-substrate siRNA: a direct application for pain research. *Mol Ther* **16**: 1331–1339.
240. Dong, XW, Goregoaker, S, Engler, H, Zhou, X, Mark, L, Crona, J *et al.* (2007). Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. *Neuroscience* **146**: 812–821.
241. Cardoso, AL, Simões, S, de Almeida, LP, Plesnila, N, Pedroso de Lima, MC, Wagner, E *et al.* (2008). Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. *J Control Release* **132**: 113–123.
242. Eguchi, A and Dowdy, SF (2009). siRNA delivery using peptide transduction domains. *Trends Pharmacol Sci* **30**: 341–345.
243. Eguchi, A, Meade, BR, Chang, YC, Fredrickson, CT, Willert, K, Puri, N *et al.* (2009). Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. *Nat Biotechnol* **27**: 567–571.
244. Michiue, H, Eguchi, A, Scadeng, M and Dowdy, SF (2009). Induction of *in vivo* synthetic lethal RNAi responses to treat glioblastoma. *Cancer Biol Ther* **8**: 2306–2313.
245. Al-Jamal, KT, Gherardini, L, Bardi, G, Nunes, A, Guo, C, Bussy, C *et al.* (2011). Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. *Proc Natl Acad Sci USA* **108**: 10952–10957.
246. Geusens, B, Strobbé, T, Bracke, S, Dynoodt, P, Sanders, N, Van Gele, M *et al.* (2011). Lipid-mediated gene delivery to the skin. *Eur J Pharm Sci* **43**: 199–211.
247. Leachman, SA, Hickerson, RP, Hull, PR, Smith, FJ, Milstone, LM, Lane, EB *et al.* (2008). Therapeutic siRNAs for dominant genetic skin disorders including pachonychia congenita. *J Dermatol Sci* **51**: 151–157.
248. Hickerson, RP, Vlassov, AV, Wang, Q, Leake, D, Ilves, H, Gonzalez-Gonzalez, E *et al.* (2008). Stability study of unmodified siRNA and relevance to clinical use. *Oligonucleotides* **18**: 345–354.
249. Gonzalez-Gonzalez, E, Ra, H, Hickerson, RP, Wang, Q, Piyawattanametha, W, Mandella, MJ *et al.* (2009). siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. *Gene Ther* **16**: 963–972.
250. Leachman, SA, Hickerson, RP, Schwartz, ME, Bullough, EE, Hutcherson, SL, Boucher, KM *et al.* (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. *Mol Ther* **18**: 442–446.
251. Hickerson, RP, Flores, MA, Leake, D, Lara, MF, Contag, CH, Leachman, SA *et al.* (2011). Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachonychia congenita model. *J Invest Dermatol* **131**: 1037–1044.
252. Uchida, T, Kanazawa, T, Takashima, Y and Okada, H (2011). Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002. *Chem Pharm Bull* **59**: 196–201.
253. Song, KH, Fasano, A and Eddington, ND (2008). Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. *Int J Pharm* **351**: 8–14.
254. Takanashi, M, Oikawa, K, Sudo, K, Tanaka, M, Fujita, K, Ishikawa, A *et al.* (2009). Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. *Gene Ther* **16**: 982–989.
255. Wu, Y, Navarro, F, Lal, A, Basar, E, Pandey, RK, Manoharan, M *et al.* (2009). Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. *Cell Host Microbe* **5**: 84–94.
256. Palliser, D, Chowdhury, D, Wang, QY, Lee, SJ, Bronson, RT, Knipe, DM *et al.* (2006). An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. *Nature* **439**: 89–94.
257. Yi, X, Zhao, G, Zhang, H, Guan, D, Meng, R, Zhang, Y *et al.* (2011). MITF-siRNA formulation is a safe and effective therapy for human melasma. *Mol Ther* **19**: 362–371.
258. Dannull, J, Leshner, DT, Holzknicht, R, Qi, W, Hanna, G, Seigler, H *et al.* (2007). Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. *Blood* **110**: 4341–4350.
259. Singhal, SS, Awasthi, YC and Awasthi, S (2006). Regression of melanoma in a murine model by RLIP76 depletion. *Cancer Res* **66**: 2354–2360.
260. Suo, WH, Zhang, N, Wu, PP, Zhao, L, Song, LJ, Shen, WW *et al.* (2011). Anti-tumor effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer. *Br J Pharmacol* **165**: 135–147.
261. Dharmapuri, S, Peruzzi, D, Marra, E, Palombo, F, Bett, AJ, Bartz, SR *et al.* (2011). Intratumor RNA interference of cell cycle genes slows down tumor progression. *Gene Ther* **18**: 727–733.
262. Liu, X, Madhankumar, AB, Slagle-Webb, B, Sheehan, JM, Sarguladze, N and Connor, JR (2011). Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. *Cancer Res* **71**: 2240–2249.
263. Gu, W, Putral, LN, Irving, A and McMillan, NA (2007). The development and future of oligonucleotide-based therapies for cervical cancer. *Curr Opin Mol Ther* **9**: 126–131.
264. Jonson, AL, Rogers, LM, Ramakrishnan, S and Downs, LS Jr (2008). Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. *Gynecol Oncol* **111**: 356–364.
265. Yamato, K, Yamada, T, Kizaki, M, Ui-Tei, K, Natori, Y, Fujino, M *et al.* (2008). New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. *Cancer Gene Ther* **15**: 140–153.
266. Gu, W, Putral, L, Hengst, K, Minto, K, Saunders, NA, Leggatt, G *et al.* (2006). Inhibition of cervical cancer cell growth *in vitro* and *in vivo* with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. *Cancer Gene Ther* **13**: 1023–1032.
267. Wu, SY, Singhania, A, Burgess, M, Putral, LN, Kirkpatrick, C, Davies, NM *et al.* (2011). Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. *Gene Ther* **18**: 14–22.
268. Seth, S, Matsui, Y, Fosnaugh, K, Liu, Y, Vaish, N, Adams, R *et al.* (2011). RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. *Mol Ther* **19**: 928–935.
269. Gillespie, DL, Whang, K, Ragel, BT, Flynn, JR, Kelly, DA and Jensen, RL (2007). Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth *in vivo*. *Clin Cancer Res* **13**: 2441–2448.
270. Chen, H, Chen, L, Sun, L, Zhen, H, Li, X and Zhang, Q (2011). A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. *Gastric Cancer* **14**: 339–352.
271. Golzio, M, Mazzolini, L, Ledoux, A, Paganin, A, Izard, M, Hellaudais, L *et al.* (2007). *In vivo* gene silencing in solid tumors by targeted electrically mediated siRNA delivery. *Gene Ther* **14**: 752–759.
272. Nakai, N, Kishida, T, Shin-Ya, M, Imanishi, J, Ueda, Y, Kishimoto, S *et al.* (2007). Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. *Gene Ther* **14**: 357–365.
273. Won, YW, Yoon, SM, Lee, KM and Kim, YH (2011). Poly(oligo-D-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. *Mol Ther* **19**: 372–380.
274. Yuesekdag, G, Drechsel, M, Rössner, M, Schmidt, C, Kormann, M, Illeenyi, MC *et al.* (2010). Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways. *Eur J Pharm Biopharm* **75**: 305–310.
275. Bitko, V and Barik, S (2007). Intranasal antisense therapy: preclinical models with a clinical future? *Curr Opin Mol Ther* **9**: 119–125.
276. Bitko, V and Barik, S (2008). Nasal delivery of siRNA. *Methods Mol Biol* **442**: 75–82.
277. Barik, S (2009). Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs. *Methods Mol Biol* **487**: 331–341.
278. Fulton, A, Peters, ST, Perkins, GA, Jarosinski, KW, Damiani, A, Brosnahan, M *et al.* (2009). Effective treatment of respiratory alphaherpesvirus infection using RNA interference. *PLoS ONE* **4**: e4118.
279. DeVincenzo, J, Cehelsky, JE, Alvarez, R, Elbashir, S, Harborth, J, Toudjarska, I *et al.* (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). *Antiviral Res* **77**: 225–231.
280. DeVincenzo, J, Lambkin-Williams, R, Wilkinson, T, Cehelsky, J, Nochr, S, Walsh, E *et al.* (2010). A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. *Proc Natl Acad Sci USA* **107**: 8800–8805.
281. Zamora, MR, Budev, M, Rolfe, M, Gottlieb, J, Humar, A, Devincenzo, J *et al.* (2011). RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. *Am J Respir Crit Care Med* **183**: 531–538.
282. Fattal, E and Bochot, A (2006). Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. *Adv Drug Deliv Rev* **58**: 1203–1223.
283. Campochiaro, PA (2006). Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. *Gene Ther* **13**: 559–562.
284. Murata, M, Takahashi, T, Shimizu, S, Kubota, Y, Horiuchi, S, Habano, W *et al.* (2006). Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). *Curr Eye Res* **31**: 171–180.
285. Turchinovich, A, Zoidl, G and Dermietzel, R (2010). Non-viral siRNA delivery into the mouse retina *in vivo*. *BMC Ophthalmol* **10**: 25.
286. Kleinman, ME, Yamada, K, Takeda, A, Chandrasekaran, V, Nozaki, M, Baffi, JZ *et al.* (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. *Nature* **452**: 591–597.
287. Kleinman, ME, Kaneko, H, Cho, WG, Dridi, S, Fowler, BJ, Blandford, AD *et al.* (2011). Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. *Mol Ther* (epub ahead of print).
288. Kaiser, PK, Symons, RC, Shah, SM, Quinlan, EJ, Tabandeh, H, Do, DV *et al.*; Sirna-027 Study Investigators. (2010). RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. *Am J Ophthalmol* **150**: 33–39.e2.
289. Morgan, PE, Correa, MV, Ennis, IE, Diez, AA, Pérez, NG and Cingolani, HE (2011). Silencing of sodium/hydrogen exchanger in the heart by direct injection of naked siRNA. *J Appl Physiol* **111**: 566–572.
290. Tillman, LG, Geary, RS and Hardee, GE (2008). Oral delivery of antisense oligonucleotides in man. *J Pharm Sci* **97**: 225–236.
291. Wilson, DS, Dalmasso, G, Wang, L, Sitaraman, SV, Merlin, D and Murthy, N (2010). Orally delivered thiolated nanoparticles loaded with TNF- $\alpha$ -siRNA target inflammation and inhibit gene expression in the intestines. *Nat Mater* **9**: 923–928.
292. Laroui, H, Theiss, AL, Yan, Y, Dalmasso, G, Nguyen, HT, Sitaraman, SV *et al.* (2011). Functional TNF $\alpha$  gene silencing mediated by polyethyleneimine/TNF $\alpha$  siRNA nanocomplexes in inflamed colon. *Biomaterials* **32**: 1218–1228.
293. Aouadi, M, Tesz, GJ, Nicoloso, SM, Wang, M, Chouinard, M, Soto, E *et al.* (2009). Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. *Nature* **458**: 1180–1184.
294. Tesz, GJ, Aouadi, M, Prot, M, Nicoloso, SM, Boutet, E, Amano, SU *et al.* (2011). Glucan particles for selective delivery of siRNA to phagocytic cells in mice. *Biochem J* **436**: 351–362.
295. Xiang, S, Fruehauf, J and Li, CJ (2006). Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. *Nat Biotechnol* **24**: 697–702.
296. Sellick, P, Layton, MG, Rodger, J and Robertson, D (2008). A method for introducing non-silencing siRNA into the guinea pig cochlea *in vivo*. *J Neurosci Methods* **167**: 237–245.



297. Nakamura, Y, Kogure, K, Futaki, S and Harashima, H (2007). Octaarginine-modified multifunctional envelope-type nano device for siRNA. *J Control Release* **119**: 360–367.
298. Akita, H, Kogure, K, Moriguchi, R, Nakamura, Y, Higashi, T, Nakamura, T *et al.* (2011). Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. *J Control Release* **149**: 58–64.
299. Ripoll, E, Pluvinet, R, Torras, J, Olivar, R, Vidal, A, Franquesa, M *et al.* (2011). *In vivo* therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection. *Gene Ther* **18**: 945–952.
300. de Wolf, HK, Snel, CJ, Verbaan, FJ, Schiffelers, RM, Hennink, WE and Storm, G (2007). Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. *Int J Pharm* **331**: 167–175.
301. Merkel, OM, Librizzi, D, Pfestroff, A, Schurrat, T, Béhé, M and Kissel, T (2009). *In vivo* SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. *Bioconjug Chem* **20**: 174–182.
302. Choi, B, Hwang, Y, Kwon, HJ, Lee, ES, Park, KS, Bang, D *et al.* (2008). Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. *J Dermatol Sci* **52**: 87–97.
303. Mook, O, Vreijling, J, Wengel, SL, Wengel, J, Zhou, C, Chattopadhyaya, J *et al.* (2010). *In vivo* efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts. *Artif DNA PNA XNA* **1**: 36–44.